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Abstract 
 
The novel mechanism of simocyclinone D8 (SD8) against DNA gyrase has inspired medicinal 
chemists for over a decade. The search for antibiotics with new mechanisms of action has never 
been more important with ever increasing prevalence of resistance.  This project had three 
objectives. Firstly to contribute towards the total synthesis of SD8, by exploring chlorination 
reactions of dihydroxycoumarins and their corresponding starting reagents. Additionally, there was 
a need to establish a viable route towards the complex polyketide scaffold.  Secondly, to generate 
a library of coumarins and screen for a low molecular weight fragment that could be taken forward 
as a lead compound. Thirdly, inspired by the bi-functional mode of action of SD8, the project sought 
to design and synthesise a coumarin-quinolone hybrid via a fragment-based approach.  
Herein we exploit ortho and para directing effects of phenolic OH groups to selectively chlorinate 
starting materials. However, we show chlorination of reagents prior to forming a coumarin is not a 
viable synthetic strategy. This is due to the reduced nucleophilicity imparted by the halogen on 
adjacent atoms. Consequently, this abrogates any ring closure reaction.  
We illustrate that a previously established Diels-Alder route can furnish a novel isomerised 
pericyclic adduct. This provides a good starting point for reaction optimisation and the onward 
enantioselective synthesis of the complex polyketide scaffold.  
Lastly, 27 different coumarin fragments were synthesised and assessed for biological activity. We 
illustrate that simple coumarins lack inhibition in supercoiling assays against DNA gyrase. 
Furthermore, when ciprofloxacin is attached to a linker there is an attenuation of activity. Strikingly, 
when a simple coumarin is joined to ciprofloxacin, via a linker there is a restoration of activity. We 
show DNA gyrase inhibition is via cleavage stabilisation. Moreover, we demonstrate activity is 
related to the coumarin structure and not the presence of an aromatic ring. 
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This chapter introduces bacteria, antimicrobial resistance (AMR) and orientates the reader to the 
arrangement of DNA, exemplifying the flexibility and conformational variation which gives rise to the 
unique biological properties of the building block of life. Additionally it examines DNA topology, 
topoisomerase enzymes and discusses the aminocoumarin and quinolone inhibitors. Lastly it 
highlights the simocyclinones (SD4 and SD8), whose novel mode of action and exquisite structure 
has inspired medicinal chemists for the last 15 years.  
1.0 Gram-positive and Gram-negative bacteria 
Hans Christian Gram developed the now widespread method of differentiating between two classes 
of bacteria based on the structural and physical characteristics of cell walls. Gram-positive 
organisms have a single membrane surrounded by a thick peptidoglycan layer (murine) that retains 
the dye, crystal violet (positive test result) giving them a purple appearance. Peptidoglycan is a 
rigid polymer lattice composed of two alternating sugars, N-acetylglucosamine (NAG) and N-acetyl 
muramic acid (NAM) linked by a β,1,4-glycosidic bond. The NAM carboxylic acid residues are 
further substituted with a pentapeptide cross-bridge.1 This varies among species of Gram-positive 
and Gram-negative bacteria, but always terminates with two D-alanine residues.2 Whilst the NAG 
and NAM units are linked together in the cell cytoplasm, their crosslinking takes place by 
membrane bound transpeptidase enzymes. They create a peptide bond between the D-alanine and 
the amine of L-lysine or pimelic acid in Gram-positive and Gram-negative bacteria respectively. As 
well as giving bacteria their shape, peptidoglycan also anchors cellular components, such as 
proteins, to its surface. Gram-positive bacteria contain lipoteichoic and teichoic acids that provide 
additional structural support and form pathogen associated molecular patterns (PAMP).  
In contrast, Gram-negative organisms have a thin peptidoglycan layer that cannot retain crystal 
violet during the de-staining (negative test result). Instead it stains pink with a counterstain 
(fuchsine or safranin). The thin peptidoglycan layer is separated from the cell wall by the 
periplasmic space and is encapsulated by an outer membrane (OM).3 In contrast to the 
cytoplasmic membrane, the OM is decorated mainly with lipopolysaccharides (LPS), as well as 
phospholipids and proteins termed outer membrane proteins (OMP). It should be noted that the 
OM, although containing phospholipids in its inner leaflet, is not a phospholipid bilayer.4 LPS, which 
decorates the outer surface, has the ability to be recognised by the immune system and is an 
endotoxin.5 It is comprised of 3 parts, an inner lipid, a core oligosaccharide (short sugar) and an 
outer polysaccharide (o-antigen, long sugar). The aqueous compartment in between the OM and 
cellular membrane is known as the periplasm. This contains hydrolytic enzymes, binding proteins, 
detoxifying enzymes and chemoreceptors not found in the cytoplasm.  
Chapter 1. Introduction 
 
 
 
22 
 
Figure 1. Structural differences between Gram-positive and Gram-negative bacteria. WTA = wall 
teichoic acid, CAP, covalently attached protein, LTA, lipoteichoic acid, IMP, integral membrane 
protein, LPS, lipopolysaccharide, OMP, outer membrane protein, LP, lipoprotein.6  
The protective outer membrane of Gram-negative bacteria and the periplasm are partly responsible 
for the inherent difficulty in targeting these microorganisms with antibiotics. These structural 
differences are highlighted in Figure 1.  
1.01 Antimicrobial resistance and mechanisms of resistance 
The serendipitous discovery of penicillin in 1928 by Alexander Fleming serves as an example of 
how natural products can be harnessed as chemotherapeutic agents against bacteria, and marks 
the inauguration of modern antibiotics.7,8 Unfortunately, multi-drug-resistance (MDR) to antibiotics 
has increased globally and is now considered one of the greatest threats to health.8–10 
Resistance can be intrinsically present, having arisen through fortuitous mutations during 
replication of DNA or via the dissemination of DNA among bacteria. The use of antibiotics in society 
contributes to the problem by creating selection pressure, allowing resistant strains to dominate 
their non-resistant counterparts.  
Intrinsic resistance is due to inbuilt structural or functional characteristics that prevent a 
microorganism being sensitive to a given drug.11 Daptomycin, a lipopeptide, inserts itself into the 
cell membrane. This causes depolarisation that leads to the loss of vital intracellular components. 
This agent is only effective against Gram-positive bacteria. The reason for a lack of efficacy against 
Gram-negative organisms is due to a lower proportion of anionic phospholipids that consequently 
provides insufficient sites for calcium-mediated insertion of daptomycin into the cell membrane.12 
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Vancomycin is an additional example that is effective against Gram-positive microbes by inhibiting 
peptidoglycan synthesis. However, vancomycin has no effect on Gram-negative organisms, as it 
cannot cross the OM to reach the target transpepdidases in the periplasm.13 
Acquired resistance arises through three main mechanisms: firstly by inactivation of the antibiotic, 
secondly through modification of the target site and thirdly those that can decease the intracellular 
concentration of the antibiotic.11 An archetypal example of inactivation comes from the discovery of 
β-lactamase.14 This class of enzyme hydrolyses the sterically strained β-lactam ring of penicillin, 
opening it up and abolishing its activity. Since their initial discovery, new improved antibiotics have 
come to market, but the ever-increasing group of β-lactamases that can inactivate a broad range of 
penicillins, structurally related cephalosporins and synthetic fluoroquinolones has also continued to 
develop. They are known as extended-spectrum beta-lactamases (ESBL) and over 200 have been 
identified.15–17 Resistance can be disseminated among bacteria via plasmids encoding genes for 
ESBL or through domination of resistant species via Darwinian selection.17 
Antibiotics will often bind to a specific region of their target; in the case of the fluoroquinolones, they 
bind to a specific site on a topoisomerase (topo) enzyme, DNA gyrase, as well as its structurally 
related family member topo IV (discussed in further detail in section 1.15). Resistance to this class 
of antibacterial is attributed to point mutations that often encode for a serine residue and 
aspartic/glutamic acid residues.18 The loci of the specific genes are termed the quinolone 
resistance-determining region (QRDR).19,20 This substitution in amino acid residues dramatically 
alters the efficacy of the drug by abrogating its binding to the target topo enzyme.  
The physiology of Gram-negative organisms illustrates how decreasing antibiotic concentrations 
can confer resistance. The OM of Gram-negative species is inherently less permeable to antibiotics 
and serves as an intrinsic mechanical barrier. In addition, the OM contains porins, specialised 
channels that allow the movement of molecules through the OM into the periplasmic space. Down 
regulation and reduced expression of porins in the bacterial OM has been associated with 
resistance to carbapenams and chephalosporins.21–23 Hydrolysing enzymes can target 
cephalosporins. This demonstrates the multi-faceted nature of resistance; often a combination of 
different mechanisms will confer an evolutionary advantage. 
The injudicious use of antibiotics in humans and animals is the single most important factor for 
developing AMR. In the 1950’s soon after the initial approval of antibiotics in livestock as growth 
promoters, concerns were raised regarding their use in intensive farming. Antibiotics were being 
used in livestock at sub-therapeutic doses, in the absence of disease, to enhance feeding and 
improve the growth of an animal (animal growth promotion termed AGP). In 1969, the British 
Government requested the Swann Committee to report on antibiotic usage in humans and animals. 
They concluded that animal feed antibiotics should not be used in humans due to the risk of 
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transmission of resistant strains. Furthermore, they recommended the Government should 
establish a permanent committee who would take responsibility for antibiotic usage.24 However, it 
was another 30 years before the Specialist Advisory Committee on Antimicrobial Resistance 
(SACAR) was formed.25 The link between antibiotic use in animals and subsequent transmission of 
resistant microbes to humans was established from investigations in oxytetracycline fed chickens 
and farm personnel. Oxytetracycline-fed chickens developed intestinal flora containing almost 
exclusively tetracycline-resistant organisms within one week of ingestion of the antibiotic. In 
correlation, farm members who were responsible for handling the animals and were not taking 
antibiotics, also developed increased numbers of tetracycline resistant intestinal bacteria. In 
contrast, their neighbours did not develop any change in microflora in this study.26 Subsequently, a 
larger study looking at the streptothricin antibiotic, nourseothricin, in pig farming confirmed the 
earlier findings. Plasmid borne resistance to streptothricin was found in E. coli isolated from 
nourseothricin fed pigs, their handlers and the family members of the handlers. Additionally, in the 
larger study, resistance plasmids were detected in people in the surrounding community. These 
people had no contact with the pig farms but were present in areas where nourseothricin was used. 
This contrasted with a control territory where nourseothricin was not used, and no plasmid-encoded 
resistance was detected.27 Sweden was the first European country to phase out AGP in 1986, 
followed by Denmark. In the UK, there has been a decrease in AGP since 1998 and the European 
Union (EU) banned antibiotic use as growth promoters in 2006.28 Unfortunately, an estimated 70% 
of all antimicrobials continue to be used for non-therapeutic uses in agriculture in the USA.29 The 
usage in developing nations such as Africa and India is currently unknown.28 The ways in which 
antibiotics can disseminate into the environment are summarised Figure 2. 
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Figure 2. Dissemination of antibiotics into the environment.30  
There is a positive correlation between human antibiotic consumption and microbial resistance.31 
Examples of inappropriate prescribing include: using antibiotics unnecessarily, ineffective doses, 
ineffective treatment duration or unsuitable antibiotic selection. Furthermore, problems arise from 
the way in which patients/animals take medicines. Inappropriate patient habits/animal 
administration include: not taking/giving antibiotics in accordance with a prescriber’s instruction, 
missing doses and not completing prescribed courses. Antimicrobial stewardship (AMS) seeks to 
redress these anthropological derived problems. AMS, as defined by the Society for Healthcare 
Epidemiology of America (SHEA), Infectious Diseases Society of America (IDSA) and the 
Paediatric Infectious Diseases Society of America (PIDS) represents a co-ordinated effort to 
improve and measure appropriate utilisation of antibiotics.32 Thus, the dwindling pool of efficacious 
antibiotics can be preserved for life threatening conditions. This can be achieved through the 
education and cultural change of healthcare professionals, patients and children.33  
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Cooperativity among countries is key to achieving the success of AMS as international travel, has 
forever changed the microbial landscape, eradicating physical barriers to transmission. Thus, 
international efforts are required to encourage a harmonised approach to antibiotic prescribing. A 
lack of antibiotic regulation in less economically developed countries is a contributing factor in the 
emergence of AMR; this includes lack of effective legislative enforcement, lack of financial 
resources and poor education and awareness of AMR.34 Unfortunately, information regarding the 
unregulated sale of antibiotics and prescribing habits is scarce.  
The interplay of factors that contribute to AMR is complex; the benefit of using an antibiotic comes 
with the price of introducing selective pressure that consequently drives resistance not only of the 
causative pathogen but also background microflora. The interplay between host, pathogen and 
indigenous microflora (commensal) is highlighted in Figure 3. Consequently, once a drug comes to 
market it is not long before resistant pathogens emerge (Table 1). AMR combined with a lack of 
antimicrobial investment from pharmaceutical companies has created a deficit of novel chemical 
entities coming to market. Drugs originally left undeveloped as lead compounds have been re-
evaluated as conferring at least some advantage. Daptomycin is an example that was discovered 
in the 1980’s by Eli Lily. It was originally shelved due to adverse side effects and what the company 
considered an unsatisfactory performance in clinical trials. In 1997, its patent was purchased by 
another company, Cubist, who considered the benefit outweighed the risk in an environment 
whereby an ever increasing proportion of resistant microbes were being identified.35 The drug was 
subsequently approved by the FDA in 2003.   
 
Figure 3. The infection pyramid: describes the relationship between humans (Host), bacteria 
(Pathogens, Commensals) and antibiotics (Therapy).33  
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Table 1. Timeline of discovery, coming to market and detection of antibiotic resistance.36  
1.02 Current clinical targets for antibiotics 
There are five main validated drug targets that are currently exploited in antimicrobial 
chemotherapy (Figure 4). A selection of drug structures that exploit these targets are shown in 
Figure 5. Disruption of cell wall synthesis is probably the most eminent drug target. Penicillin 
(amoxicillin, flucloxacillin, penicillin V) targets the enzymes involved in the synthesis of 
peptidoglycan, a cell wall component, by binding covalently to the active serine site of the 
transpeptidase enzymes (also termed a penicillin binding protein PBP).37 Transpeptidases are a 
unique to bacteria and, therefore, a rational drug target. Penicillin and its derivatives are effective 
due to the highly reactive β-lactam ring that is structurally similar to D-alanine.2 Consequently, the 
enzymes utilises the β-lactam as a substrate and become inactive, accordingly the enzyme is 
unable to cross-link the bacterial cell wall, resulting in cell lysis and death. Thus, the penicillins are 
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bactericidal in their mode of action. Similarly, cephalosporins (cephalexin, cefotazime, cefradine) 
contain a β-lactam ring fused to a dihydrothaizine ring; their mode of action is the same as the 
penicillins. The carbapenams (meropenem, ertapenem) also react with transpeptidase enzymes, 
entering cells via the OMP.38,39 Due to the cell being unable to cross-link peptidoglycan, the 
bacteria burst under osmotic pressure. Analogously aztreonam exerts its effect by binding to the 
PBPs of mainly Gram-negative bacteria. However, unlike the previous classes of β-lactams it has 
no fused ring system. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Clinically exploited antibiotic drug targets.36  
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Figure 5. Examples of structures of clinically exploited antibiotics. 
In contrast to the β-lactam antibiotics, the glycopeptide antibacterials (vancomycin, teicoplanin) are 
large complex molecules consisting of amino acids that can be decorated with halogens, OH 
groups, and sugars. The compounds disrupt a late stage in cell wall formation by binding to the D-
Ala-D-Ala C-terminus of the disaccharide pentaptide repeating unit of the peptidoglycan.40 The 
binding of the glycopeptide prevents the transpeptidase enzyme from binding to the amino acids, 
abrogating cross-linking of the cell wall, and thus inhibiting peptidoglycan formation.41 
Protein synthesis is another heavily targeted bacterial process. The macrolides are lactone rings 
adorned with sugars. They target the 50S subunit of the bacterial ribosome, close to the peptidyl 
transferase centre.42 This plays a vital role in the formation of peptide bonds during protein 
elongation. The binding sites of the macrolides (telithromycin) overlap with substrates of peptidyl 
transferase inhibiting the reaction.43–45 The lincosamides (clindamycin), while structurally distinct, 
operate via a similar mechanism. Erythromycin is an exception, rather than inhibiting the peptidyl 
transferase reaction it sterically blocks the ribosomal tunnel through which newly created peptides 
exit the ribosome. Thus causing t-RNA to dissociate prematurely from the enzyme.46,47 In contrast, 
chloramphenicol also binds to the 50S ribosomal subunit, but instead of sterically blocking the 
subunit, it irreversibly interacts with the receptor site to prevent amino acid transfer from peptidyl 
transferase.48,49 
The aminoglycoside antibiotics (gentamycin, tobramycin) are amino sugars that bind to a 
conserved sequence of 16S ribosomal RNA (rRNA) in the 30S subunit of a ribosome.50 The binding 
of the antibiotic stabilises a tRNA-mRNA interaction preventing the disassociation of tRNA. 
Consequently, this causes misreading of mRNA and the insertion of incorrect amino acids into 
polypeptides.51 The tetracyclines (oxytetracycline, lymecycline) also target the 30S ribosome.  They 
are composed of a linear fused tetracyclic scaffold decorated with a variety of functional groups, 
such as alcohols, amines and amides.52 The tetracyclines prevent binding of aminoacyl tRNA with 
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the ribosome by sterically blocking tRNA binding.53 Oxazolidinones (linezolid) are novel synthetic 
compounds that have a distinct mode of action that is not yet fully elucidated.54 Structurally, 
linezolid contains an oxazolidinone ring, substituted with an acetyl protected primary amine. 
Furthermore, the oxazolidinone ring is coupled to a fluorinated aromatic ring with a morpholine 
substituent. Linezolid is only effective against Gram-positive bacteria. This antibiotic has been 
shown to bind to the 50S subunit and compete with chloramphenicol for binding. This suggests that 
the linezolid binding site is in close proximity to that of chloramphenicol.55,56 However, the 
oxazolidinones do not inhibit peptidyl transferase or block the elongation or termination of peptide 
chains.   
The sulphonamides and trimethoprim inhibit a pathway which produces tetrahydrofolate, a crucial 
precursor to the thymidine that is used in bacterial DNA synthesis. However, the two compounds 
exert their modes of action at different points in the pathway. The sulphonamides 
(sulfamethoxazole) are competitive antagonists of para-aminobenzoic acid (PABA) and prevent 
substrate binding to dihydropteroate synthetase. They all contain a sulphonamide functional group; 
although it should be mentioned that other non-antibacterial agents can also contain this moiety. 
This is attached to an aniline scaffold. The compound achieves its competitive inhibition due to its 
structural similarity with the natural metabolic substrate. It is noteworthy that whilst not broad 
spectrum, the drug has good Gram-positive activity. Trimethoprim binds to dihydrofolate reductase, 
an enzyme that catalyses the reduction of dihydrofolic acid to tetrahydrofolic acid, a later step in the 
tetrahydrofolate pathway. Often trimethoprim and sulfamethoxazole are given together to try and 
reduce the chances of resistance emerging.  
Rifampicin is a semisynthetic compound derived from the rifamycins. The family of compounds can 
contain either naphthalene, napthoquinone, benzene or benzoquinone aromatic cores with an alkyl 
chain that forms a closed system.57 Rifampicin has Gram-positive activity and some Gram-negative 
activity. It works by selectively inhibiting bacterial RNA synthesis via an interaction with RNA 
polymerase.58 
The quinolones are synthetic compounds that inhibit both DNA gyrase and topo IV. These 
enzymes are crucial for resolving DNA topological complications that arise during cellular events 
such as replication. Subsequent generations of analogues have yielded successful broad-spectrum 
antibiotics. Their history and mode of action is discussed in detail in section 1.15-1.16. In order to 
understand this class of antibiotic fully, it is first necessary to review some fundamental aspects of 
DNA and its structure. 
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1.03 DNA 
While growing resistance drives the need for development of new antibiotics, focusing on DNA 
topology is necessary in order to understand the biochemical processes that take place at a cellular 
level. Deoxyribonucleic acid (DNA) is the hereditary unit by which genetic information is stored and 
passed on. The pioneering discovery of its structure in 1953 at Cambridge University by James 
Watson and Francis Crick subsequently allowed information relating to it’s organisation and 
function to be elucidated.59 
DNA is composed of repeating nucleic acid monomers termed nucleotides. Nucleotides have three 
components, a sugar, a phosphate group and one of four nitrogen heterocyclic bases: the purines 
adenine (A) and guanine (G), or pyrimidines, cytosine (C) and thymine (T). Individual nucleoside 
constituents are linked; bases via the 1 position of the sugar ring and the phosphate groups in the 
3’ and 5’ positions (Figure 6), forming a nucleotide, the repeating unit of DNA, the blueprint of life.  
 
Figure 6. A polynucleotide chain 1, demonstrating the 5’-3’ phosphodiester linkages.60 Magnified 
view of a polynucleotide 2 demonstrating atom numbering of a polynucleotide (blue box).61 
Hydrogen bonding affinities between bases creates specificity; adenine and thymine are linked by 
two hydrogen bonds whereas guanine and cytosine have three hydrogen bonding interactions 
(Figure 7). This allows for the sequence specific storage of information that can be read 
(translated) by highly specialised enzymes to direct protein formation, via an RNA intermediate. 
Transcription is the term for this first step of gene expression in which RNA is synthesised from the 
DNA template. Genes are the names given to defined areas of DNA, which can be translated into a 
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protein product. The collection of genes that make up a human genome are compacted down into 
more manageable sizes. This condensation of genetic matter forms a chromosome.  
 
Figure 7. Hydrogen bonding between nucleobases 3 (A.T) 4 (G.C) illustrating Watson-Crick 
pairing. 
The five membered 2-deoxy-D-ribose sugar ring of DNA is not planar, instead it has twist and 
strain. This is the first example of how rotation and flexibility affects the geometry of DNA. The 
twisting or ‘puckering’ is a result of steric interactions. Thus the ring adopts the most energetically 
favourable conformation in which substituents are as distant as possible from each other. The most 
frequent spatial arrangement encountered is C2’ endo puckering whereby the C2 atom of the sugar 
diverges above the plane of the ring or conversely C3’ endo where it is the C3 carbon (Figure 8).  
 
Figure 8. Sugar puckering 5 C2’ endo 6 C3’ endo arrangements.61 
In an analogous fashion the stereochemistry at the anomeric C1’ position is assigned. The 
glycosylated bond can orientate below the sugar (axial), termed an α-nucleoside, or above 
(equatorial) termed a β-nucleoside. This classification is included for completeness, as in vivo 
nucleotides only exist in β form. Moreover, nucleobases have free rotation around the n-
glycosylated bond (χ) uniting the sugar ring to the base at the N-9 and N-1 position for purines and 
pyrimidines, respectively. Bases can therefore exist in two different states termed anti and syn 
(Figure 9). 
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Figure 9. Example of anti 7 and 8 syn conformation of pyrimidine nucleoside. 
Purine bases (A/G), like the sugar, are not co-planar; rather they sit almost at right angles to the 
sugar. They are permitted to rotate into either the syn or anti conformation. However pyrimidine 
bases (C/T) if syn to the sugar ring, experience steric clashing between their carbonyl group and 
the hydrogen at the C2’ position of the sugar. Therefore, they predominate in the more 
energetically favourable anti conformation. Strain is not confined internally to the sugar ring (τ0-τ4), 
the phosphodiester backbone also experiences rotation around each of the sp3 hybridised sigma 
bonds (Figure 10). 
 
Figure 10. Positions of free rotation in DNA.61 
Accordingly the free rotation means a helical axis is not straight; instead possessing intrinsic 
curvature, contributing to its biological function. Protein-DNA interactions in the major or minor 
groove provide an example of the relationship between shape, recognition and function. Ultimately, 
the flexibility of the components of DNA directly influences the higher order structures that can form 
in vivo and in vitro.  
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1.04 DNA higher order structures 
B-form DNA is the most common arrangement of DNA within cells (Figure 11). It consists of a right-
handed anti-parallel α-helix with Watson-Crick pairing. The sugar phosphate backbone exhibits C2’ 
endo puckering with anti glycoside bond angles (χ). Each 360° turn contains 10.5 base pairs, with a 
separation of 3.4 Å between base pairs (helical rise) and a helical diameter of 20 Å. The helical 
nature of B-form DNA is the most energetically favourable conformation due to the orientation of 
the hydrophobic base pairs relative to their environment and the bond angles (α-ζ) of the sugar 
phosphate backbone. When double stranded DNA is separated into individual strands, water 
molecules hydrogen bond in place of a complementary base. As individual strands re-associate, 
water is eliminated from the central helical core, increasing the disorder and hence entropy of the 
system. This thermodynamically favourable reaction contributes to the overall stability of the helix. 
Stabilisation also comes from π-π stacking interactions of the planar bases above each other so 
that they are orientated approximately perpendicular to the helical axis.  
A-form DNA represents an alternative conformation able to form in vitro (Figure 11). Rosalind 
Franklin illustrated using X-ray fibre diffraction studies that as the water content of DNA was 
reduced its structure transformed.62 A-form DNA is also a right-handed α-helix with Watson-Crick 
pairing. Contrasting with B-form, it is shorter and broader with an extra base pair per turn. 
Important differences exist in the orientation of the sugar rings between A and B-form DNA. A-form 
is C3’ endo whereas B-form is C2’-endo. Due to the twist of the sugar, the base pairs are tilted 
away from the central helix in A-form DNA, and consequently less hydrogen bonding interactions 
occur with the sugar phosphate backbone and its surroundings. Thus the A-form preferentially 
emerges in a dehydrated state.  
In 1979 crystallographic studies of an alternating guanine-cytosine oligonucleotide revealed an 
unconventional structure compared to A and B-form DNA. This new assembly was termed Z-form 
DNA due to the zigzag profile of the sugar phosphate backbone (Figure 11). This structure uniquely 
possesses a left-handed helix and has no major groove. The shape of the backbone is due to 
strain generated by alternating syn-anti conformations of the nucleobases.  
After Watson and Crick published their seminal paper on the structure of DNA they quickly realised 
separation of double stranded (duplex) DNA would be associated with helical rotation, resulting in 
strain. When two strands of DNA are separated, rotation ahead and behind the replication fork 
occurs resulting in over twisting (supercoiling). This supercoiling needs to be resolved before 
replication can resume. To surmount this barrier to cellular processes topoisomerase enzymes 
catalyse transient breaks into DNA allowing resolution of the strain.  
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Figure 11. Structures of A-, B- and Z-form DNA respectively.63 
1.05 Topology and geometry of DNA 
To understand how topoisomerase enzymes function it is essential to appreciate the arrangement 
of DNA in space and how we describe this geometrically. DNA is supercoiled through over or under 
winding; the term twist (Tw) is used to describe the number of times one strand crosses over 
another. The amount of twist a molecule has is the same in both its linear and circular form. The 
term writhe (Wr) indicates the number of times that double stranded DNA crosses over itself to 
form supercoils. The linking number (Lk) is an integer that mathematically describes the topological 
changes that occur within a molecule, it is the sum of the twist and the writhe (Equation 1). The 
linking number cannot change within a closed system (such as a bacterial plasmid) without 
introducing breaks into the DNA strands. Put simply, the linking number is the number of times one 
strand would need to be passed through another in order for separation to occur.60 
Lk = Tw + Wr 
Equation 1. Relation of linking number to twist and writhe. 
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ΔLk = Lk - Lk0 
Equation 2. Change in linking number. 
In addition to the linking number it is common to report the ΔLk. This quantitatively expresses the 
linking difference, termed Lk0, when compared to a relaxed DNA molecule (Equation 2). 
1.06 DNA replication in Prokaryotes 
 
Figure 12. DNA replication.64 
To access information stored within the base sequences of DNA, strand separation must occur. 
DNA helicase breaks hydrogen bonds between base pairs allowing complementary strands to 
disconnect and form a replication fork. This creates a leading strand, where DNA polymerase binds 
to a 3’ end and synthesises a new daughter strand continuously in a 5’ to 3’ direction (Figure 12). 
The lagging strand requires DNA primase to add primers for the addition of RNA by polymerase III. 
Subsequently this is converted into DNA by polymerase I whilst DNA ligase re-anneals the free 3’-
OH to the 5’-sugar phosphate backbone permitting DNA synthesis to occur in a discontinuous 
fashion. Topological changes occur in front and behind the replication fork. As replication 
progresses the proportion of unreplicated DNA ahead of the fork diminishes whilst the amount of 
strain and thus supercoiling increases (+ supercoiling). Crucially, there is an ever-decreasing 
amount of space in which to contain the supercoils. Strain is not confined to the unreplicated region 
of DNA, rather it can disseminate into the replicated region, culminating in the inter-winding of 
daughter strands to form “precatenanes”, termed because they precede catenanes. 
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1.07 Topoisomerase enzymes 
Topo enzymes regulate the topology of DNA. Separation of DNA causes rotation, creating 
topological strain. The problem of strain is a result of the double helix architecture of DNA. 
Consequently, if unresolved this would impede cellular processes. To overcome this topo enzymes 
resolve supercoiling by transiently cleaving and annealing DNA. The topoisomerase nomenclature 
is complex with overlap between the numbers denoting the type of enzyme and numbering 
denoting the time of discovery. The first topoisomerase (ω-protein) was isolated from E. coli in 
1971.65 The enzyme was able to relax negative supercoiled λ bacteriophage DNA. A year later a 
second topoisomerase from mouse embryo cells was found which unlike the ω-protein, could 
remove both positive and negative supercoils.66 Both enzymes were evolutionary unrelated and 
mechanistically distinct.67 They introduced single strand breaks (topoisomerase I) and are 
classified as topoisomerase IA and IB. Topoisomerase V remains discovered in a single species 
and is classified separately under topo IC as it is structurally distinct from IA and IB but has a single 
strand breakage mechanism. This forms the basis of topoisomerase I classification. Similarly to the 
topo IA and B family, type II topoisomerases, which introduce double strand breaks, are further 
differentiated based on architecture and mechanism. The following gives a brief description of each 
with an in depth focus on DNA gyrase, a type IIA topoisomerase. 
1.08 Type IA  
Type IA enzymes have an elongated toroid structure with a lumen large enough to accommodate 
B-form DNA.67,68 They regulate DNA topology via a mechanism that ligates a single strand and 
then passes a second strand through the opening.69 Subsequently, after the strand passage event, 
the ligated strand is re-annealed. Strand cleavage is mediated by tyrosine that hydrolyses the 
sugar phosphate backbone forming a covalent intermediate. This class of enzyme attacks the 5’ 
end and releases a 3’-OH group.70 Topo I, III and reverse gyrase are all members of this category; 
topo I and III are ATP independent whereas reverse gyrase requires ATP to perform its cellular 
reactions. The main function of topo I is to relax negatively supercoiled DNA, in contrast, topo III 
catenates and decatenates replicating daughter DNA molecules.71 Lastly, reverse gyrase is unique 
to hyperthermophiles, it introduces positive supercoils and renatures DNA.72,73 
1.09 Type IB  
The type IB enzymes contain four domains that transiently clamp around DNA.74 They can remove 
positive and negative supercoils. Unlike type IA enzymes, they relax DNA by nicking a single 
strand of duplex DNA by forming a covalent intermediate at the 3’ end. This allows the 5’-OH 
strand end to rotate with respect to the intact strand. However, this is not unhindered, the 
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mechanism is torque sensitive involving a swivel mechanism where there is friction between the 
rotating DNA and the enzyme.66,75 
1.10 Type IC 
Topo V is the only member of this family.76 Similar to topo IB enzymes, it functions by a nicking-
swivelling mechanism relaxing both positively and negatively supercoiled DNA.77 It is structurally 
divergent at its catalytic site compared to topo IB.78 A summary of all type I topo enzymes is shown 
in Figure 13.  
 
Figure 13. Comparisons of type I topoisomerase enzymes. Topo 1A (PDB 1I7D), Topo 1B (PDB 
1A31) Topo V (PDB 2CSB, 2CSD).78  
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1.11 Type IIA (DNA gyrase) 
Type IIA enzymes have a strand passage mechanism like the type IA enzymes. However they 
introduce two transient breaks into DNA instead of one and pass an unbroken strand through the 
opening of the cleaved strand. They can relax positive and negative supercoiled DNA and perform 
catenation/decatenation reactions. The mechanism of DNA gyrase, a prokaryotic type IIA topo, is 
discussed in detail in section 1.13. Topo IV is a structural homologue to DNA gyrase, consisting of 
a parC (84-kDa) domain and a parE (70-kDa) domain which forms a C2E2 heterotetramer. The topo 
IV mechanism is similar to gyrase but with an important difference, it does not wrap DNA around 
itself.79 
1.12 Type IIB  
The topo IIB enzymes (also called topo VI) are analogous to IIA and have two subunits that 
associate into a heterotetramer. The B subunit contains a conserved nucleotide binding fold 
(Bergerat fold) that is evolutionarily related to the IIA enzymes.67,80–82 Two crucial distinctions are 
made in the mechanism of IIB compared to IIA enzymes. Firstly, cleavage is dependent on ATP. 
Secondly, the double strand breaks only have a 2 base pair overhang. Whilst the A subunit has no 
sequence similarity to IIA enzymes, sequence similarities for eukaryotic Spo11 protein from S. 
cerevisiae and Archaeal topo VI A subunit exist.80 
1.13 Mechanism of DNA gyrase supercoiling 
The mechanism by which DNA gyrase achieves negative supercoiling has yet to be fully 
elucidated. However, a model termed the ‘two-gate mechanism’ is supported by crystallographic 
and biochemical data.83 DNA gyrase is a prokaryotic type II topoisomerase, the active enzyme 
associated with DNA has a heterotetramer (A2B2) structure.84 GyrA has been shown to be a dimer 
in solution whereas GyrB is a monomer by x-ray scattering data (Figure 14. 1).85,86 This strongly 
agrees with in vivo data that shows most GyrA and GyrB molecules are not associated together but 
randomly distributed throughout the cytoplasm of the cell.87 There is a conformational change in the 
presence of DNA. DNA (Gated/G-segment) binds to the N-terminal domain of the GyrA subunit  
(97-kDa) and the metal binding topo/primase (TOPRIM) domain of GyrB.88 The DNA is folded 
around the C-terminal domain in a right-handed supercoil of ~130 base pairs.89,90 X-ray 
crystallography of the GyrA C-terminal domain from Borrelia burgdorferi consists of a six bladed β-
pinwheel containing the ‘GyrA box’ the part of the enzyme responsible for bending DNA to 180°, 
which if deleted abrogates supercoiling activity.91,92 The right-handed wrapping of DNA facilitates a 
secondary segment from the same DNA molecule (transported/T-segment) to reach the N gate 
above the G-segment (Figure 14. 2) in a positive crossover. The association of ATP to the N-
terminal domain of GyrB causes dimerisation of the N gate on the B subunit (90-kDa) trapping the 
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T-segment within the active site.93,94 A tyrosine residue (Try122) hydrolyses the DNA backbone 
(Figure 15), creating a double strand break in the G-segment to form a covalently linked 
intermediate to GyrA.95 This requires magnesium ions as a divalent co-factor in order to occur. 96,97 
A conformational change segregates the two hydrolysed G-segment strands of DNA, allowing the 
intact T-segment to pass through the cleaved opening into the GyrA cleft. The cleaved strands are 
subsequently re-annealed. The free energy from ATP hydrolysis is utilised to drive forward the 
energetically unfavourable procedure.98 The strand is then able to leave via the exit gate. The 
overall effect is to alter the linking number (Lk) of DNA by -2 consequently resolving topological 
strain. One supercoiling cycle introduces two negative supercoils; this requires energy from two 
ATP molecules. When no ATP is present DNA gyrase can relax negatively supercoiled DNA by the 
reverse mechanism.  
 
Figure 14. DNA gyrase mechanism: 1 proteins in their free state, 2 association of DNA around the 
C-terminal domain in a right handed manner presents the T segment above the G-segment, 3 GyrB 
dimerization in the presence of ATP transiently cleaving the G-segment, 4 GyrB rotates, the GyrA 
cleft widening and transportation of the T-segment through the G-segment driven by ATP 
hydrolysis, 5 re-annealing of G-segment and the introduction of two negative supercoils, release of 
T-segment and resetting of the enzyme.86 Symbols indicate: Circle; ATP binding pocket, Star; 
position of residues involved in DNA cleavage. Colour coding: Orange; GyrA59 N-terminal domain, 
Cyan; GyrA C-terminal domain, Navy Blue; GyrB43 N-terminal domain, Red; TOPRIM domain, 
Green; tail domain, Purple; T-segment, Black; G-segment. The locations of gates: N; N-gate, D; 
DNA gate, E, Exit gate.99  
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Figure 15. DNA cleavage by tyrosine in the presence of Mg2+ cations.96 
At multiple points in the DNA gyrase catalytic cycle there are opportunities for small molecule 
ligands to interfere: with (i) DNA binding (ii), ATP hydrolysis (iii) and DNA ligation (Figure 14). 
Validated antimicrobial agents that target DNA gyrase include the aminocoumarin antibiotics; the 
quinolones, and more recently, the discovery of the simocyclinone D8 (SD8), a new class of 
angucycline antibiotics. SD8 has a novel mode of action and has therefore reignited interest in 
developing lead compounds both due to its bi-functional structure and its novel mode of action.  
1.14 Aminocoumarin antibiotics 
The aminocoumarins novobiocin, clorobiocin (also called chlorobiocin) and coumermycin A1 are 
natural products derived from Streptomyces. Novobiocin was first discovered in 1965 subsequently 
followed by coumermycin A1 (Kawaguchi, H.; Naito, T.; Tsukiura, H.,1965, Berger, J., et al 1966 
cited Fedorko, J.; Katz, S.; Allnoch, H., 1969) and clorobiocin (Ninet, L., et al 1972 cited Maxwell, 
A., 1993).100–106 All have structural similarities, notably a 4,7-dihydroxylated 3-aminocoumarin 
centre with a noviose sugar (Figure 16). Clorobiocin is similar to novobiocin except it contains a 
chlorine atom at the 8-position instead of a methyl group and has a 5-methyl-pyrrole ring instead of 
a carbamoyl group at the 3 prime position of the noviose sugar. Both novobiocin and chlorobiocin 
have a prenylated phenolic benzoic acid at the 3 position of the coumarin. Coumermycin A1 is a 
dimer linked by a 3-methyl-2,4-dicarboxyl pyrrole linker. It has the same substituted sugar as 
chlorobiocin. 
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Figure 16. Aminocoumarin antibiotics. 
Initial observations with S. aureus showed the accumulation of uridine nucleotide precursors as 
well as inhibition of protein and nucleic acid synthesis in the presence of novobiocin.107 This was 
later extended to inhibition of DNA synthesis in E. coli.108 While early theories predicted hindered 
cell wall formation, analogous to penicillin, this was later recanted.109 The observation that 
novobiocin had an ability to bind magnesium, led to an additional hypothesis of induced 
magnesium ion deficiency which in turn compromised membrane integrity, this was also 
subsequently disproved.110,111  
Insight into their true intracellular target came from the identification of clorobiocin resistance which 
mapped to the GyrB locus.112 With the seminal discovery of DNA gyrase, it was revealed the 
aminocoumarins inhibited DNA gyrase catalysed supercoiling via competitive inhibition of ATP.113–
115 This was unexpected due to the lack of structural parity between aminocoumarins and ATP. The 
aminocoumarins bind tightly to a 24-kDa N-terminal domain on the GyrB subunit.116 X-ray 
crystallography illustrated that while novobiocin bound to a region independent of ATP, the noviose 
sugar overlapped the ATP binding domain, thus acting as a steric block.117 A year later a high-
resolution structure of clorobiocin bound to the same 24-kDa GyrB subunit was published.118 This 
structure shows the coumarin and prenyl group make important contacts around a Pro79 residue. 
The prenyl group is folded back onto the coumarin, reducing the hydrophobic surface of the 
molecule as well as making contacts with the protein. This had previously been observed with the 
novobiocin-GyrB24-kDa structure. The amide bond is cis, creating a bent ‘staple’-like conformation 
in the crystal structure and in solution. This was confirmed by nuclear overhauser effect 
spectroscopy (NOESY) and total correlation spectroscopy (TOCSY) data from radiolabelled 
15N,13C-GyrB24-novobiocin.  
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Arg136 was identified as critical for hydrogen bonding to the exocyclic carbonyl group of the 
coumarin. This supported earlier mutational data that showed abrogation of inhibitory activity 
towards aminocoumarins in mutants lacking this residue.119 In contrast to novobiocin, the pyrrole 
group of chlorobiocin displaces water from the pocket. However, no conformational changes were 
seen in the protein. The difference in enthalpy from this displacement is not significant, as 
conveyed by isothermal titration calorimetry (ITC) experiments. However, it should be noted, 
binding of novobiocin and clorobiocin to gyrase is enthalpy driven at 25 °C. The relative 
stoichiometric binding of aminocoumarins is 1:1 for novobiocin and clorobiocin. In contrast 
coumermycin A1 has a 0.5:1 ratio of drug to GyrB43-kDa subunit.120 To date no crystal structure 
exists of coumermycin A1 bound to DNA gyrase. Curiously the results suggest coumermycin A1 
must induce a different DNA gyrase dimer in order for the coumarin moieties to occupy the same 
pockets on the GyrB subunit as novobiocin and clorobiocin.121 Despite strong inhibition in vitro the 
aminocoumarins have had limited clinical applications due to their poor water solubility, poor 
stability, low activity against Gram-negative organisms and toxicity towards eukaryotic cells.106,122 
1.15 Quinolone antibiotics history and SAR 
 
Figure 17. Quinoline, napthyridine and nalidixic acid. 
Nalidixic acid was the first quinolone antibiotic identified serendipitously in 1962 as a by product of 
chloroquine synthesis.123 This origin distinguishes quinolones from other antibiotics that are largely 
derived from, or metabolites of, natural products.124–126 Chemically speaking nalidixic acid does not 
posses a quinoline scaffold, that is, two fused heterocycles with one containing nitrogen (Figure 
17). Instead, this forerunner to the fluoroquinolones contains a 1,8-naphthyridine core (Figure 17). 
However, successive generations of quinolones derived from the parent quinoline scaffold see 
different structural motifs and spectrums of activity. Their classification is non-standardised and 
arbitrary. Several attributes have previously been taken into account including their date of 
marketing, clinical indication, SAR, and spectrum of activity. More recently they have been 
classified according to their in vitro activity and clinical indications.127,128 The major SAR is 
discussed below, and a selection of drugs is shown in Figure 18. First generation quinolones had 
limited potency and activity against Gram-negative bacteria, they had a short half life and were 
highly protein bound. Their poor pharmacokinetic profiles restricted clinical usage to community-
acquired urinary tract infections.129  
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Figure 18. Structures of quinolone antibiotics 
Examples are oxolinic acid, cinoxin, pipemidic acid, and flumequine. These agents provided slight 
improvements over nadilixic acid but still lacked broad-spectrum activity or high bioavailability.130–
132 Flumequine was the first example of a fluorinated quinolone.133 It was utilised briefly until it was 
shown to have adverse ocular toxicity.134 Whilst not routinely used for human treatment it found 
applications in the animal and fishing industry along side other quinolones.135–137 Pipemedic acid 
and piromidic acid are early examples whereby the introduction of a basic nitrogen alongside a five 
or six membered ring was favourable for enhancing the spectrum of activity, penetration and 
bioavailability.138 Moreover, it demonstrated the degree of variability that can be accommodated at 
this position.139 Alkylation of the ring system increased activity against Gram-positive organisms 
and increased the half-life of the drug. Norfloxacin, a second-generation quinolone, showed 
improved activity against Gram-negative bacteria and resistant strains of Pseudomonas aeruginosa 
and MRSA.140 However, little enhancement was observed against Gram-positive or anaerobic 
organisms.132 Norfloxacin combined successful structural modifications from the first generation 
quinolones, a fluorine at position 6, and a piperazine ring at the 7 position and a carbon instead of 
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a nitrogen at the 8 position. Significantly enhanced activity was attributable to the introduction of a 
fluorine atom at the 6’ position and represents one of the major SAR findings.139,140 The enhanced 
action has been linked with improved cell penetration. Alkylation of the N1 position with a 
cyclopropyl group was more beneficial than ethyl or isopropyl groups. This modification resulted in 
the hugely successful ciprofloxacin, which outperformed all previous compounds and is often used 
as a benchmark comparator when evaluating efficacy. The incorporation of an oxygen-containing 
fused ring connecting the N1 and C8 position, reminiscent of flumequine gave the racemic second-
generation ofloxacin. It was later shown that the S-isomer was twice as potent as the R-isomer 
leading to the development of levofloxacin.141,142 Functionalisation of the 2 and 3-position is seldom 
undertaken and associated with poor SAR.138 This is reflected in the successfully marketed 
quinolones which all contain a free carboxylic acid. 
 
Figure 19. Potent inhibitors with functionalisation at the 3 position. 
Two notable exceptions are the discovery of the 2,4 diones (PD 0305970 and PD 0326448), and 
ACH-702 an isothiazolequinolone (Figure 19). Both are structurally related to quinolones, and have 
dual inhibition of DNA gyrase and topo IV with potent broad spectrum of activities as well as 
efficacy against fluoroquinolone resistant isolates.143–146 The mechanism of action of the 2,4 diones 
is distinct from traditional quinolones and is discussed further in section 1.16 below. The 
isothiazolequinolones mechanism of action remains to be elucidated.  
1.16 Quinolone mechanism of action 
In addition to being one of the most clinically successful classes of antibiotics, the quinolones also 
delivered fundamental insight into topoisomerase structure and function. It was demonstrated with 
nalidixic acid and oxolinic acid that, unlike the aminocoumarins, the quinolones inhibited both 
negative supercoiling and relaxation of DNA gyrase.148 It was successively found that inhibition also 
extended to the homologous topo IV enzyme.149 Our mechanistic understanding of the quinolone 
drugs was improved indirectly from biochemical experiments that showed they formed a drug-DNA-
enzyme complex.148,150 From these early observations it was predicted the mechanism was via 
intercalation between DNA bases.151 More recently a crystal structure of moxifloxacin, levofloxacin 
and clinafloxacin with Streptococcus pneumoniae topo IV shows the quinolones interrupt the 
cleavage-religation process by intercalating themselves between DNA bases at both scissile bonds 
(Figure 20).147 These are staggered and consequently two quinolone drug molecules intercalate 
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separated by 4 base pairs. This data; showed that interaction of the 3-carboxylic acid end of the 
quinolones with a Ser79 and Asp83 is important for binding. These residues are frequently mutated 
in quinolone-resistant bacteria and were in agreement with previous work. It is worth noting that the 
exact location of C7 substituent was different in all three structures. 
 
 
Figure 20. Topo IV with moxifloxcain (red) intercalated into DNA (green). Tyrosine is denoted in 
orange.  Front and top views (PDB 3FOE and 3FOF).147 
A subsequent crystal structure using dione PD0305970 and levofloxacin with the same S. 
pneumoniae topo IV enzyme showed both compounds intercalated into DNA twice, with Mg2+ 
playing a role in facilitating this interaction by interacting with tyrosine177 and the DNA backbone 
(Figure 21).152 In both structures the compounds are orientated with their carboxylic acids facing 
downwards towards the α4 helix of ParC (corresponds to GyrA in DNA gyrase) and the 7-ring 
orientated towards the TOPRIM domain (corresponds to GyrB in DNA gyrase).  
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Figure 21. PD 0305970 (PDB 3LTN) and levofloxacin (PDB 3K9F) intercalated into DNA. DNA 
backbone (navy blue), the bases/sugars (yellow). Topoisomerase active site tyrosine (orange) and 
drug mutation sites (red). Magnesium ion co-ordination (purple).152 
A separate crystal structure of moxifloxacin in complex with Acinetobacter baumannii supports 
previous observations that two quinolone compounds are intercalated into the DNA with a 4 bp gap 
mediated by van der Waals and π-π stacking interactions (Figure 22).153 Additionally, a non-
catalytic magnesium ion with an octahedral coordination sphere composed of two oxygen atoms 
from the quinolone carbonyl groups, and four water molecules mediates the interaction between 
the protein and drug. The water molecules were in close enough proximity to hydrogen bond with 
serine and the acidic aspartate and glutamate residues. The authors concluded this water-ion 
interaction bridged the drug to the enzyme. The orientation of the quinolone is unlike the structure 
obtained with moxifloxacin (Figure 20) but is similar in orientation to structures obtained with 
levofloxacin (Figure 21) but without the non-catalytic magnesium ion bound. 
Functional studies show that mutation of either the serine or the acidic residues decreases the 
number of metal ions that can participate in quinolone activity. Decreased affinity of the drug-
enzyme complex for the non-catalytic magnesium ion is also observed.  Mutation at either residue 
was detrimental to quinolone binding, and complete abrogation of activity is seen when both 
mutations are present.154,155 These findings indicate that the interaction of quinolones for type II 
topoisomerase is via the water-metal ion bridge. This helps to rationalise historic SAR showing the 
detrimental effect of modifying the 3 position and accounts for the large tolerance to 
functionalisation at the 7 and 8 position. Comparison of human and bacterial topoisomerases 
shows human enzymes lack the residues necessary to form the water-metal ion bridge (Figure 
23).18,156 This disparity accounts for the preferential way quinolones target bacterial enzymes.156 
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Figure 22. A crystal structure of moxifloxacin (yellow) intercalated into DNA (green), in complex 
with ParC (red) and ParE (Blue) of Acinetobacter baumannii topo IV (PDB 2XKK).153 
 
Figure 23 Water-metal ion bridge (left) between ciprofloxacin and the Ser and Glu/Asp residues. 
Alongside contrasting sequences (blue box) of A. baumannii (Ab), Bacillus anthracis (Ba), E. coli 
(Ec) Staphylococcus aureus (Sa) and S. pneumonia (Sp) DNA gyrase (GyrA) and topoisomerase 
IV (ParC/GrlA). The homologous regions of human topoisomerase hTIIα and hTIIβ are shown for 
comparison.18  
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Interestingly the 2,4 quinazolinedione PD 0305970 cannot efficaciously form the C3/C4 water-metal 
ion bridge and its action must therefore be dependent on other structural components providing 
significant interactions with the enzyme. Mutation of serine, the acidic residues, or both, does not 
affect quinazolinedione affinity for topo IV or DNA gyrase.154 The quinazolinediones are potent 
inhibitors in vitro and in vivo with a broad spectrum of activity against Gram-positive and Gram-
negative bacteria.146 Despite the ability to overcome quinolone resistance, this class has been 
shown to have undesirable cross reactivity to human topoisomerase IIα (hTIIα). This is ascribable 
to the 3’-(aminomethyl)-or 3’-aminoethylpryrrolidinyl moiety at the 7 position.156 No clinically utilised 
quinolones to date contain this motif. A future challenge for the 2,4 diones is to design structures to 
minimise cross reactivity to human topoisomerase whilst retaining antibacterial activity.   
1.17 Cellular response to quinolones 
The mechanisms through which quinolones exert their lethal effect are complex and not yet fully 
elucidated. It was theorised that collision of replication forks with DNA-drug-enzyme complexes 
caused fork breakage and DNA release, and that this was the mechanism by which the quinolones 
exerted their therapeutic effect.157 However, experiments showed that despite nalidixic acid having 
a pronounced effect arresting DNA replication, it did not alter the biological integrity of the DNA.158 
Cells exposed to nalidixic acid for 3 hours were able to recover after the drug was removed 
demonstrating that whilst the quinolones bound to DNA this binding was not tight. Moreover 
cleavage complex formation was reversible. The association between cell death and inhibition of 
DNA synthesis therefore warranted further investigation. Bacteriostatic concentrations of oxolinic 
acid had been shown to trap the DNA gyrase enzyme and prevent ligated DNA from being released 
from the enzyme. The release of fragmented DNA only occurred at high concentrations. 
Furthermore the release of DNA and consequent cell death at high concentrations was blocked by 
chloramphenicol, a known inhibitor of protein synthesis. The authors concluded that additional 
protein synthesis is required in order to free the broken DNA from the enzyme. Interestingly, 
ciprofloxacin could act independently in the presence of chloramphenicol, and was postulated to be 
able to cause dissociation of gyrase subunits.159,160 Thus, it became apparent the quinolones could 
not only have a bacteriostatic but bactericidal effect depending on their structure and concentration. 
First generation nalidixic acid acid cannot kill E. coli in the presence of chloramphenicol or under 
anaerobic conditions. However, norfloxacin could maintain cell lethality in anaerobic conditions 
provided chloramphenicol was not present. In contrast, ciprofloxacin can kill cells regardless of the 
presence of anaerobic conditions or chloramphenicol. It was noted however, that higher 
concentrations of ciprofloxacin were required under the anaerobic conditions.161 Therefore, the 
rapid killing of bacterial cells is currently described as a two-step process. Step one is the 
reversible formation of a drug-DNA-gyrase complex containing DNA breaks. The second is the 
release of DNA breaks from the enzyme which causes chromosome fragmentation and cell death. 
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The requirement for continuing protein synthesis in order for chromosome fragmentation to occur 
with certain quinolones is poorly understood. Current predictions include break down of DNA 
gyrase by protease, cleavage of the cleaved complex by nuclease and denaturation of the enzyme 
mechanisms by which broken DNA is released from the enzyme.162 
1.18 Contribution of ROS to cell death 
Following the addition of norfloxacin to E. coli it has been shown that levels of hydroxyl radicals 
increase.163 In addition, agents that reduce levels of hydroxyl radicals (thiourea and 2,2’-bipyridyl) 
also reduced norfloxacin lethality. A separate group showed norfloxacin was not as lethal to an E. 
coli mutant lacking superoxide dismutase A (sodA) and B (sodB). This is consistent with the 
observation that cellular stress leads to increased levels of superoxide which can be converted into 
peroxide and ultimately form toxic hydroxyl radicals.164 Thus, oxidative stress also plays a role in 
contributing to the quinolones lethal action. Interestingly thiourea and 2,2’-bipyridyl also inhibited 
oxolinic acid, a quinolone that works via the chloramphenicol sensitive pathway. However, as this 
did not prevent chromosome fragmentation; this step must precede ROS formation. Moreover, the 
same experiments with PD161144 a C8 methoxy derivative which kills anaerobically and via the 
chloramphenicol independent pathway (i.e. without the need for additional protein synthesis) was 
unaffected even though this quinolone stimulated hydroxyl radical formation (Figure 24).165 Since 
their discovery over 50 years ago we are still unravelling insights into the full quinolone mechanism 
of action. The validity of targeting the DNA-cleavage-reunion cycle is eloquently exemplified by 
their pharmaceutical success. A new class of inhibitor with a completely separate mode of action 
against DNA gyrase has created further interest in exploiting this unique enzyme. The remainder of 
this chapter explores the literature regarding simocyclinone and our current understanding of its 
action. 
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Figure 24. Quinolone mediated lethality and ROS: (a) DNA and gyrase associate to form a 
complex, (b) quinolones form a complex with DNA and gyrase; DNA is broken and constrained 
thus inhibiting DNA replication and growth, (c) chromosomal fragmentation that can be blocked by 
chloramphenicol (CHL) a known inhibitor of protein synthesis, (d) chromosome fragmentation 
increases reactive oxygen species and eventual hydroxyl radical formation (e), (f) quinolones can 
also kill via a protein synthesis-independent, ROS-independent chromosomal fragmentation 
pathway.165  
1.19 Isolation of the simocyclinone antibiotics 
SD8 was first identified from a soil sample of Argentinean origin using high performance liquid 
chromatography with diode array detection and mass spectrometry (HPLC-DAD-MS).166 An extract 
using ethyl acetate and methanol was compared to an in-house antibiotic database. The UV peaks 
of interest that were considered novel were then further investigated by mass spectrometry and two 
new compounds, termed simocyclinone D4 (SD4) and D8 (SD8) were revealed (Figure 25).  
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Figure 25. Structure of the simocyclinones. 
It was recognised that the simocyclinones contained structural motifs reminiscent of other 
antibacterial agents. The polyketide had a classical aglycone moiety with angularic oxygens and a 
C-glycosidic bond to a D-olivose sugar similar to the napthoquinone aquayamycin; the unsaturated 
tetraene linker was known to be present in the antibiotic fumagillin and the chlorinated 
dihydroxylated coumarin was present in the aminocoumarin antibiotic chlorobiocin.167,168 Thus, the 
simocyclinones themselves are considered natural product hybrids.  
The simocyclinones were isolated from a Streptomyces genus. This was founded on the 
composition of the peptidoglycan layer of the bacteria, morphology, pigmentation and sporulation 
characteristics. Analysis of carbon utilisation allowed strain Tü 6040 to be differentiated from S. 
naganishii and assigned as a S. antibioticus species. This was in accordance with standardised 
procedures for the chemotaxonomic classification of Streptomyces.169 This first report of the 
simocyclinones also evaluated their biological activities. The authors found that as well as activity 
against Gram-positive bacteria, SD4 and SD8 could cytostatically inhibit cancer cells. Inhibition of 
growth in MCF-7 (breast cancer) cells occurred with an IC50 of 5.6 µM, 0.95 µM respectively. 
Additionally the IC50 for HMO-2 (gastric cancer) cells was 0.3 µM, 0.5 µM respectively.  
1.20 Fermentation and classification of simocyclinones  
 
Figure 26. Classification of simocyclinones A-D. 
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 A1 B2 C2 C4 D6 D4 D8 D7 
R1 H OH OH OH OH OH OH H 
R2 - H H COCH3 H COCH3 COCH3 COCH3 
R3 - - - - H H Cl Cl 
Table 2. Classification of simocyclinones A-D. 
Investigation of the medium composition on antibiotic production contributed interesting results. A 
combination of glycerol and L-lysine or L-arginine produced the highest yield of SD8 with the 
optimal carbon:nitrogen ratio being 20. Variation of K2HPO4, NaCl and MgSO4 concentrations did 
not affect cellular growth. However, maximum metabolite production occurred at concentrations 
previously reported.166 Variation of the carbon and nitrogen sources allowed for the isolation of 
different structural elements of the simocyclinones. The authors categorised the structural motifs 
into four series from A-D (Figure 26 & Table 2). Confusion may arise because the nomenclature 
used to describe the contiguous rings of the polyketide is also denoted from A-D. Attention is drawn 
to the polyketide A1, which could only be isolated from a combination of mannitol and L-lysine. 
Additionally the linker, sugar, polyketide fragment (SC4) was solely isolated when grown in the 
presence of glycerol and L-arginine.170 
Later investigations showed the addition of NaCl shifted the production of metabolites towards 
SD8. Conversely use of NaI exclusively constructed the dechlorinated SD4 analogue. This early 
work formed the foundation to the pioneering exploitation of S. antibioticus as a tool to produce new 
analogues for antibacterial screening. Moreover, the elucidation of different constituent 
intermediates of SD8 meant predictions about the biosynthetic pathways involved could start to be 
made.  
1.21 Structural elucidation of SD4 and SD8 
SD4 and SD8 were later fully assigned based on 1H NMR, 13C NMR, COSY and HMBC.171 
Although elemental analysis and MS confirmed the number of carbons as 46 for SD4 and SD8, the 
quaternary epoxide carbon 12a was not observed in NMR experiments. The authors attributed this 
phenomenon to parameters of the NMR experiments that made it unfavourable to measure this 
signal (Kalinowsk, H. O.; Berger, S.; Braun, S.; 1984 cited Holzenkämpfer, M.; Walker, M.; Zeeck, 
A.; Schimana, J.; Fiedler, HP., 2001). 
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An alternative to a distortionless enhancement by polarisation transfer (DEPT) experiment, an 
attached proton test (APT) was used to differentiate between carbons of the simocyclinones. Unlike 
DEPT, which supresses quaternary signals after multiple acquisitions, the APT displays these as a 
negative signal. The APT experiment showed the polyketide contained two carbonyl groups as 
indicated by the largely downfield chemical shifts and negative signals. The APT results 
differentiated between the aromatic carbons and the carbons attached to oxygen. The methyl group 
appeared as a distinctive positive signal in an upfield region. In contrast, the two CH2 groups 
appeared as negative signals alongside the quaternary carbons. The sugar was identified as β-D-
olivose via a combination of coupling constants and homonuclear correlation spectroscopy (COSY) 
analysis as the aglycone moiety at the anomeric centre is above the plane of the sugar. Ester 
groups mask the 3’ and 4’-OH groups, HMBC revealed through bond coupling of the C1” carbon of 
the tetraene linker to the 3’-axial proton of the β-D-olivose sugar confirming the presence of an 
ester linkage. Due to restricted rotation around the C=C bonds of the tetraene linker each double 
bond carbon is attached to a univalent carbon. Thus, the fixed geometrical configuration of the 
double bonds can be assigned. The 3J value of 15 Hz signifies an all-E stereochemistry. In 
contrast, if a Z configuration were present a smaller 3J value would have been observed. Lastly, a 
coumarin chromophore is the only arrangement possible whereby the 13”-OH can be chelated from 
the carbonyl of the linker. This structure was also supported by the upfield signal of the quaternary 
C12”. As a secondary substantiation, the chemical shifts of the coumarin were concordant with 
values of novobiocin. The 13C NMR for SD4 and SD8 are identical except for the replacement of a 
protonated carbon for a quaternary signal. A more deshielded position characteristic of a halogen, 
is present in SD8.  
1.22 Radiolabelled feeding experiments 
Studies had suggested the angucyclic core could be synthesised from acetate. Additionally 
classical angucyclinones were postulated to be derived from decaketides initiated by acetyl-CoA 
and elongated by 9-malonyl-CoA units. Radiolabelled feeding experiments had shown the side 
chain of fumagillin could be produced from acetate. However, acetate itself was known to abolish 
the production of simocyclinones. Consequently malonic acid-2-13C, malonic acid-1,3-13C2 were 
used instead to probe the biosynthetic pathways. As predicted, when fed to S. antibioticus, 
radiolabelled carbon was present in both the polyketide and linker. Further experiments with L-
tyrosine-13C illustrated exclusive incorporation into the aminocoumarin scaffold.  
1.23 SD8 a novel mode of action 
The simocyclinones were compared with novobiocin by varying the concentration of ATP in a 
supercoiling assay. At low ATP concentrations novobiocin showed strong inhibition, conversely at 
high ATP concentrations inhibition was abrogated. In contrast, SD8 had no change in its IC50 with 
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varying ATP, illustrating that its effect is independent of competition with ATP for binding. 
Interestingly, DNA-dependent ATPase activity, which is stimulated in the presence of DNA, was 
prevented by SD8, whereas DNA independent ATPase activity remained unaffected.172 A ten-fold 
increase in IC50 value for SD8 was observed with a quinolone resistant mutant gyrase.172,173 The 
Ser-83 to Trp point mutation on GyrA occurred in a region thought to be adjacent to the site of DNA 
cleavage (Heddle, J. G.; Barnard, F. M.; Wentzell, L. M.; Maxwell, A.; 2000 cited Flatman et al 
2005).172 Concomitant resistance to SD8 and ciprofloxacin indicated the involvement of this area in 
SD8 binding. Importantly, while the quinolones stabilised DNA after cleavage, no such observations 
were found with SD8. Furthermore, it was shown that SD8 could prevent ciprofloxacin and Ca2+ 
induced cleavage of supercoiled DNA. Surface plasmon resonance (SPR) showed SD8 blocked the 
association of DNA to the gyrase enzyme. Subsequent analysis with a GyrB43 subunit showed no 
interaction. Additionally, only a small response was elicited from GyrA59. The authors attributed the 
lack of response in GyrA59 as a limitation that arose from the SPR experiment not being 
representative of what occurs in solution.  
ITC was used as a supplementary experiment, unlike the SPR data, ITC showed an interaction 
between SD8 and GyrA but not for GyrB. A binding constant of 50 to 100 nM indicated a 1:1 
stoichiometry. These results suggested two molecules of SD8 bind to each A2B2 heterotetramer in 
solution. To ascertain if SD8 inhibition was unique to DNA gyrase, assays were performed on the 
closely related topoisomerase IV (topo IV) and eukaryotic topoisomerase I, II (topo I, topo II). No 
inhibition was observed with topo IV or topo I at 40 µM. However strong inhibition was seen in topo 
II decatenation concordant with earlier observations of a cytostatic effect on tumour cells.166 In 
contrast, both aminocoumarins and quinolones acted on topo IV. This work was later expanded to 
show SD8 was a potent catalytic inhibitor of human topo II in vitro, against non small cell lung 
cancer (NSCLC) and mesothelioma (MM).174 Unlike other inhibitors such as etoposide, which form 
a DNA-drug-enzyme ternary complex preventing strand religation, analogous to ciprofloxacin’s 
effect on gyrase, SD8 did not induce DNA cleavage. Subsequent efforts demonstrated that high 
concentrations of SD8 (100 µM) could inhibit topo I in relaxation assays.175 Similar to topo II, this 
did not induce cleavage. The concentrations at which inhibition were observed were higher than the 
original 40 µM investigated.172 As previously noted, no relaxed topoisomers were visible at 50 µM. 
This raises an interesting unanswered question as to how SD8 exerts its affect on topo I, due to the 
fact it does not share structural similarity with type II topoisomerase enzymes.  
1.24 Crystal structure of SD8 bound to N-terminal GyrA59  
The first crystal structure of SD8 bound to an N-terminal fragment of GyrA59 from E. coli at a 
resolution of 2.6 Å was published in 2009.176 This structure showed GyrA59 dimers bound to four 
SD8 molecules. The data showed that two distinct pockets existed on the GyrA59 subunit; an 
aminocoumarin pocket and a polyketide pocket. No conformational change to the enzyme was 
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observed after subtracting the ligand-bound structure from the unbound breakage-reunion domain 
of gyrase.177 While two SD8 molecules had been isolated on each subunit, it was recognised that a 
single SD8 molecule could be modelled in a ‘bent’ arrangement to connect with both the 
aminocoumarin and polyketide pockets on the same subunit at the same time sustaining the 
contacts seen in the crystal structure (Figure 27 & 28). Analytical ultracentrifugation was used as a 
method of quantitative analysis, giving insight into the size of protein in solution.178 When SD8 was 
absent or at low concentrations, the MW of GyrA59 was ~120 kDa, suggesting a dimer. 
Conversely, at high ligand to protein ratios of greater than 4:1, GyrA59 had a molecular weight of 
~250 kDa which would be consistent with a tetramer (Figure 27). These observations were also 
confirmed by nanoelectrospray ionisation mass spectrometry (nanoESI MS) indicating that this was 
not an artefact of the crystallisation process. The full implication of these findings is not yet 
completely understood. 
The crystal structure revealed critical information about intermolecular interactions. Lys42 was 
important for hydrogen bonding interactions with the amide carbonyl group of SD8. Similarly 
Ser172 and Arg91 were hydrogen bonded to the lactone ring carbonyl and the 4’-OH group 
respectively. The Asn165 residue was observed to be hydrogen bonded to the 7-OH group whilst 
the halogen interacted with a Gly170 residue. Non-bonding interactions were attributed to Leu98 
and His45 with the aromatic ring of the coumarin. The polyketide portion was seen to be associated 
with Mg2+ ions complexing with the OH groups of the A, C and D ring. Lastly, hydrogen-bonding 
contacts were formed between the ketone of the C ring and the epoxide by arginine residues 
(Figure 28). 
 
Figure 27. SD8 bound as two separate molecules (red) on each subunit (yellow). A single SD8 
molecule bound in a ‘bent’ conformation (green) with Magnesium counter ions as spheres.176  
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Figure 28. Key bonding interactions for SD8 bound in a ‘bent’ conformation. Dashed black bonds 
represent hydrogen bonding, dashed blue lines represent magnesium co-ordination, solid red lines 
represent hydrophobic interactions, solid blue circles are shown for water molecules.176 
Accompanying investigations were performed with spontaneous resistant E. coli mutants with a 
permeable strain (NR698) that possessed a deletion in the increased membrane permeability gene 
(imp). The authors found 31 mutants, with 22 containing mutations to the gyrA region. The other 9 
isolates were resistant to bile salts and consequently postulated to have secondary site mutations 
which had restored their imp function; thus they were not explored further.179 All of the amino acid 
changes were in residues in close proximity to the purported binding site of SD8 based on the 
crystal structure data. Based on these findings the authors performed selected site directed 
mutations in GyrA59. Mutation to the aminocoumarin pocket at His45 or Arg91 or the polyketide 
pocket at His80 and Gly81 had a detrimental affect on supercoiling. Moreover, mutation to H78A on 
the polyketide produced an inactive enzyme; SPR showed a reduced affinity of SD8 for the mutant 
over the wild type. Circular dichroism (CD) demonstrated that the enzyme was correctly folded with 
a near identical spectrum obtained for the mutant and wild type. It is noteworthy that excluding the 
inactive mutant, all mutations to the aminocoumarin or polyketide conferred susceptibility to 
quinolones. Conversely, mutations to the quinolone resistance determining region (QRDR), which 
lies in close proximity to the SD8 binding area, reduced the inhibitory effect of SD8.  
To explore the role of each functional unit of SD8 constituent fragments SC4 and MGD8N2A were 
analysed for their ability to inhibit supercoiling compared to the parent compound IC50 of 0.6 µM 
(Figure 29). Fascinatingly the individual fragments of SD8 showed only modest inhibition in 
supercoiling assays at 70 µM and 50 µM respectively. This indicated that while both functional 
groups could exert modest inhibition individually, when combined they had a synergistic effect 
resulting in potent inhibition. An eloquent example of nature’s own fragment based drug.  
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Figure 29. Structures of constituent fragments of SD8. 
1.25 Mass spectrometry studies into SD8 binding 
As a complementary technique to investigate SD8 binding, mass spectrometry was employed. 
Nano electrospray ionisation (nanoESI) mass spectrometry of the Gyr59-SD8 complex supported 
previous findings that a stoichiometry of 1:1 SD8 ligand:subunit exists at pharmacologically 
relevant concentrations.180 Tetramer formation was also seen when a large molar excess of SD8 
was used, consistent with previous observations from the original crystal structure of SD8 binding. 
Interestingly, the data indicated a preference for SD8 molecules to bind as a pair to one GyrA dimer 
(Figure 30 c) even at low concentrations rather than one molecule binding (Figure 30 b) to one 
subunit of a dimer. This preference indicated positive cooperativity in binding. Statistically, it is 
more likely that occupancy of independent sites would bind in a manner depicted in Figure 30 (b), 
particularly at low concentrations.  
 
Figure 30. SD8 occupancy of Gyr59 dimer. (a) represents an unoccupied Gyr59 dimer, (b) one 
molecule of SD8 bound to one subunit of a dimer, (c) two SD8 molecules bound to the same dimer. 
Adapted from Edwards et al 2011.180  
Deployment of the fragments SC4 and MGD8N2A revealed a difference in affinities, with the 
polyketide having a 5 fold greater binding affinity compared to the aminocoumarin. However, there 
is no enhancement observed when the individual fragments were used concomitantly. 
Consequently it can be unequivocally stated that the tight binding of SD8 is a consequence of both 
fragments being linked together as a single molecule. This was in agreement with the previous 
body of work by the same authors and also supported the hypothesis of SD8 binding in a ‘bent’ 
conformation to occupy sites on the same monomer.  
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1.26 Evidence of binding to Gyrase B  
Circular dichroism (CD) can be a useful technique for studying protein-ligand interactions. Many 
molecules, including proteins, exhibit chirality in their structure. CD measures the difference in 
polarised light that has been passed through a solution of the molecules of interest. When a ligand 
or small molecule binds to the protein of interest it can induce a conformational change, this causes 
a change in the CD signal termed an “induced circular dichroism” (ICD). However, if no structural 
perturbation occurs then there is no change in the CD signal.181 The addition of SD8 to 
reconstituted gyrase (A2B2 heterotetramer) showed no significant changes in the 200-250 nm 
range, indicating a distinct lack of conformational change to the enzyme structure upon SD8 
binding.182 Similarly when SD8 was added to individual GyrA, GyrA59, GyrB and GyrB43 no ICD 
was observed in agreement with the A2B2 behaviour.  
To further probe SD8 interaction, protein thermal stability experiments were performed with 
ciprofloxacin, SD8, novobiocin and adenylyl imidodiphosphonate (ADPNP), a non-hydrolysable 
form of ATP. Ciprofloxacin was the only compound that was able to shift the Tm of GyrA as 
previously noted.183 As expected ADPNP and novobiocin, which are known to bind to the B subunit, 
also failed to give an increased Tm for the GyrA and GyrA59 proteins. In contrast, SD8 modestly 
increased the Tm at low concentrations (10 µM) by 5.5 °C. When the concentration of SD8 was 
plotted against Tm, a sigmoidal curve was obtained indicating two molecules of SD8 having a co-
operative effect, supporting previous observations. More surprisingly, all the ligands except for 
ciprofloxacin showed a concentration dependent increase on GyrB Tm. There were differences 
observed in the shifts, the Tm with ADPNP was entirely dependent on magnesium ion concentration 
whereas novobiocin and SD8 effects were independent of the Mg2+ concentration. An interaction 
for SD8 was only found at the C-terminal domain of GyrB47 and showed a stabilisation of its 
natural conformation This contrasted with the GyrB43 N-terminal domain where no effect was 
seen. It is important to note that the GyrB47 C-terminal domain does not contain the ATP or 
coumarin-binding site but instead is involved in DNA binding. This was substantiated with 
proteolytic cleavage assays using trypsin in which SD8 delayed the appearance of a 25-kDa 
degradation product of the C-terminal fragment.  
The changes in Tm in the simultaneous presence of multiple ligands gave further insight into the 
respective binding domains of each compound. Novobiocin showed an ability to displace GyrB-
ADPNP complex. When ADPNP was added to a GyrB-SD8 complex an increased thermal shift that 
was larger than the Tm of each individual ligand was noted. This signified a synergistic stabilisation 
of the subunit. Similar results were obtained with the addition of novobiocin to GyrB-SD8 complex. 
The same was true for a GyrB-novobiocin complex when SD8 was added. The authors then 
switched their attention to observing these effects on supercoiling. ADPNP and novobiocin both act 
to prevent the association of ATP to the gyrase B subunit, denying the release of energy from the 
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hydrolysis of the sugar phosphate backbone. This abolishes the enzymes ability to introduce 
negative supercoils into the bacterial DNA. The two ligands are unable to block the ATP-
independent relaxation of supercoiled DNA. However, because SD8 can block the binding of DNA, 
it can abolish both supercoiling and relaxation of DNA. No effects were seen on the inhibitory 
activity of SD8 when either ADPNP or novobiocin were used simultaneously. Consequently, this 
body of work demonstrated the binding sites for aminocoumarins and SD8 are distinct. The authors 
concluded, based on the data indicated by the melting experiments, that SD8 has a higher affinity 
for GyrA over GyrB. Interestingly, the overall increased melting point is more pronounced for the full 
A2B2 tetramer of gyrase than the individual subunits, indicating two interaction events contributing 
to the observed activity. The overall implications of two binding sites for SD8 are not fully 
understood and further investigation is required to elucidate the full mode of action.  
1.27 A new crystal structure gives fresh insight into SD8 binding 
In 2014 a new crystal structure was obtained that consisted of SD8 bound to a N-terminal 55-kDa 
fragment.184 The purpose of the shorter gyrase fragment was to obtain a crystal structure with SD8 
bound in way that was more representative of its binding in solution at low concentration. The key 
differences between this fragment and its predecessor, GyrA59, were that 10 of the 12 amino acid 
residues recognised as stabilising the tetramer at dimer-dimer interface were missing as well as the 
N-terminal alpha helix. CD spectra and ITC of the new 55-kDa GyrA fragment supported previous 
data obtained from the GyrA59 fragment indicating that the new truncated gyrase had formed the 
correct tertiary protein structure. Strikingly, the conformation of SD8 in the crystal structure of the 
Gyr55-SD8 complex was different to the previously published structure. The structure revealed SD8 
bound within one homodimer with the polyketide spanning two GyrA55 monomers. Hydrogen 
bonding occurs from Met120 of an adjacent monomer as well as direct hydrogen bonding from 
His80 and Gly81 (Figure 31). Indirect bonding via water comes from Pro79 and Asp87. The 
aminocoumarin pocket was fundamentally the same as previously reported.176 However, the 
orientation of the coumarin in the pocket was different. The key residues implicated in both crystal 
structures are Lys42 hydrogen bonding to the carbonyl group of the lactone, Ser172 hydrogen 
bonding to the 4-OH group and Arg91 hydrogen bonding to the exocyclic carbonyl group of the 
lactone ring. Hydrophobic contacts from Val44 and His78 were now apparent as well as hydrogen 
bonding from His80 to the ester of the tetraene linker.  
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Figure 31. New crystal structure data for SD8 binding to a 55-kDa fragment, the amino acid 
residues that are present in both crystal structures but their orientation is different are highlighted 
with red arrows.184 
Previously, mutation data for the GyrA59-SD8 complex was not completely understood. The new 
crystal structure helped to illuminate some of the formerly unanswered questions. Substitutions at 
the Arg32 and Arg47 residues were initially identified as important for binding the polyketide 
terminus. However, no changes were observed for these mutants as indicated by supercoiling 
assays and surface plasmon resonance compared to the wild type. The new orientation indicates 
that two arginine residues are away from the polyketide scaffold, showing they are not involved in 
binding. In contrast, changes to Gly81 and Asp87 bestowed resistance with no obvious explanation 
as to the residues responsible for this in the GyrA59-SD8 complex. This new structure shows the 
epoxide of SD8 hydrogen bonds to Gly81 and water hydrogen bonds to a hydroxyl group via 
Asp87, thus providing an answer to this mystery.  
To confirm the authenticity of the new GyrA55-SD8 complex, three further mutants were created 
and tested. Changes were made at the Lys42 residue in the aminocoumarin pocket, Met120 in the 
polyketide pocket and the Ala85 residue in the α-helix 4 that runs parallel to the tetraene linker. As 
predicted, the mutations to the aminocoumarin and polyketide binding site dramatically altered 
susceptibility to SD8 (50 fold and 60 fold respectively). Interesting to note is that the increased α-
helix 4 had no effect on activity, the authors concluded that it must adopt a conformation that does 
not interfere with binding. Crucially, this new structure illustrated that SD8 positions itself to “staple” 
the dimer interface closed and prevent the DNA gate from opening, which is a necessary step for 
allowing DNA binding and strand passage to occur. The α-helix 4 residues are held in place by the 
hydrogen bonding occurring from the polyketide. Furthermore, the catalytic tyrosine residue 
responsible for DNA ligation cannot arrange itself in the correct position due to preclusion by the 
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polyketide. The aminocoumarin contact at Arg91 would prevent the stabilisation of DNA during 
association between the DNA and the enzyme (Figure 32). Lastly, ITC experiments agreed with 
previous work, that a 1:1 stoichiometry occurred in vitro upon the addition of SD8 to GyrA55.  
 
Figure 32. Superposition of the DNA gates of GyrA55-SD8 (blue) and S. aureus GyrA-DNA-
GSK299423 (ligand not shown, yellow).184  
1.28 Significance of the polyketide  
In 2015 a new simocyclinone derivative termed “7-oxo-SD8” was isolated from investigations into 
the function of the SimC7 enzyme (Figure 33).185 Due to difficulties in creating mutants of S. 
antibioticus, the authors cloned the sim gene cluster and analysed it in a heterologous system 
using S. coelicolor M1152 as the host.  
 
Figure 33. Structure of 7-oxo-SD, the different substituent to SD8 is highlighted in red. 
This advantageously gave a simplified metabolite profile and improved production of secondary 
metabolites. Strikingly, an in-frame deletion of the SimC7 gene resulted in a novel simocyclinone 
being produced. The new compound had a different retention time, as assessed by HPLC to SD8. 
Assessment using high-resolution mass spectrometry and NMR confirmed the compound 
contained a ketone at the C7 position of the polyketide instead of an OH group. Thus, it transpired 
the true function of SimC7 is as a NAD(P)H-dependent ketoreductase. To test this hypothesis, His-
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tagged SimC7 in E. coli was purified and incubated with 7-oxo-SD8. This readily converted into 
SD8 using NADH or NADPH for the reduction. Of more significance is the consequential effect 
seen on biological activity. To test for 7-oxo-SD8’s ability to inhibit bacterial growth, a permeable 
strain of E. coli NR698 was used. This contains an in-frame deletion in the increased membrane 
permeability (imp) gene. Without this mutation the simocyclinones cannot penetrate into Gram-
negative bacteria. SD8 exhibited an IC50 of 0.3 µM, in contrast the bacterial strain continued to 
grow in the presence of 7-oxo-SD8 up to a concentration of 17.5 µM. This indicated the binding of 
the 7-oxo-SD8 had been compromised. Supercoiling assays substantiated the in vivo data, 
showing 7-oxo-SD8 had an IC50 of 50-100 µM, contrasting with the normal 0.1-0.5 µM for SD8. 
Similarly, much higher concentrations of 7-oxo-SD8 were required for cleavage stabilisation to be 
observed. SPR was only able to detect non-specific binding to gyrase, confirming the abrogation in 
activity. The authors predict the reduced activity is due to an inability to hydrogen bond with Arg121 
and Pro79, mediated via a water molecule as indicated by the GyrA55 crystal structure (Figure 
31).184 Furthermore, the adjacent phenolic OH would be expected to have reduced binding to His80 
an important amino acid for polyketide binding. This study eloquently highlights the importance of 
the polyketide for the potent action of SD8.  
1.29 Fragment based drug design  
Traditionally methods such as high throughput screening (HTS) or combinatorial chemistry have 
been used to screen large libraries of compounds in order to identify potent hits that can be taken 
forward for development.186 Furthermore, the use of in silico ligand screening can help to 
streamline the number of compounds required for analysis and inform decision making as to 
potential lead compounds.187 Imatinib (Gleevec), a tyrosine-kinase inhibitor serves as an example 
of the successes that can be achieved by employing these methods in drug design. Despite 
development of these technologies, the attrition rates of novel chemical entities remain high.188,189 
Fragment based drug design (FBDD) is an alternative method whereby low affinity fragments are 
identified during screening and used to optimise lead drug design. Its founding principles are that a 
drug can be considered a function of its different binding fragments.190,191 The advantages over 
HTS are a more diverse chemical space can be covered and ligand efficiency can be improved. 
HTS often focuses on large MW compounds with potent activity, however this has not always 
proved fruitful as the average MW of a drug decreases at each checkpoint towards coming to 
market.192 Conversely, FBDD uses relatively low MW fragments typically in the 140-300 Da 
range.193 This is in accordance with ligand efficiency that suggests the energy contributed by each 
ligand atom to the overall binding energy is inversely proportional to the MW.193,194 With this in 
mind, FBDD serves as a useful method for developing potential novel inhibitors of DNA gyrase by 
exploring the inhibition with different low molecular weight fragments. 
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1.30 Aims of the study 
The structure of SD8 and the body of literature investigating its bi-functional mode of action indicate 
two key binding pockets. These are well defined, with evidence from both x-ray crystallography and 
mutational data. Crucially, synergy from both fragments is fundamental for the observed potent 
activity. Having outlined the need for new antibiotics, the biological importance of DNA topology, 
and the validity of DNA gyrase as a therapeutic target, the aims of this study are as follows: 
1. To make synthetic efforts towards constructing the chlorinated dihydroxylated coumarin 
chromophore present in SD8 as well as developing and validating a viable pathway for 
synthesis of the polyketide scaffold (Figure 34 red and green highlighted areas).  
 
2. To synthesise a range of 3-aminocoumarin compounds with increasing steric bulk at the 3’-
position. Subsequently evaluate their potential as small molecule, low affinity fragments for 
inhibiting activity of DNA gyrase using established supercoiling assays as a measurement 
of activity (Figure 34 blue highlighted areas) 
 
3. To synthesise a coumarin-quinolone hybrid and investigate its biological activity. This 
would be achieved by combining an identified low affinity coumarin ligand and coupling it to 
the established quinolone ciprofloxacin as an example of a fragment based approach to 
developing new inhibitors (Figure 34 highlighted in orange).  
 
Figure 34. Aims of the study: chlorination of the coumarin (red), synthesis of aminocoumarins 
(blue) and synthetic efforts towards the polyketide (green) and construction of coumarin hybrids 
(orange).  
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The generation of the aminocoumarin (AC) and polyketide (PK) moieties of simocyclinone D8 
(SD8) is synthetically challenging. Despite the isolation of SD8 over a decade ago, successful 
synthetic methodologies for the compound have not been reported. This has justified the 
exploration and development of viable procedures to synthesise both constituent fragments. This 
work was undertaken to investigate the contribution, if any, of the chlorinated AC chromophore on 
DNA gyrase inhibition. Furthermore, this would facilitate synthetic access to other analogues such 
as chlorobiocin, for which no total synthesis has yet been described. Consequently, this work would 
contribute to the overall total synthesis of two natural products. This chapter introduces the 
coumarin chromophore and describes efforts towards the synthesis of the chlorinated 
dihydroxylated AC found in SD8. Additionally, it investigates the use of a Diels-Alder methodology 
to generate the polyketide scaffold.   
2.1 Coumarin and related heterocycles 
The word coumarin finds its etymological origin from ‘cumaru’ the indigenous name for Dipteryx 
odorata, a tree native to South America.195 It is the tonka bean seeds produced by the tree from 
which the compound was first extracted in the 19th century.196,197 Coumarin and chromone are 
examples of plant-derived oxygen-containing heterocycles that belong to the benzopyrone family. 
Structurally the parent benzopyran core termed a chromene scaffold by the International Union of 
Pure and Applied Chemistry (IUPAC) consists of an aromatic benzene ring fused to either a 2H- or 
4H-pyran ring system (Figure 35).198 
 
Figure 35. Numbering of 2H-chromene 9, 4H-chromene 10, 1H-isochromene 11, 3H-isochromene 
12, coumarin 13 and chromone 14. 
The location of the oxygen atom in the benzopyran core can have two locations, resulting in two 
isomers, chromene (1-benzopyran) 9 and isochromene (2-benzopyran) 11. The numbering denotes 
the position of the oxygen in the six-membered ring (Figure 35). The same nomenclature is used to 
describe architecturally related compounds where the sp3-hybridised carbon, either adjacent or 
opposite to the oxygen, is replaced with a carbonyl group. Substitution at the 2-position results in 
coumarin 13 (2H-chromen-2-one), an α-benzopyrone. Substitution at the 4-position, however, gives 
chromone 14 (4H-chromen-4-one), a γ-benzopyrone and a structural isomer of coumarin (Figure 
35). A distinguishing functional feature of coumarin is the presence of the cyclic ester termed a 
lactone. In contrast, chromone has no such feature.  
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2.2 Classification of coumarins 
Six categories have been described in the literature to classify coumarins: simple coumarins, 
pyranocoumarins, furanocoumarins, dimeric/trimeric coumarins and isocoumarins.197,198 7-
hydroxycoumarin, has been proposed as the parent structure for more complex compounds 
(Keating, G.; O’Kennedy, R.; 1997 cited Lacey, A.; O’Kennedy, R., 2004). Subdivisions of 
compound classification exist which are dependent on the substitution pattern within the framework 
and this is indicated by numbering.199 Assemblies with additional rings are differentiated according 
to the site of fusion and described as either angular or linear.198,200 The structural diversity of 
coumarins means they may come under more than one heading.201 This classification is not 
definitive and will need updating as the field of coumarins progresses.  
2.3 Dihydroxylated coumarins  
 
Figure 36. Target compound 8-chloro-4,7-dihydroxy-2H-chromen-2-one. 
 
Scheme 1. Synthetic methodology to access the dihydroxylated coumarin scaffold.202,203 
The overall goal was to establish a route to the target chloro-substituted AC 15 (Figure 36). In order 
to access this scaffold it was envisaged that an existing procedure could be utilised (scheme 1). 
The first method explored uses an acetyl protected 2,4-dihydroxybenzoic acid 20, which is 
converted into the corresponding acyl chloride 21 and coupled to a tert-butyl carbamate (Boc) 
protected malonate group. Subsequently, the intermediate is cyclised to form the Boc-protected 
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coumarin 23. The Boc group can then be removed using acid to give the corresponding coumarin 
salt 24 (Scheme 1) as previously described.202,203 It was predicted that chlorination of the 
dihydroxylated scaffold 24 or the starting benzoic acid 19 could provide a viable synthetic strategy 
for generating the AC chromophore. The first priority was to validate the previously described 
procedure by repeating the work.  
 
Scheme 2. Synthesis of 1,3-diethyl 2-{[(tert-butoxy) carbonyl] amino} propanedioate. 
Commercially available diethyl aminomalonate 16 can have a carbamate-protecting group 
introduced onto the free amine using Boc2O (Scheme 2).204–206 Compound 17 was isolated as a 
colourless oil. 1H NMR showed a doublet at 7.63 ppm (J = 8.0 Hz) assigned as the nitrogen proton 
and confirmed by HSQC. A doublet at 4.86 ppm was correlated to the 2-H, a reciprocal J value of 
8.0 Hz, confirmed its interaction with the N-H proton. A complex multiplet was observed between 
4.22-4.11 ppm for the CH2 groups, this was ascribed to the free rotation of the sigma bond of the 
Boc protected nitrogen. The integration corroborated this assignment (4 H). A large singlet at 
1.39 ppm (9 H) was confirmatory of the introduction of the Boc group. A triplet at 1.20 ppm 
occurred for the CH3 signals. 13C NMR showed 7 resolved signals. Due to the chemical 
equivalence of the CH2, CH3 and Boc groups. Downfield signals at 166.6 ppm and 155.1 ppm were 
ascribed to carbonyl groups. A triple height signal at 28.0 ppm was attributed to the Boc group. IR 
analysis showed a medium intensity absorption at 3371 cm-1 ascribed as the CON-H stretch. 
Additional absorptions at 2979 cm-1 and 2941 cm-1 were ascribed to the CH3 and CH2 stretches. 
Two strong absorptions at 1745 cm-1 and 1714 cm-1 were assigned as two carbonyl groups. The 
broad peak meant it likely masked one of the unaccounted for carbonyl absorptions. An absorption 
at 1368 cm-1 was attributed to the C-N stretch. Two prominent absorptions at 1182 cm-1 and 
1158 cm-1 were attributed to C-O stretches of both esters. An accurate high-resolution mass of 
276.1442 [M+H]+ was found.  
Saponification of one ester was achieved using a strong base (Scheme 3).202 Compound 18 was 
isolated as a colourless powder. 1H NMR showed a doublet at 7.47 ppm for the N-H proton. The 2-
H signal at 4.71 ppm also appeared as a doublet. The a-H2 signal remained a multiplet between 
4.18-4.10 ppm, but the integration had changed (2 H), indicating the loss of the ethyl group. The 
Boc signal showed as a singlet at 1.38 ppm. An upfield triplet at 1.19 ppm was assigned to the CH3 
of the ester. 13C NMR showed 8 well-resolved signals. The most downfield signal at 167.8 ppm was 
assigned to the C1 of the carboxylic acid. The next most de-shielded signal at 167.3 ppm was 
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ascribed to the C3 of the ester. In contrast, the carbon of the carbamate carbonyl had more 
electron density due to conjugation with the adjacent nitrogen atom and therefore had a more 
upfield signal at 155.1 ppm. IR analysis showed a medium intensity absorption at 3272 cm-1 
assigned to the CON-H stretch. Absorptions at 2980 cm-1 and 2933 cm-1 were ascribed to the CH3 
and CH2 stretches. These overlapped a broad OH stretch of the carboxylic acid. Intense 
absorptions at 1747 cm-1, 1723 cm-1 and 1650 cm-1 were ascribed to the carbonyl stretches. Two 
strong absorptions at 1182 and 1154 cm-1 were assigned to the C-O stretches. An accurate high-
resolution mass of 248.1129 [M+H]+ was found. 
 
Scheme 3. Synthesis of 2-{[(tert-butoxy) carbonyl] amino}-3-ethoxy-3-oxopropanoic acid. 
Commercially available 2,4-dihydroxybenzoic acid 19 can be acetylated to form the key 
intermediate 20. Phenolic OH groups can be deprotonated using an organic base, such as 
pyridine. Nucleophilic attack of acetic anhydride by the phenoxy anion will acetylate the 
corresponding OH groups. DMAP is often included as a catalyst to facilitate the reaction. This step 
was found to be troublesome, as cited in the literature. Often a mixture of mono or di-acetylated 
product would be obtained. 1H NMR illustrated a progressive loss of an acetyl singlet over a 24 h 
period. A corresponding increase in an acetic acid peak is also noted. Consequently, and in 
subsequent reactions the mixture was covered to protect it form light exposure.  Additionally, the 
acetic anhydride was added dropwise to limit the release of exothermic energy, minimising the 
degradation of the product, facilitating the near complete conversion into the desired product 
(Scheme 4).  
 
Scheme 4. Synthesis of 2,4-bis(acetyloxy) benzoic acid. 
Compound 20 was isolated as an off white powder. 1H NMR showed a broad singlet at 13.13 ppm 
for the carboxylic acid peak. A doublet at 7.92 ppm was attributed to the 6-H proton, and a doublet 
of doublets at 7.18 ppm to the 5-H position. A doublet at 7.08 ppm was ascribed to the 3-H proton, 
a J value of 2.4 Hz, indicated meta coupling. Two upfield singlets at 2.29 ppm and 2.24 ppm were 
ascribed to the acetate CH3 groups. 13C NMR showed 11 resolved peaks, signals at 168.9 ppm, 
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168.6 ppm and 164.9 ppm were indicative of the three carbonyl groups. The upfield signals at 
20.8 ppm and 20.7 ppm were ascribed to the CH3 groups of both acetates. IR analysis showed 
medium absorptions at 2981 cm-1 and 2941 cm-1 attributable to CH3 stretches. Absorptions at 
2645 cm-1 and 2539 cm-1 were ascribed as aromatic C-H stretches. Three prominent signals at 
1773 cm-1, 1681 cm-1 and 1607 cm-1 were assigned to the carbonyl stretches. A high-resolution 
accurate mass of 237.0405 [M-H]- was observed.  
Subsequently, the acetylated benzoic acid was refluxed in thionyl chloride and anhydrous DCM to 
generate the corresponding acyl chloride 21 (Scheme 5). The sulfur atom is electron-deficient due 
to the electronegativity of the chlorine atom. Nucleophilic attack of the chloride on 20 c leads to the 
formation of an unstable tetrahedral intermediate 20 d which then decomposes to generate the acyl 
chloride 21. This reaction is not in equilibrium as HCl and SO2 gas are generated as side products 
which are lost from the reaction mixture, and therefore is entropically favourable (Scheme 6).  
 
Scheme 5 Synthesis of 3-(acetyloxy)-4-(carbonochloridoyl) phenyl acetate. 
 
Scheme 6. Mechanism of acyl chloride formation. 
The acyl chloride 21 was carried directly forward into the next reaction and added to a solution of 
Boc protected malonate 18 in anhydrous THF to form intermediate 22 (Scheme 7). The predicted 
mechanism is shown in Scheme 7. The acidic proton at the 2 position of the malonate 18 a is 
removed by an organic base, such as triethylamine. Consequently, a negative charge can resonate 
through the carbonyl group. The magnesium cation likely co-ordinates the negative charge onto the 
oxygen atom in intermediate 18 b. Addition of the acyl chloride 21 permits a nucleophilic 1,4-
conjugate addition to occur. Subsequently, an acidic work up generates the desired compound 22. 
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Scheme 7. Conjugate addition to acid chloride. 
The intermediate 22 was not purified but used crude in the next reaction by adding it to a solution of 
NaOH in methanol. The strong base was predicted to remove an acetate group, forming a 
phenoxide anion intermediate 22 b (Scheme 8). The lone pair of electrons is free to attack the 
carbonyl group of the nearby ester to form the lactone ring 22 c. Protonation of the carbonyl group 
in the 4-position is likely to be driven by the resultant thermodynamically favourable α,β-conjugation 
within the coumarin ring 23 (Scheme 9).  
 
Scheme 8. Synthesis of tert-butyl N-(4,7-dihydroxy-2-oxo-2H-chromen-3-yl) carbamate. 
 
Scheme 9. Synthesis of tert-butyl N-(4,7-dohydroxy-2-oxo-2H-chromen-3-yl) carbamate. 
Aminocoumarin 23 was reacted with ethereal HCl to remove the tert-butyl protecting group. This 
worked well to remove impurities that had been carried forward, as assessed by TLC. The desired 
compound 24 was isolated as an orange brown precipitate (Scheme 10). 1H NMR of compound 24 
showed a downfield doublet at 7.88 ppm (1 H) that correlated to the 5-H, followed by a doublet of 
doublets at 6.90 ppm ascribed to the 6-H (J1 = 8.8 Hz, J2 = 2.4 Hz, 1 H). The reciprocal J values 
confirmed the ortho coupling to the 5-H and meta coupling to the 8-H that appeared as a doublet at 
6.77 ppm (J = 2.0 Hz). 13C NMR showed 9 resolved peaks as expected. Signals at 126 ppm, 
115 ppm and 104 ppm were all protonated as shown by HSQC and were therefore assigned as the 
C5, C6 and C8 signals respectively. IR analysis showed two broad absorptions at 3345 cm-1 and 
2929 cm-1 assigned as the two OH groups. This was likely masking the N-H stretch. A strong 
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absorption at 1710 cm-1 was attributed to the carbonyl group of the lactone. An absorption at 
1639 cm-1 was ascribed as N-H bending. Medium absorptions at 1564 cm-1 and 1526 cm-1 were 
attributed to C=C aromatic stretches. A high-resolution accurate mass of 192.0303 [M-H]- was 
observed. 
 
Scheme 10. Synthesis of 4,7-dihydroxy-2-oxo-2H-chromen-3-aminium chloride. 
2.4 Sodium hypochlorite as a chlorinating agent 
A key feature of the AC found in SD8 and chlorobiocin is the presence of a chlorine substituent in 
the 8-position. A key objective of the work in this chapter was to develop a viable route to correctly 
place this substituent within the AC framework. The ease of handling and cheap cost of NaOCl 
made it an attractive reagent, compared to alternatives such as Cl2 and N-chlorosuccinimide 
(NCS). Sodium hypochlorite reacts with water (Equation 3) to generate hypochloric acid (HOCl) and 
sodium hydroxide (NaOH). 
 
 
Equation 3. Formation of hypochloric acid and dissociation into hypochlorite anion. 
Hypochloric acid has a pKa of ~7.5, therefore under basic conditions equilibrium will be driven 
towards the dissociation of the proton from the hypochlorite anion (-OCl).207,208 Consequently, only 
a small proportion of hypochloric acid will be free for reaction at any given time. Crucially, this 
allows for control of the chlorination process. In contrast, no such control exists when using Cl2 as a 
chlorinating agent and this is a disadvantage of this alternative methodology. Control was 
necessary to prevent chlorination occurring at multiple sites on the coumarin ring. Hypochloric acid 
will react with a nucleophile allowing electrophilic substitution of an aromatic ring to take place. The 
AC found in SD8 contains two hydroxyl moieties. It was theorised the ortho and para-directing 
effect, of the OH groups, could be used to introduce the halogen in the desired location.  
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Scheme 11. Attempted synthesis of 8-chloro-4,7-dihydroxy-2-oxo-2H-chromen-3-aminium chloride. 
Several attempts were made to chlorinate coumarin 24 directly in the 8-position using sodium 
hypochlorite and basic conditions to obtain compound 25 (Scheme 11).209 The reaction produced 
multiple spots by TLC with no major product spot. Attempts to purify the mixture by flash column 
chromatography failed to yield the desired product. It was theorised the strong oxidising conditions 
were responsible for the multiple reaction products observed by TLC. Similarly, attempts were 
made to chlorinate the starting reagent of 2,4-dihydroxybenzoic acid (Scheme 12). The two 
hydroxyl groups are ortho and para-directing making the 3-and 5-position the most favourable sites 
for substitution to take place. However, no chlorinated product was isolated. 1H NMR and TLC 
showed a complex mixture of products. 
 
Scheme 12. Synthesis of 3-chloro-2,4-dihydroxybenzaldehyde. 
Successful chlorination of 2,4-dihydroxybenzaldehyde 26 had previously been reported.210 We 
therefore turned our attention to chlorinating an aldehyde derivative and oxidising the compound to 
the corresponding carboxylic acid. This could then, in turn, be used in the previously validated 
dihydroxycoumarin procedure (Scheme 12).209 Compound 27 was isolated as colourless crystals 
after being purified by flash column chromatography and recrystallised from DCM. This two-step 
purification process was necessary as the reaction generated a black “tar” like side product. 1H 
NMR showed a singlet at 9.69 ppm assigned to the aldehyde proton. A doublet at 7.49 ppm was 
ascribed as the 6-H as it was more de-shielded relative to the 5-H. A doublet at 6.59 ppm was 
attributed to the 5-H. 13C NMR showed 7 individual carbon signals. A signal at 195.8 ppm was 
characteristic of a carbonyl, due to its downfield chemical shift. Two further de-shielded signals at 
162.6 ppm and 160.8 ppm were assigned as the C2 and C4 atoms respectively. IR analysis 
showed absorptions at 3294 cm-1 and 3084 cm-1 assigned to the OH stretches. An absorption at 
2878 cm-1 was assigned as an aromatic C-H stretch. A prominent signal at 1618 cm-1 was assigned 
as the carbonyl stretch. A high-resolution accurate mass of 173.0000 [M+H] was found.  
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This side product formation was attributed to the effect of the strong oxidiser, HOCl, which is 
generated in situ. A short reaction time was found to give moderate yields and facilitate efficient 
purification. This is due to limiting the amount of oxidative side reactions that can take place. 
Moreover, the reaction needed to be carefully monitored as over-chlorination was observed which 
resulted in the di-chlorinated benzaldehyde 28 (Scheme 13).  
 
Scheme 13. Synthesis of 3,5-dichloro-2,4-dihydroxybenzaldehyde. 
Compound 28 was isolated as an off white solid. 1H NMR showed a broad downfield signal at 
11.48 ppm ascribed to the OH signal. Unusually, the other OH signal was not visible in the 
spectrum. A singlet at 9.88 ppm was attributed to the aldehyde proton. A singlet at 7.77 ppm was 
assigned to the 6-H proton, as confirmed by HSQC. 13C NMR showed 7 individually resolved 
peaks. A signal at 192.6 ppm was the most downfield in the spectra, and assigned as the carbonyl 
group of the aldehyde. Two signals at 156.9 ppm and 156.1 ppm were attributed to the C4 and C2 
atoms respectively. The signal at 130.8 ppm was assigned as the 6-H, as confirmed by HSQC. IR 
analysis showed no peak for the OH groups, however an absorption at 2941 cm-1 was assigned as 
an aromatic C-H stretch. A strong absorption at 1623 cm-1 was ascribed to the carbonyl of the 
aldehyde. A peak at 741 cm-1 and 714 cm-1 was attributed to the C-Cl stretches. A high-resolution 
accurate mass of 204.9461 [M-H]- was observed, alongside the isotopic m/z pattern of [M+2]+ and 
[M+4]+. The splitting pattern was in a ratio of 9:6:1 indicating the presence of two chlorine atoms. 
The predicted mechanism for chlorination by hypochloric acid is shown below (Scheme 14).   
 
Scheme 14. Proposed mechanism of chlorination by hypochloric acid. 
Chlorination with NaOCl is an example of electrophilic aromatic substitution with the hypochloric 
acid being the active species. The reaction is under basic conditions in order to deprotonate the –
hydroxyl-salicylaldehyde, so that it is soluble in the aqueous reaction mixture. Additionally, 
deprotonation of the phenol groups increases electron density at the aromatic centre. The chlorine 
atom of the hypochloric acid will have a positive molecular dipole due to the lower electronegativity 
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compared to the adjacent oxygen atom 26 a. This allows electrophilic substitution to take place 
ortho or para to the phenol.  The observation of the formation of 27 and 28 support this hypothesis.  
One approach to oxidise an aldehyde into a carboxylic acid is to use peroxide. The use of Cu(II) in 
the presence of peroxide is predicted to occur via a free radical mechanism. It has been reported 
that Cu(II) and H2O2 can react together via a one electron redox process that converts H2O2 into the 
highly reactive free radical species (O2
.-).211 A method for the oxidation of chlorinated aldehydes to 
carboxylic acids had previously been identified. This procedure used a catalytic amount of Cu(II)Br2 
in the presence of tert-butyl hydroperoxide solution.212 A hypothesised mechanism is shown in 
Scheme 15.  
 
Scheme 15. Predicted aldehyde oxidation via a hydroxyl radical mechanism. 
 
Scheme 16. Attempted oxidation to 3-chloro-2,4-dihydroxybenzoic acid. 
The direct conversion of aldehyde 27 into the corresponding carboxylic acid 33 using tert-butyl 
hydroperoxide (LuperoxTM 70%) did not succeed (Scheme 16), with multiple products visible by 
TLC analysis. It has been described that under oxidative conditions, free phenolic OH groups can 
form ortho and para-linked dimeric and polymeric products.213 Thus, a protecting group was 
introduced to prevent the nucleophilic character interfering with the oxidation step. Iodomethane 
was utilised to mask the alcohols as alkyl ethers (Scheme 17). 
 
Scheme 17. Synthesis of 3-chloro-2,4-dimethoxybenzaldehyde.  
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Compound 34 was isolated as a colourless solid. 1H NMR showed a downfield singlet at 10.17 ppm 
for the aldehyde. Two doublets at 7.72 ppm and 6.79 ppm were ascribed to the 6-H and 5-H 
signals respectively. They showed a reciprocal coupling constant of 8.8 Hz. Two singlets at 
3.94 ppm and 3.93 ppm (3 H) indicated the successful methylation of the OH groups. 13C NMR 
showed 9 resolved signals. The successful methylation was apparent with two signals at 63.0 ppm 
and 56.7 ppm for the alkyl ethers of the C2 and C4 atoms. IR showed the presence of ethers with 
two absorptions at 2950 cm-1 and 2869 cm-1 as well as a carbonyl stretch at 1673 cm-1. A correct 
high-resolution accurate mass of 201.0313 [M+H]+ was found. 
 
Scheme 18. Synthesis of 3-chloro-2,4-dimethoxybenzoic acid. 
Compound 35 was isolated as a colourless solid (Scheme 18). 1H NMR showed a carboxylic acid 
peak as a singlet at 12.82 ppm, and a corresponding loss in the aldehyde peak. The carboxylic 
acid was much more deshielded than the parent aldehyde 34. This signified the oxidation had been 
successful. The 6 and 5-H protons appear as two doublets at 7.75 ppm and 6.99 ppm. The two 
methyl groups appear as two singlet’s at 3.90 ppm and 3.80 ppm. 13C NMR showed 9 carbons 
were still present in the molecule. IR confirmed the insertion of the oxygen atom with a broad 
absorption at 2564 cm-1 for the OH stretch. A carbonyl stretch appeared at 1664 cm-1 whilst the two 
C-O stretches occur at 1284 cm-1 and 1221 cm-1 respectively. An accurate high-resolution mass of 
217.0261 [M+H]+ was observed.  
Boron tribromide (BBr3), a strong Lewis acid, was used to remove the methoxy protecting groups 
(Scheme 19). The trivalent boron has an empty p orbital that accepts a lone pair of electrons from 
the oxygen atom of the aryl ether 37 a. This forms an oxonium cation intermediate that can then 
undergo nucleophilic SN2 attack by a bromine anion. An aqueous organic work up generates 
boronic acid and hydrobromic acid as water-soluble side products.  
 
Scheme 19. BBr3 mediated O-demethylation.  
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Scheme 20. Synthesis of 3-chloro-2,4-dihydroxybenzoic acid. 
The desired product 33 was obtained as a colourless solid in good yield (Scheme 20), this key 
intermediate had not been previously described in the literature. 1H NMR showed a doublet at 
7.64 ppm (1 H), assigned as the 6-H because of its more deshielded location, relative to the 
remaining doublet at 6.47 ppm (1 H). Consequently, the remaining doublet at 6.47 ppm was 
assigned as the 5-H. A coupling constant of 8.0 Hz, confirmed the reciprocal ortho coupling to each 
other. The remaining phenolic OH groups and carboxylic acid protons were not visible due to the 
presence of H2O in the deuterated MeOH solvent. 13C NMR showed 7 individually resolved carbon 
signals. The loss of the methyl groups was highlighted by the lack of signals at 61 ppm and 56 
ppm, confirming the deprotection was successful. IR analysis showed a broad signal at 3445 cm-1 
assigned to the O-H stretch. An additional absorption at 3056 cm-1 was ascribed to the carboxylic 
acid O-H stretch. A strong absorption at 1643 cm-1 was representative of the carbonyl stretch. A 
high-resolution accurate mass of 188.9947 [M+H]+ was observed.  
Subsequently, the chlorinated dihydroxylated benzoic acid 33 was subjected to the same reaction 
conditions as 2,4-dihydroxybenzoic acid to acetylate both alcohols. This intermediate was predicted 
to be critical to the reaction pathway. Knowing that the product was unstable and sensitive to light, 
the same procedural modifications were used; namely, protecting the reaction from light and adding 
the acetic anhydride dropwise (Scheme 21).  
 
Scheme 21. Synthesis of 2,4-bis(acetyloxy)-3-chlorobenzoic acid. 
1H NMR showed a doublet at 7.96 ppm ascribed to the 6-H. A more upfield doublet at 7.40 ppm 
was assigned as the 5-H. Two singlets at 2.37 ppm and 2.33 ppm were indicative of the acetate 
groups. The product was labile with rapid decomposition into either mono-acetylated compound or 
the starting material. Therefore, no 13C NMR was obtainable for compound 39. A high-resolution 
accurate mass of 271.0016 [M-H]- was observed. No IR or MP analysis was performed due to the 
instability of the product. Several attempts were made to react the di-acetylated compound 
onwards. However, the harsh conditions of refluxing in SOCl2 were considered inappropriate for the 
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unstable intermediate. To surmount this barrier a switch was made to oxalyl chloride at room 
temperature with a catalytic amount of DMF (Scheme 22). Multiple spots were seen at each step 
with no one major product formation observable by TLC. No Boc protected chlorinated AC was 
isolated.  
 
Scheme 22. Synthesis of tert-butyl N-(8-chloro-4,7-dihydroxy-2-oxo-2H-chromen-3-yl) carbamate. 
The intrinsic instability of 39 likely arises due to the deactivating effect of the chlorine atom. Due to 
the nature of the procedure, whereby the product is assumed to have formed and carried forward 
into each subsequent reaction it is difficult to ascertain which step is problematic. However, it is 
highly likely the instability of di-acetylated 39 means the difficulty is with the acid chloride and 
conjugation to the malonate derivative. If a free OH group is present, then nucleophilic attack to the 
acid chloride in an intermolecular fashion can take place. 
An alternative method for generating the desired chlorinated AC chromophore was explored using 
a 2,4-dihydroxyacetephenone derivative. Previously, this methodology had successfully been used 
to create the 3-methyl-4,7-dihydroxycoumarin present in novobiocin (scheme 23).214 This protected 
one of phenols leaving one unprotected. Subsequently, the authors took advantage of the directing 
effect from the free OH group, to selectively nitrate in the 3-position. The procedure performed a 
simultaneous zinc reduction and acetate protection of the formed amine. It was theorised that the 
starting hydroxy-acetephenone could be chlorinated selectively in the 8-position after the benzyl 
protection step. Subsequently, the product could be reacted onwards to give the chlorinated 
coumarin scaffold. It was predicted the presence of a singular OH group would reduce the 
formation of di-chlorinated product. 
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Scheme 23. Synthetic pathway described for novobiocin.214 
To validate the pathway, 2-hydroxyacetephenone 47 was employed as a model reactant.215 The 
reaction likely relies on a base preferentially deprotonating the acidic phenol. The phenolate anion 
is then able to act as a nucleophile towards the carbonyl group of diethyl carbonate 47 a. Ethoxide 
can act as a good leaving group due to its ability to stabilise a negative charge. A basic species is 
then able to remove an α-H, generating an enolate at the ketone carbonyl 47 c. Subsequently, this 
can attack the carbonyl group of the diethyl carbonate giving the dione 47 f. The acidic proton in 
the 3-position can be removed with a base to generate the conjugated coumarin structure 48. The 
predicted mechanism is shown below (Scheme 24). 
 
Scheme 24 Predicted mechanism for coumarin formation with diethyl carbonate.  
 
Scheme 25. Synthesis of 4-hydroxy-2H-chromen-2-one. 
Compound 48 was obtained as a cream powder in good yield (Scheme 25). 1H NMR showed a 
broad singlet at 12.62 ppm (1 H) assigned as the 4-hydroxyl proton. This was confirmed by HSQC. 
A doublet of doublets at 7.82 ppm was assigned to the 5-H. The remaining aromatic protons 
appeared as multiplets between 7.66-7.62 ppm (1 H) and 7.37-7.32 ppm (2 H). The most 
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deshielded multiplet was assigned as the 6-H, due to the electron distribution within the coumarin 
system. The carbon had through bond coupling to the adjacent 5-H but had no signal for the 8-H, 
confirming the assignment. The 7 and 8-H signals were in similar environments and thus 
overlapped each other. This give a multiplet that was more upfield. A singlet at 5.65 ppm was 
indicative of the 3-H. 13C NMR showed 9 individually resolved carbon signals. The presence of the 
3-H allowed the determination of the C2 through observed through-bond coupling in the HMBC 
experiment. The signal at 161.9 ppm was the only quaternary carbon not visible to protonated 
carbons other than the 3-H. This, therefore, must have been the carbonyl signal. The more 
downfield signal at 165.7 ppm was assigned as the C4. IR analysis showed absorptions at 
2941 cm-1 and 2555 cm-1 ascribed to the aromatic protons. This was overlapped by a broad signal 
at 2896 cm-1 assigned as the OH group. An absorption at 1608 cm-1 was attributed to the carbonyl 
group of the lactone. Three medium intensity absorptions at 1556 cm-1, 1562 cm-1 and 1504 cm-1 
were ascribable to the C=C aromatic stretches. A signal at 1273 cm-1 was assigned to the O-H 
bend. A high-resolution accurate mass of 161.0244 [M-H]- was observed.  
 
Scheme 26. Nitration of 4-hydroxycoumarin. 
A crucial step for introducing the amino group functionality was to nitrate selectively in the 3-
position (Scheme 26). This was found to be difficult to achieve without nitrating the aromatic ring. 
Despite the presence of an OH group to direct electron-density to the 3-position, and help facilitate 
aromatic substitution at this carbon, low yields were obtained. A short reaction time was needed, 
otherwise no product was generated, based on experimental observation. Furthermore, it was 
found that reproducibility was problematic. The optimum conditions developed were stirring for 1 
hour in an ice bath. The nitrating mixture was also cooled to zero degrees and premixed prior to the 
addition to the coumarin. This is an example of electrophilic substitution. The premixing of the 
sulphuric acid with the nitric acid generates the electrophilic nitronium cation 50 c. Subsequently, 
electrophilic attack from the electrons at the C3-C4 position, adds the NO2 group to the C3 carbon 
of coumarin 50 e. The removal of the proton restores conjugation to the system. 
NO2HO NO2O
H
H
+
H2O
O O
OH
N
O
O
N
O
O
O O
O H
NO2
S
O
OHO
O
H
O O
S
OO
HO O
H
OH
NO2
S
O
OHO
O
+ S
O
OHO
HO
50 a 50 b 50 c 50 d
50 e 50 f 51 49
S
OO
HO OH
49
+ HNO3
50
O O
OH
+
48
Chapter 2. Synthetic efforts towards key fragments of SD8 
 
 
 
81 
 
 
Scheme 27. Synthesis of 4-hydroxy-3-nitro-2H-chromen-2-one. 
Compound 51 was obtained as a yellow powder (Scheme 27). 1H NMR showed a doublet of 
doublets at 7.89 ppm ascribed to the 5-H. A deshielded multiplet between 7.55-7.50 ppm was 
attributed to the 6-H. A multiplet at 7.24-7.17 ppm was assigned as the 7 and 8-H protons. The loss 
of a singlet confirmed that nitration had taken place in the 3-position. 13C NMR showed 9 
individually resolved peaks. The most downfield signal at 166.8 ppm was assigned as the C4. Two 
proton signals had through bond coupling to this signal, therefore it was not the C2 of the carbonyl 
group. A signal at 157.3 ppm and 120.7 ppm had no though bond coupling to any other signals. 
These were ascribed to the C2 and C3 respectively. Signals at 132.6 ppm, 125.6 ppm, 123.3 ppm, 
and 116.2 ppm were assigned as the aromatic protonated carbons, as confirmed by HSQC. In the 
preceding parent compound the C3 carbon appeared at 91 ppm, as determined by HSQC. In 
contrast, the product had no such signal. Further confirming the correct product has been obtained. 
IR analysis showed absorptions at 2941 cm-1 and 2555 cm-1 ascribed to the aromatic proton 
stretches. This was overlapped by a broad OH signal. The strong absorption at 1605 cm-1 was 
attributed to the carbonyl group of the lactone. The strong absorption at 1422 cm-1 was ascribed to 
the N-O asymmetric stretch, whereas a strong absorption at 1144 cm-1 was assigned to the N-O 
symmetric stretch. The lower than usual wavenumbers for the asymmetric and symmetric stretch 
was likely a result of enhanced deshielding due to the extended conjugation of the coumarin. 
Having synthesised the model 4-hydroxycoumarin, efforts where focused on taking advantage of 
this route as a means of generating the chlorinated AC scaffold. The first step was to selectively 
protect one phenol. This was achieved by refluxing 2,4-dihydroxyacetaphenone 52 in acetone, in 
the presence of a mild base, with benzyl bromide (Scheme 28). This is an example of an SN2 
nucleophilic substitution reaction. The observed selectivity for the 4-hydroxyl group over the 2-
hydroxyl group is likely due to steric hindrance from the adjacent ketone. Additionally, it is likely that 
the carbonyl group of the ketone is hydrogen bonded to the ortho OH group, consequently 
preventing it from reacting.  
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Scheme 28. Synthesis of 1-[4-(benzyloxy)-2-hydroxyphenyl] ethan-1-one. 
Compound 53 was obtained as colourless crystals (Scheme 28). 1H NMR showed a downfield 
singlet at 12.63 ppm that was characteristic of a phenolic OH group. A downfield doublet at 
7.84 ppm (1 H) was ascribed to the 6-H. A large multiplet occurred between 7.46-7.32 ppm (5 H), 
this was indicative of the benzyl aromatic group. The similar environment experienced by each 
proton resulted in overlapping signals. A doublet of doublets at 6.60 ppm (1 H) was attributed to the 
5-H. This was experiencing ortho coupling from the 6-H and meta coupling from the 3-H. This was 
illustrated in the coupling constants of 8.0 Hz and 2.4 Hz. A more upfield doublet at 6.56 ppm was 
assigned as the 3-H. A singlet at 5.19 ppm (2 H) was ascribed to the CH2 group of the benzyl 
moiety. A prominent upfield singlet at 2.55 ppm (3 H) was indicative of the CH3 group. 13C NMR 
showed 13 individually resolved carbon signals. The benzyl group had a plane of symmetry running 
through it, therefore only 4 signals were observed instead of 6 due to chemical equivalence. These 
signals were recognisable by their double height at 128.5 ppm and 127.8 ppm. The most downfield 
signal at 203.1 ppm was characteristic of the carbon of the ketone moiety.  IR analysis showed 
absorptions at 3026 cm-1, 3002 cm-1 and 2937 cm-1 ascribed to the aromatic C-H stretches. A 
prominent absorption at 1617 cm-1 was assigned to the carbonyl of the ketone. A strong absorption 
1363 cm-1 was attributed to a C-O stretch. A high-resolution accurate mass of 243.1018 [M+H]+ 
was found. 
 
Scheme 29. Synthesis of 1-[4-(benzyloxy)-3-chloro-2-hydroxyphenyl] ethan-1-one. 
Sodium hypochlorite was deployed using the previously validated conditions, to selectively 
chlorinate the 3 position (Scheme 29). Compound 54 was obtained as fuchsia crystals in moderate 
yield. 1H NMR showed a downfield singlet at 13.14 ppm ascribed to the 2-hydroxyl proton. A 
doublet at 7.94 ppm was assigned to the 6-H. A multiplet between 7.49-7.33 ppm (5 H) was 
attributed to the benzyl group. A doublet at 6.91 ppm was assigned to the 5-H. Based on the 
presence of two doublets the chlorine was confidently assigned as having been added to the 3-H 
position. If substitution had occurred onto the para 5-H position, the 6 and 3-H would appear as 
singlets. A singlet at 5.36 ppm was attributed to the CH2 group and the singlet at 2.62 ppm the CH3 
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group.13C NMR showed 12 individually resolved carbon signals. 7 protonated carbons were noted 
in the HSQC and DEPT135 experiment. One quaternary signal was not visible in the NMR spectra. 
This was rationalised as an artefact of the experimental NMR conditions. IR analysis showed 
absorptions at 3048 cm-1, 3029 cm-1, 2940 cm-1 and 2881 cm-1 assigned to the aromatic C-H 
stretches. A strong absorption at 1627 cm-1 was ascribed to the carbonyl stretch. An absorption at 
1277 cm-1 was attributed to the C-O stretch. A strong absorption at 1055 cm-1 was assigned to the 
C-O stretch. A medium intensity absorption at 919 cm-1 was ascribed to the O-H bend. An 
absorption at 840 cm-1 was assigned as the C-Cl stretch. A high-resolution accurate mass of 
277.0628 [M+H]+ was observed. 
 
Scheme 30. Synthesis of 7-(benzyloxy)-8-chloro-4-hydroxy-2H-chromen-2-one. 
When intermediate 54 was refluxed in the presence of diethyl carbonate, no formation of product 
was observed by TLC (Scheme 30). Comparable to the previous synthetic route this lack of 
coumarin formation was rationalised as a consequence of the deactivating properties of the 
halogen. At the same time as these investigations, a body of work probing the same procedures to 
access the SD8 chromophore was published.216 Similarly, when a chlorine atom was inserted into 
the 3 position of either a 2,4-dihdroxybenzoic acid or 2,4-dihydroxyacetaphenone derivative no ring 
closure was achieved. Interestingly, iodine was also explored as an alternative to chlorine due to its 
reduced electronegativity. However, attempts to iodinate the 3-position were not successful. The 
work presented here is concordant with the observations that the chlorine substituent reduces the 
nucleophilicity of the hydroxyl groups and therefore, precludes any ring closure event from taking 
place. Having explored the possibility of generating a dihydroxylated chlorinated coumarin, efforts 
were shifted to making streamlined mono-substituted analogues. The shorter reaction pathway 
meant a library of different coumarins could be made quickly and efficiently. Moreover screening a 
diverse library was hoped to provide SAR insight that could be used to design new inhibitors 
(Chapter 3). Additionally this would give a pool of starting AC from which novel hybrids could be 
made (Chapter 4). These findings demonstrate that a new approach is required inorder to access 
the elusive chlorinate AC moiety. One solution to accessing the chlorinated AC could be to degrade 
the natural product SD8 and isolate the desired AC, this could then be biologically evaluated to 
determine if it possesses any intrinsic inhibition for DNA gyrase. Whilst not answering the question 
of how to access the scaffold, it would potentially answer the question of its necessity for biological 
activity.  
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2.5 Polyketide synthesis 
The polyketide portion of SD8 56 is a highly complex angucyclic core, with 6 contiguous 
stereocenters (Figure 37). Therefore, in order to access the desired scaffold we sought to use a 
modified intermolecular Diels-Alder methodology as a proof of principle methodology. Previous 
unpublished work within the Searcey group had found the Diels-Alder problematic with no 
successful adducts isolated. The Diels-Alder procedure is a type of concerted pericyclic reaction to 
generate a heterocycle. The diene is an important component of the reaction, there is a 
requirement for the substrates to be able to adopt a s-cis conformation in order for orbital overlap to 
occur. Similarly, the dienophile commonly has an electron-withdrawing group present. This is 
conjugated to the alkene and has the effect of enhancing the reactivity by lowering the 
HOMO/LUMO energy barrier.  
 
Figure 37. The polyketide portion of SD8 with stereocenters marked with a red asterisk. 
The synthetic strategy is outlined in Scheme 31. The aim was to use commercially available 5-
hydroxy-1,4-naphthoquinone as a chiral dienophile. The presence of the two ketone groups makes 
the double bond in the naphthoquinone particularly electron-deficient, and thus is a useful substrate 
for this type of reaction. The dienophile has a partially fixed s-cis arrangement ascribable to the 
double bonds reducing free rotation into the unreactive s-trans conformation. In order to test the 
validity of the Diels-Alder approach to accessing the benzo[a]anthracene nucleus the synthesis of 
ochromycinone was performed as outlined in Scheme 31. 
 
Scheme 31. Synthetic pathway to the polyketide scaffold.217–220 
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The first step was an acid catalysed conjugate addition using para-toluenesulfonic acid and 
EtOH.217–219 The dione 57 can exist in either a keto or corresponding enol form. The C=O bond 
(720 KJ mol) is much stronger than the C=C (620 KJ mol). This difference in bond energies 
explains why the keto tautomer predominates. Compound 57 obeys the Erlenmeyer rule which 
states that alcohols which are directly bonded to a C=C double bond will preferentially exist in their 
keto form. The presence of an acid shifts this equilibrium from the keto to enol form (Scheme 32). 
Protonation of the oxygen of the carbonyl group of 57 a creates an electrophilic centre. 
Subsequently, the alcohol can act as a nucleophile performing an addition to the α,β-unsaturated 
double bond. A rearrangement then takes place, consequently eliminating water, and the α,β-
unsaturated system is regenerated to give 58.  
 
Scheme 32. Acid catalysed conjugate addition mechanism. 
 
Scheme 33. Synthesis of (±) 3-ethoxy-5-methylcyclohex-2-ene-1-one. 
Compound 58 was isolated as a yellow oil (Scheme 33). 1H NMR showed a singlet at 5.30 ppm 
ascribed to the 2-H. The deshielded signal was due to the conjugation of the double bond to the 
adjacent ketone. A multiplet between 3.90-3.83 ppm was attributed to the CH2 group of the ethoxy 
moiety. The unusual highly complex splitting was postulated to be a consequence of free rotation 
and interaction with the 2-H and 4-H2 protons (Figure 38). HSQC illustrated the correlation of the 
carbon signal to a proton, thus the CH2 and CH3 carbons of the ethoxy group could be determined. 
The multiplet between 3.90-3.83 ppm possessed through bond coupling to a carbon signal at 
14.2 ppm, assigned as the adjacent CH3 group and 177.4 ppm for the C3 position. In contrast to 
the CH2 signal, the CH3 showed an expected triplet at 1.33 ppm and reciprocal through-bond 
coupling to the carbon of the CH2 signal.   
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Figure 38. Splitting pattern for the ethoxy CH2 moiety. 
 
Figure 39. Cyclic protons marked with an asterisk. Green = 6-HH2, Red = 4-HH2, Blue = 5-H. 
The CH2 groups of the alkyl ring also displayed complex splitting due to their diasterotopic nature 
(Figure 39). Two multiplets between 2.41-2.39 ppm and 2.37-2.35 ppm were ascribable as either 
the 4-HH2 or the 6-HH2 protons. Due to the overlapping carbons signals, these protons could not be 
differentiated by HMBC or HSQC. A multiplet between 2.25-2.16 ppm was determined by HSQC as 
the 5-H. The 5-H signal overlapped a multiplet between 2.15-2.08 ppm for the remaining 4-HH2 
signal. HMBC analysis showed the multiplet had through bond coupling to a quaternary carbon at 
177.6 ppm assigned as the C3. Therefore, this proton was confidently assigned as the 4-HH2. 
Lastly, the multiplet between 2.03-1.96 ppm was assigned as the remaining 6-HH2. A confirmatory 
through bond coupling to a quaternary carbon at 199.9 ppm, assigned as the C1 ketone was 
observed. A doublet at 1.04 ppm (3 H) was characteristic of the 5-CH3. 13C NMR showed 9 
individually resolved signals. IR analysis showed absorptions at 2973 cm-1 and 2872 cm-1 attributed 
to the CH3 and CH2 stretches. A strong absorption at 1650 cm-1 was indicative of a carbonyl 
stretch. An absorption at 1597 cm-1 was seen for the C=C bond stretch. A high-resolution accurate 
mass of 155.1063 [M+H]+ was observed.  
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Subsequently, ethynyl magnesium chloride was utilised in a 1,4 conjugate addition reaction 
(Scheme 34).219 A lone pair of electrons on the ethoxy group of 58 co-ordinates to the Lewis acidic 
magnesium atom of a Grignard reagent. Consequently, nucleophilic attack preferentially takes 
place at the C3 rather than the C1 position. The ethoxide anion is a good leaving group and is 
formed as a by-product due to the reformation of the conjugated system.  
 
Scheme 34. Mechanism of a 1,4-conjugate addition using a Grignard reagent. 
 
Scheme 35. Synthesis of (±) 3-ethynyl-5-methylcyclohex-2-en-1-one. 
Compound 59 was isolated as a yellow oil (Scheme 35). 1H NMR showed a singlet at 6.25 ppm for 
the 2-H. A prominent singlet at 3.52 ppm (1 H) was attributed to the alkyne proton. Two multiplets 
between 2.52-2.50 ppm and 2.48-2.46 ppm were ascribed to either the 4-HH2 or the 6-HH2 protons. 
A multiplet between 2.28-2.20 ppm was attributed to the 5-H. A coalesced multiplet from 2.19-
2.05 ppm was for the remaining 4-HH2 or the 6-HH2 protons. A doublet at 1.07 ppm was for the 5-
H3. 13C NMR showed 9 well resolved signals. IR analysis showed an absorption at 3242 cm-1 
assigned as the alkyne C-H stretch. Absorptions at 2956 cm-1 and 2876 cm-1 were attributed to CH3 
and CH2 stretches. The alkyne carbon-carbon stretch appeared as a weak signal at 2092 cm-1. A 
strong absorption at 1658 cm-1 was for the carbonyl of the ketone. An absorption at 1592 cm-1 was 
ascribed as the C=C stretch. A high-resolution accurate mass of 135.0803 [M+H]+ was found.  
 
Scheme 36. Synthesis of (±) 3-[(E)-2-methoxyethenyl]-5-methylcyclohex-2-en-1-one. 
A conjugate addition with methanol to the terminus of the alkyne generated compound 60 as a 
yellow oil (Scheme 36).219 This compound was found to be very unstable and therefore only short 
NMR experiments could be performed on the compound. The product was made fresh and used 
straight away in the next reaction step. 1H NMR showed a doublet at 7.03 ppm for the a/b-H of the 
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alkene double bond. A singlet at 5.83 ppm was assignable as the 2-H. A further doublet at 
5.64 ppm was ascribable to the other a/b-H. A prominent singlet at 3.70 ppm was for the OCH3. A 
multiplet between 2.54-2.43 ppm was for the 4/6-HH2. A multiplet between 2.27-2.15 ppm was 
characteristic of the 5-H, based on the preceding parent structure this was confidently assigned. A 
multiplet between 2.11-2.01 ppm was for the 4/6-HH2. A doublet at 1.09 ppm was for the 5-CH3. 
13C NMR showed 10 individual signals. IR showed absorptions at 2952 cm-1 and 2835 cm-1 for the 
CH3 and CH2 stretches. A strong signal at 1613 cm was attributed to the carbonyl stretch. An 
absorption at 1227 cm-1 was assigned as a C-O stretch. Due to its instability no accurate mass was 
obtained for this product. The compound was used directly into the next modified Diels-Alder 
reaction.219,220 
To access ochromycinone the diene 60 was added dropwise to a light protected mixture of 
commercially available 5-hydroxy-1,4-naphthoqinone 61 and tetraacetoxy diboroxane in anhydrous 
DCM. Attempts to react the dienophile and diene without the tetraacetoxy diboroxane did not 
generate any product. Upon addition, an instantaneous colour change was noted. The reaction was 
quenched with ice water, extracted with DCM and the solvent removed under reduced pressure. 
The crude product was purified by flash column chromatography immediately. Two products were 
visible by TLC analysis. Previous reports using this procedure documented that ochromycinone 
formed via an unstable intermediate that underwent spontaneous aerial oxidation and 
aromatisation.219 Interestingly two products were isolated, ochromycinone and a pericyclic adduct 
62 not previously described. The new pericyclic adduct is a rearrangement product whereby the 
double bond migrates to become conjugated with the ketone. This conjugation would give greater 
stability and therefore can be rationalised as thermodynamically favourable to form.  
 
Scheme 37. Diels-Alder reaction pathways. 
Ochromycinone was isolated as an orange powder in a 7% yield (Scheme 37). 1H NMR showed a 
singlet at 12.28 ppm for the OH group. A downfield doublet at 8.28 ppm (1 H) was attributable to 
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the 6-H of the B ring. A multiplet (2 H) between 7.69-7.64 was ascribable to the 9/10-H protons, 
from the D ring. These are the most deshielded protons of the D ring due to the neighbouring 
phenolic OH group. A doublet at 7.55 ppm was attributed to the 5-H, this showed reciprocal 
coupling to the 6-H (8.0 Hz). The interaction was confirmed by COSY analysis. A doublet of 
doublets at 7.27 ppm was assignable as the 11-H. A multiplet between 3.06-2.98 ppm (2 H) was 
attributable to the 4-H2 alkyl protons. A doublet of doublets at 2.50 ppm and 2.61 ppm was ascribed 
to the 2-H2. A multiplet between 2.52-2.42 ppm was characteristic of the 3-H. An upfield doublet at 
1.21 ppm was indicative of the CH3 group. 13C NMR showed 19 resolved carbon signals. The most 
downfield signal at 199.3 ppm was attributed to the C1 carbonyl position. Two additional downfield 
signals at 187.7 ppm and 183.2 ppm were also indicative of carbonyl groups, however the C7/C12 
positions could not be discriminated and therefore were not assignable. A deshielded signal at 
162.2 ppm was attributed to the C8. A signal at 21.6 ppm was characteristic of the CH3 group. IR 
analysis showed absorptions between 2955 cm-1 and 2872 cm-1 assigned as the aromatic C-H 
stretches. These overlapped an OH peak. Absorptions at 1698 cm-1, 1666 cm-1 and 1631cm-1 were 
attributed to C=O stretches. A high-resolution accurate mass of 307.0965 [M+H]+ was observed. 
Alongside ochromycinone another compound was characterised. Compound 62 was isolated as an 
orange-brown solid in an 8% yield. 1H NMR showed a singlet at 12.20 ppm for the phenolic OH 
group. A triplet at 7.61 ppm was assigned as the 10-H of the aromatic ring. A de-shielded doublet 
of doublets at 7.47 ppm was ascribed to the 9-H aromatic. A doublet of doublets at 7.19 ppm was 
attributed to the 11-H aromatic. A doublet at 4.34 ppm was attributed to the 12a-H. A multiplet 
between 4.00-3.98 ppm was ascribed to the 6-H. A doublet of doublets at 3.07 ppm was attributed 
to the 7a-H. A prominent singlet at 3.00 ppm (3 H) was indicative of the OCH3 group. A multiplet 
between 2.61-2.42 ppm was attributable to the overlapping signals of the 4-H2 and 5-H2. A multiplet 
between 2.33-2.22 ppm was for the 2-H2 and the 3-H. A doublet at 1.13 ppm (3 H) was assigned 
as the CH3 group. 13C NMR showed 20 individually resolved signals. Deshielded signals at 
205.0 ppm, 197.8 ppm and 193.4 ppm were assigned as quaternary carbons of the three carbonyl 
groups C7, C10 and C18. IR analysis showed absorptions at 2953 cm-1 and 2871 cm-1 ascribed to 
the CH3 and CH2 groups. This was overlapped by a broad OH signal. Strong absorptions at 
1698 cm-1, 1667 cm-1 and 1633 cm-1 were characteristic of carbonyl stretches. A high-resolution 
accurate mass of 341.1381 [M+H]+ was observed.  
Having isolated the novel pericyclic adduct 62 it was decided to shift the focus away from the 
synthesis of the AC and PK moieties. This work successfully established a starting point for the PK 
synthesis, so efforts were concentred towards the generation of coumarin fragments for biological 
screening. It was predicted that the pursuit of coumarin fragments would generate lead compounds 
that could be identified rapidly for eventual asymmetric analogue development. In contrast, the 
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onward synthesis of the PK moiety represented a significant challenge in its own right and would 
not lend itself to the rapid synthesis of small molecule inhibitors.  
2.6 Conclusions 
This work demonstrates that selective chlorination of phenolic aldehydes and ketones with NaOCl 
is feasible. Concordant with the findings of Gaskell 2013, this simultaneous investigation showed 
whilst chlorination of hydroxylated aldehydes and ketones is possible, this inherently deactivates 
the adjacent OH groups.169 Consequently, the cyclisation of a lactone ring is problematic. This can 
be explained as a function of reduced nucleophilic character, due to induction of electron density 
away from the OH group and into the aromatic ring system by the chlorine atom.  
 
Future work would focus on introducing the chlorine once the coumarin has been formed. One such 
approach could be to form the coumarin via the diethyl carbonate methodology and then selectively 
protect the 4-OH group as methyl ether. Selective debenzylation would generate the free 7-OH 
group analogue. Consequently, a directing effect to the 6 and 8-position would occur. Chlorination 
of this intermediate could be attempted with a subsequent reduction of the nitro group to give the 
SD8 chromophore.  
This work highlights the utility of the Diels-Alder approach to creating a polyketide scaffold from 
which further stereoselective synthesis can take place. Future work will focus on optimising the 
reaction conditions to find the best possible yield for the isomerised pericyclic adduct. This can then 
be taken forward for enantioselective dihydroxylation. Furthermore, the phenolic OH can be taken 
advantage of as a co-ordinating atom for the selective reduction of the C ring ketone. The efforts 
towards the total synthesis of SD8 eloquently demonstrate that nature is a superlative natural 
product chemist. The exquisite structure and novel mechanism of action of SD8 will continue to 
inspire medicinal chemists in the coming years. 
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The AC chromophore is present in SD8, chlorobioicin, novobiocin and coumermycin A1. The 
crystal structure data, elucidated using SD8 and novobiocin, shows a well-defined pocket for AC 
binding. Moreover, the observation that inhibition is retained with the AC fragment MGD8N2A, 
warranted additional investigation into screening simplified aminocoumarin fragments against DNA 
gyrase. It was hypothesised that this would illustrate further the contribution that the 
aminocoumarin moiety makes, to DNA gyrase inhibition. Furthermore, this would facilitate the 
design of future novel inhibitory compounds. The effect of acetate, carbamate and free amine 
groups, at the 3-position, on DNA gyrase supercoiling activity was explored. This chapter 
introduces the Perkin, Pechmann and Knoevenagel reactions as classic methods for preparing 
simple coumarins. It culminates with the synthesis and biological evaluation of a library of 3-
aminocoumarin fragments, synthesised via a modified Perkin reaction. 
3.10 Perkin reaction 
In 1868 William Henry Perkin first reported the condensation of an aromatic aldehyde with an 
anhydride in the presence of a mild base to give coumarin.221,222 The publication was followed by 
the observation that the same reaction could form α,β-unsaturated carboxylic acids. It was 
originally suggested that the phenolic group of the 2-hydroxybenzaldehyde is acetylated by acetic 
anhydride and subsequent deprotonation occurs to generate an acetal anion. This anion can attack 
the carbonyl group of the formyl moiety in an intramolecular fashion, eliminating water and 
furnishing coumarin (Scheme 38). Evidence against the intramolecular reaction comes from the 
observation that when 2-formylphenyl acetate is heated in the presence of sodium acetate only 
trace amounts of coumarin are obtained.223 Similar results are noted when varying bases, solvents 
and dehydrating agents. Conversely, when acetic anhydride is added to a mixture of 2-
formylphenyl acetate and sodium acetate, coumarin readily forms. These results support 
investigations, using benzaldehyde, that show condensation occurs between an anhydride and a 
formyl group in the presence of an alkali salt. The base is predicted to catalyse the formation of 
cinnamic acid, an α,β-unsaturated carboxylic acid.224,225 An alternative mechanism is for the 
enolate to be derived from the anhydride. The enolate attacks the formyl group, followed by a 
cyclisation and loss of water to form the lactone (Scheme 39). 
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Scheme 38. Perkin condensation intramolecular hypothesis. 
 
Scheme 39. Perkin condensation coumarin formation. 
Isolation of geminal diacetate from a variety of aldehydes opposes the dogma of the generation of 
enolate from the anhydride species.226 However, this was observed in the presence of catalytic 
amounts of BF3 or anhydrous FeCl3 in the reaction mixture.227,228 The suggestion that the 
nucleophilic species could arise from a geminal-diacetate of the aromatic aldehyde is speculative 
(Scheme 40). It has been demonstrated that when benzal diacetate is refluxed in the presence of 
potassium acetate then cinnamic acid is obtained in high yield. This supports the hypothesis of the 
enolate arising from the geminal diacetate. Similarly, when benzaldehyde is refluxed with acetic 
anhydride, cinnamic acid is generated. Furthermore, if the benzal diacetate is refluxed in the 
presence of acetic anhydride, the results are unchanged, with cinnamic acid being the major 
product. Despite its discovery over a century ago and widespread use, the exact mechanism of the 
Perkin reaction remains unknown. It likely proceeds via the base catalysed formation of an enolate 
derivative with acetic anhydride participating in the reaction. 
O
OH
O
O
O O
O
-H
O
H
NaOAc O
O O O
O
O
+H
H
H
O
O
O
HH
H
O O
H+
63 63 a 63 b 63 c
63 d 65
64
O
O
O
H
NaOAc
O
O
O
O
OH
O
O
O
O
O
OO
O O
H
O O
OH
O
O
OOH
O
O OOAc
H OH OHH
OAc
64 a 64 b
53 64 e 64 f
64 g 64 h 65
64 b
Chapter 3. Synthesis and biological evaluation of coumarin fragments 
 
 
 
94 
 
Scheme 40. Geminal-diacetate mediated enolate mechanism.173 
3.11 Pechmann reaction 
Coumarins can also be synthesised by condensing phenol with a β-keto ester in the presence of 
sulphuric acid (Pechmann, H.; & Duisberg, C., 1883, cited Clayden, J.; Greeves, N.; Warren, S., 
2013). The efficiency of the reaction is dependent on the condensing agent, phenol and β-keto 
ester used. A variety of condensing agents promote the reaction, such as ZnCl2, POCl3 and 
AlCl3.229,230 Monohydric phenols give poor yields; conversely activated aromatic compounds, such 
as resorcinol are more favoured. The enhanced reactivity is attributed to increased electron density 
at the 4 and 6 position of the benzene ring.201 Experimental evidence shows that electronegative 
groups in the alkyl portion of the ester improve reactivity; this is predicted to facilitate enolisation of 
the carbonyl group. In contrast, increasing steric bulk in the α-position of the β-keto ester generally 
impedes reactions. However, a degree of alkylation can be tolerated.231 Debate still surrounds the 
mechanism which is theorised to involve trans-esterification, water elimination and cyclisation steps 
(Scheme 41). It is unknown if the ester is in its keto or enol tautomer. Intriguingly, density functional 
theory (DFT) calculations predict a high-energy barrier for the enolic route over the oxo form which 
is contrary to experimental evidence.232 
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Scheme 41. A predicted Pechmann mechanism. 
3.12 Knoevenagel reaction 
The Knoevenagel reaction uses functionalised o-hydroxybenzaldehydes and dicarbonyl 
compounds, such as diethyl malonate or malonic acid, in the presence of a mild base, such as 
piperidine. This promotes the reaction between the aldehyde and enolate but prevents self 
condensation of the aldehyde.233 The nucleophilic base deprotonates the acidic α-H from the 1,3-
dicarbonyl compound, to create a resonance stabilised enolate anion. Nucleophilic attack on the 
carbonyl group of the aldehyde by the base forms an imine intermediate, that in turn undergoes 
nucleophilic attack from the α carbon of the keto-enol tautomer. Lastly, trans-esterification with the 
OH group of the o-hydroxybenzaldehyde generates the lactone with alcohol as the side product 
(Scheme 42).    
 
Scheme 42. Knoevenagel condensation of salicylaldehyde and diethyl malonate. 
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Importantly, this is an alternative method for placing a functional handle in the 3-position of the 
coumarin. Examples include: ester, carboxylic acid, nitrile and phenyl derivatives.234–237 The 
reaction also lends itself to solid phase synthesis with the enolate derivative attached to the support 
resin.238   
3.13 Formylation of phenols 
A formyl reaction can be used in order to access the desired starting materials for the generation of 
coumarin analogues. A Reimer-Tiemann reaction is one such example that can introduce an 
aldehyde group ortho or para to a phenolic hydroxyl moiety. Normally, chloroform is used with an 
aqueous base such as sodium hydroxide. The strong base removes a proton from chloroform 
forming a carbon anion. Chlorine can act as a good leaving group to generate a stable 
dichlorocarbene 74 c, this is an electron deficient species having only 6 electrons, and thus is short 
of a full octet. The electrophilic carbene reacts with a phenolate in a substitution reaction. 
Subsequently, an intramolecular proton transfer takes place, reforming the aromatic ring. Next, a 
chlorine atom leaves intermediate 74 g. A hydroxide anion attacks the sp2-hybridised carbon 
bonded to a single chlorine, introducing an alcohol group. Successively, an additional chlorine atom 
leaves. Further nucleophilic attack of the OH group abstracts a proton resulting in formyl functional 
group. Lastly, an acidic work up reprotonates the phenol moiety to give the desired product 63 
(Scheme 43).  
 
Scheme 43. Mechanism of the Reimer-Tiemann reaction. 
Due to the immiscibility of chloroform and aqueous base, heat and vigorous stirring is required to 
instigate the formylation reaction. However, the highly exothermic nature of the reaction makes 
thermal runaway a safety concern.239 Alternatively, THF can be used with MgCl2 as a coordinating 
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ion and triethylamine as an organic base in the presence of paraformaldehyde to give two 
regioisomers.240 This reaction preferentially produces the less sterically hindered product, and is 
safer than using chloroform. The theorised mechanism involves triethylamine deprotonating the 
phenol allowing it to form the aryloxymagnesium chloride salt. This species reacts with 
formaldehyde, which is formed from the parent paraformaldehyde at elevated temperatures. 
Interestingly, without magnesium chloride, no formyl products are obtained. A cyclohexadieneone 
scaffold is generated which in turn gives an alcohol intermediate. A redox reaction can 
subsequently take place to furnish the desired benzaldehyde with methanol as a side product 
(Scheme 44).241  
 
Scheme 44. Formylation using magnesium, Et3N and monomeric formaldehyde. 
3.14 Modified Perkin reaction  
Limited routes exist for the synthesis of 3-aminocoumarins. These molecules are interesting 
because both the aminocoumarin antibiotics and SD8 both contain this moiety. Three strategies 
were proposed to access this scaffold: 1) to nitrate a coumarin in the three position and reduce to 
an amine or use a starting reagent with a nitro group already in place.242–245 2) Introduce a nitrile 
group and reduce to an amine.246,247 3) Use a starting reagent with a protected amine and cyclise to 
form coumarin.248 For simplicity, and ease of synthesis, the latter method was chosen. A previously 
described method uses different salicylaldehyde derivatives with N-acetylglycine to give the amine 
protected coumarin scaffold using a modified Perkin reaction.248 One predicted mechanism 
involves a glycine anhydride intermediate 76 c that reacts with the phenol of the salicylaldehyde 
76. The acetyl group can leave as acetic acid, crucially forming the beginning of the lactone ring. A 
key step for ring closure would be the removal of an acidic proton in the α-position by the weak 
base sodium acetate. This forms a double bond that can cyclise with the formyl group to close the 
ring and form the coumarin framework (Scheme 45). However, in agreement with the previously 
discussed mechanisms, the more likely pathway is via the enolate derived from the acetic 
anhydride attacking the formyl group 78 b as shown in the scheme 46.  
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Scheme 45.  A possible mechanism of the modified Perkin reaction. 
 
Scheme 46. Alternative mechanism of modified Perkin reaction. 
3.15 Acetate protected coumarins 
The formation of acetate protected 3-aminocoumarins created a series of parent structures, from 
which further derivatives could be synthesised. Briefly, salicylaldehyde was used as the starting 
reagent, and refluxed in acetic anhydride at 120 ºC, in the presence of anhydrous sodium acetate 
and the amino acid N-acetylglycine. The reaction was quenched with ice water to remove any 
remaining anhydride. After cooling to room temperature the reaction mixture would often form a 
sticky solid. This was difficult to work with and it was found trituration with large amounts of water 
allowed the dissolution of the sodium acetate salt. Addition of ethyl acetate (EtOAc) would cause 
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the product to precipitate in the organic layer. Filtration and washing with aliquots of solvent 
removed acetic acid from the product; no further purification was necessary. 
 
Scheme 47. Synthesis of N-(2-oxo-2H-chromen-3-yl) acetamide. 
Compound 77 was isolated as a yellow powder (Scheme 47). 1H NMR showed a singlet at 
9.76 ppm attributable to the amide proton. A less deshielded singlet at 8.60 ppm occurred for the 4-
H. The strong electronegative effect of the neighbouring carbonyl groups withdraws electron 
density away from both protons. Consequently, this exposes both environments to a stronger 
magnetic field, giving two downfield signals. The remaining aromatic protons appeared more 
shielded as a doublet of doublets at 7.69 ppm for the 5-H. A coupling constant of 8.0 Hz, and 
1.6 Hz indicated ortho and meta coupling to the 6-H and 7-H protons. A triplet of doublets at 
7.50 ppm was assigned as the 6-H. An apparent doublet appeared at 7.38 ppm (1 H), instead of 
the predicted doublet of doublets, ascribed to the 8-H. The poorly resolved signal was likely due to 
coincidental overlap. Lastly, a triplet of doublets at 7.33 ppm was attributed to the 7-H. IR analysis 
showed an absorption at 3328 cm-1 for the CON-H stretch. Two absorptions at 1707 cm-1 and 
1680 cm-1 were assigned as the lactone and amide carbonyls respectively. The 13C NMR showed 
11 resolved peaks for the coumarin scaffold. A high-resolution accurate mass of 204.0655 [M+H]+ 
was observed.  
 
Scheme 48. Synthesis of N-(8-methoxy-2-oxo-2H-chromen-3-yl) acetamide. 
Compound 79 was isolated as a yellow powder (Scheme 48). 1H NMR showed a singlet at 
8.65 ppm (1 H) for the 4-H. HSQC confirmed there was no correlation to a carbon. The amide 
proton appeared as a broad singlet at 8.08 ppm. A triplet at 7.23 ppm was ascribable to the 6-H. 
The coupling constant of 8.0 Hz was due to ortho coupling of the adjacent aromatic protons. A 
doublet of doublets at 7.09 ppm and 7.01 ppm were assigned as the 5-H and 7-H signals 
respectively. A sharp singlet at 3.97 ppm (3 H) was characteristic of the deshielded methoxy group. 
In contrast, a more upfield singlet at 2.23 ppm was assignable to the acetate of the amide.13C NMR 
showed 12 individually resolved carbons. IR analysis showed an absorption at 3333 cm-1 for the 
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CON-H stretch. Absorptions at 3087 cm-1 and 2893 cm-1 represented Ar-H stretches. Two 
absorptions at 1707 cm-1 and 1676 cm-1 were assigned as the lactone and acetate carbonyl groups 
respectively. Absorptions at 1607 cm-1, 1577 cm-1 and 1530 cm-1 were assigned as the aromatic 
C=C stretches. A high-resolution accurate mass of 234.0756 [M+H]+ was found.   
 
Scheme 49. Synthesis of N-(7-methoxy-2-oxo-2H-chromen-3-yl)acetamide. 
Compound 81 was obtained as a yellow powder (Scheme 49). 1H NMR showed a sharp singlet at 
8.63 ppm attributed to the 4-H. A broadened singlet at 7.98 ppm was ascribed to the nitrogen 
proton. This assignment was confirmed by HSQC. A doublet at 7.40 ppm was assigned as the 5-H 
proton. A doublet of doublets occurred at 6.88 ppm for the 6-H. A doublet at 6.81 ppm was 
attributable to the 8-H. The methoxy group appeared as a prominent singlet at 3.86 ppm showing 
the slightly deshielded environment. 13C NMR showed 12 individual carbons. IR analysis gave a 
strong absorption at 3347 cm-1 for the CON-H stretch. A weak absorption at 3060 cm-1 was 
assigned as the COCH3 stretch. This overlapped absorptions at 2949 cm-1 and 2843 cm-1 for the 
sp3C-H stretches. Two signals at 1702 cm-1 and 1676 cm-1 were the lactone and amide carbonyls 
respectively. Three absorptions of medium intensity at 1523 cm-1, 1519 cm-1 and 1504 cm-1 were 
assigned as the aromatic C=C stretches. A high-resolution accurate mass of 234.0762 [M+H]+ was 
observed.    
 
Scheme 50. Synthesis of N-(6-chloro-2-oxo-2H-chromen-3-yl) acetamide. 
The novel compound 83 was isolated as a yellow powder in a reasonable yield (Scheme 50). Due 
to the poor solubility of compound 83 it was necessary to obtain carbon spectral data on a 
800 MHz NMR machine. 1H NMR showed a deshielded singlet at 9.82 ppm for the N-H, HSQC 
confirmed the assignment. The singlet at 8.60 ppm was ascribed to the 4-H proton. A doublet at 
7.87 ppm was attributed to the 5-H (J = 2.4 Hz). A doublet of doublets at 7.52 ppm (J1 = 8.8 Hz, J2 
= 2.8 Hz) was ascribed to the 7-H. A doublet at 7.42 ppm was assigned to the 8-H. A reciprocal J 
coupling of 8.8 Hz to the 7-H was observed. The CH3 moiety gave an expected singlet at 2.17 ppm. 
HSQC allowed the assignment of the protonated carbons. The C4 was observed at 121.1 ppm, C5 
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at 127.1 ppm, C7 at 129.7 ppm and the C8 at 117.9 ppm. The C4 carbon was correlated to 6 
signals, two of which had no through bond coupling to any other protonated carbon.  Thus, allowing 
the assignment of the C2 at 158.4 ppm and C3 at 125.0 ppm. The remaining signals were 
quaternary, the C5 and C7 both had through bond coupling to a signal at 130.7 ppm. 
Consequently, this must be attributed to the C6 position.  All protonated carbons had through bond 
coupling to signals at 148.3 ppm and 121.9 ppm. Based on the electronegativity of the adjacent 
oxygen atom the signal at 148.3 ppm was likely the C8a carbon, whereas the signal at 121.9 ppm 
was the C4a carbon. 13C NMR showed 11 individual carbon signals. IR analysis showed an 
absorption at 3337 cm-1 for the CON-H stretch. Weak absorptions at 3093 cm-1, 3056 cm-1 and 
3030 cm-1 were assigned as Ar-H stretches. Two absorptions at 1711 cm-1 and 1676 cm-1 were 
assigned as the lactone and amide carbonyl respectively. Three medium signals at 1568 cm-1, 
1537 cm-1 and 1524 cm-1 were assigned as the aromatic C=C stretches. A prominent absorption at 
828 cm-1 was assigned to the C-Cl stretch. A high-resolution accurate mass of 238.0265 [M+H]+ 
was observed.  
 
Scheme 51. Synthesis of N-(8-chloro-2-oxo-2H-chromen-3-yl) acetamide. 
Compound 85 was isolated as a colourless powder (Scheme 51). 1H NMR showed a broad singlet 
at 9.87 ppm for the N-H. HSQC confirmed the assignment. The previous 6-chlorocoumarin, 83, 
paralleled the observed chemical shift. A singlet at 8.64 ppm was assigned to the 4-H. A 
deshielded doublet of doublets at 7.66 ppm was ascribed to the 5-H (J1 = 7.6 Hz, J2 = 1.2 Hz), 
consistent with previously assigned compounds. A doublet of doublets at 7.61 ppm was attributed 
to the 7-H (J1 = 8.0 Hz, J2 = 1.6 Hz). Due to the neighbouring electronegative chlorine, the 7-H 
signal was more deshielded than normal. A triplet at 7.33 ppm was ascribed to the 6-H. A singlet at 
2.18 ppm was ascribed to the acetate group. 13C NMR showed 11 carbon signals. IR analysis 
showed an absorption at 3337 cm-1 for the CON-H stretch. Two absorptions at 1711 cm-1 and 
1676 cm-1 were assigned as the lactone and amide carbonyl, respectively. A strong signal at 
767 cm-1 was assigned as the C-Cl stretch. A high-resolution accurate mass of 238.0265 [M+H]+ 
was found.  
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Scheme 52. Synthesis of 3-acetamide-2-oxo-2H-chromen-8-yl acetate. 
The novel compound 87 was isolated as an off white powder (Scheme 52). 1H NMR showed a 
singlet at 8.68 ppm, ascribed to the 4-H. Conversely, a broad singlet at 8.06 ppm was assigned as 
the N-H. HSQC shows no correlation to carbon, confirming the assignment. HMBC analysis 
allowed discrimination between the 5-H and 7-H signals of the coumarin that both appeared as 
doublet of doublets. The 5-H proton had through bond coupling to the C4 position, whereas the 7-H 
did not. Moreover, the 7-H had through bond coupling to the quaternary C8 position. This was not 
seen in the sister doublet. Therefore the first downfield doublet of doublets at 7.39 ppm was 
ascribed to the 5-H proton. A coupling constant of 8.0 Hz was noted for the 6-H. While a coupling of 
1.6 Hz was observed for the 5-H. A triplet at 7.28 ppm was, as predicted, for the 6-H proton. A J 
value of 8.0 Hz was consistent with ortho coupling. The remaining doublet of doublets at 7.20 ppm 
was assigned as the 7-H. This designation was consistent with the observation of the 4-H and 5-H 
positions being areas of diminished electron density. 13C NMR shows 13 resolved signals. Bond 
coupling to the quaternary C8 carbon made it possible to determine the acetate group signal. Thus, 
the signal at 2.42 ppm in the 13C NMR was the ester and the signal at 2.25 ppm was the amide. IR 
analysis showed an absorption at 3284 cm-1 for the CON-H stretch. Absorptions at 1773 cm-1, 
1711 cm-1 and 1676 cm-1 were characteristic for the carbonyl stretch signals. The similarity of the 
values for the lactone and the ester carbonyl groups meant they cannot be assigned. The amide 
was assigned as the 1676 cm-1 absorption. A high-resolution accurate mass of 262.0712 [M+H]+ 
was observed.  
 
Scheme 53. Synthesis of 3-acetamido-7-acetoxy-2H-chromen-2-one. 
Compound 88 was isolated as a pale yellow powder (Scheme 53). 1H NMR showed the 4-H was a 
singlet downfield at 8.67 ppm. A broad singlet at 8.03 ppm was assigned as the N-H. HSQC 
showed no correlation to a carbon, confirming the assignment. A doublet at 7.51 ppm (J = 8.0 Hz), 
was assigned as the 5-H. The coupling constant was indicative of ortho coupling, to the 6-H 
position. A doublet at 7.13 ppm was ascribed to the 8-H. A J value of 2.4 Hz is consistent with the 
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expected meta coupling to the 6-H. A doublet of doublets at 7.07 ppm was attributed to the 6-H. 
HMBC analysis did not reveal any through bond coupling from the amide proton, nor did the 4-H 
proton have through bond coupling to the Ca carbon. Therefore, differentiation between acetate 
groups was not possible. 13C NMR showed 13 resolved carbons. IR analysis showed a strong 
absorption at 3340 cm-1 for the CON-H stretch. A weak absorption at 3079 cm-1 was assigned as 
an Ar-H stretch. A broadened and strong absorption at 1532 cm-1 was attributed to the aromatic 
C=C stretches, it is likely this peak masks the other two signals.  Three carbonyl absorptions at 
1757 cm-1, 1716 cm-1 and 1678 cm-1 confirmed the correct product been isolated. The signals at 
1757 cm-1 and 1716 cm-1 were ascribed for the ester and lactone. However, due to their similar 
values they cant specifically be assigned. The amide was assigned as the absorption at 1678 cm-1. 
A high-resolution accurate mass of 262.0715 [M+H]+ was found.  
 
Scheme 54. Synthesis of N-(6-nitro-2-oxo-2H-chromen-3-yl) acetamide. 
Compound 90 was isolated as an off white powder at the highest yield for this set of analogues 
(Scheme 54). This provides evidence in support of the mechanism proposed earlier whereby the 
enolate attacks the formyl group. The presence of the nitro-group would withdraw electron density 
away from the formyl carbonyl through induction making it more electropositive. Furthermore, the 
nitro-group would help stabilise a negative charge on the oxygen of the formyl carbonyl. 1H NMR 
showed a deshielded singlet at 8.76 ppm for the 4-H. This is an electron poor region of the 
molecule due to the adjacent acetamide, and the electronegative effect of the nitro group. A doublet 
at 8.44 ppm (J = 2.6 Hz) was attributed the 5-H proton with meta coupling to the 7-H. A doublet of 
doublets at 8.30 ppm represents the 7-H (J1 = 8.0 Hz, J2 = 2.4 Hz). A broad singlet at 8.08 ppm 
was assigned as the N-H. HSQC showed no carbon was correlated with this signal, confirming the 
assignment. A singlet at 2.28 ppm was ascribed to the CH3 group. 13C NMR showed 11 resolved 
peaks for the coumarin framework. IR analysis showed an absorption at 3372 cm-1 for the CON-H 
stretch. Two weak absorptions at 3096 cm-1 and 3080 cm-1 were attributed to Ar-H stretches. Two 
carbonyl absorptions occurred at 1722 cm-1 and 1686 cm-1 for the lactone and amide, respectively.  
Additionally, absorptions at 1519 cm-1, 1515 cm-1 and 1504 cm-1 were ascribed to the aromatic C=C 
stretches. A prominent absorption at 1332 cm-1 is attributed to the C-NO2 stretch. A high-resolution 
accurate mass of 307.0920 [M+H]+ was observed. 
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3.16 Boc protected coumarins 
 
Scheme 55. Routes for acetate removal.248,249 
Acetate removal can be problematic as the lone pair of electrons on the nitrogen atom is. 
Delocalised through the amide bond. Two approaches to acetate removal were pursued (Scheme 
55). The first was via Boc group protection and Boc removal to give the corresponding free amine. 
The second was via direct cleavage with acid (discussed in section 3.17). A common technique to 
facilitate acetyl removal is to Boc protect the nitrogen atom first. This removes the ability of the lone 
pair of electrons to be fully available for conjugation, consequently allowing the acetate to be 
removed with a strong base. The tert-butyl carbamate is base stable but acid labile. In contrast, the 
acetate group can be removed under both basic and acidic conditions. To encourage nucleophilic 
attack from the remaining lone pair of electrons of the acylated nitrogen atom, N,N-
dimethylaminopyridine (DMAP) can be used (Scheme 56). Pyridine itself has nucleophilicity 
because the lone pair of electrons are orthogonal to the p-orbitals of the ring system. Thus, they 
cannot become delocalised. The dimethyl amino group is a strong electron-donator via inductive 
effects. This enhances the nucleophilic character of the pyridine-based compound. Normally, it is 
sufficient to use catalytic amounts of DMAP for carbamate or acetyl protection. However, the 
nucleophilic character of the acylated nitrogen in coumarin is reduced by cross conjugation. Thus, 
five equivalents of DMAP are used to promote the protection step.  
 
Scheme 56. Boc protection of acetylated coumarin.  
The likely mechanism for acetate removal is via nucleophilic attack; the lone pair of electrons on 
the nitrogen of the hydrazine would attack the acetate carbonyl of the coumarin (Scheme 57). This 
O O
NHAc
O O
NHBoc
O
i) Boc2O, DMAP
THF
ii) Hydrazine, MeOH HCl, EtOAc
Conc. HCl
O
NH2
R
R
R
O
O
O
O
O
N NMe2 N NMe2
O
O
O
O N
NMe2
O O
H
N
O
N
NMe2
O O
N
O
OO
+
-H
91 a 91 b
91 c 92 93
Chapter 3. Synthesis and biological evaluation of coumarin fragments 
 
 
 
105 
generates a negative charge on the electronegative oxygen atom of the acetate group. 
Subsequently, the bond between the Boc protected nitrogen atom and the hydrazine adduct breaks 
and the side product acetyl hydrazine leaves. A proton transfer onto the nitrogen atom of the 
liberated Boc protected coumarin would allow for the conservation of charge. This is likely a 
concerted reaction. The carbamate group is more stable due to electron induction into the bond 
from the alkyl group, as well as the lone pair of electrons being present on the adjacent oxygen and 
nitrogen atoms. Consequently, this reduces the overall dipole moment experienced by the carbon 
of the carbonyl group and makes nucleophilic attack from hydrazine less favourable. Furthermore, 
the sterically hindered environment contributes to the stability of the carbamate moiety. Generation 
of tert-butyl protected compounds allowed investigation of the effect introducing larger steric 
functionalities would have on the coumarin compounds. All of the Boc protected coumarins were 
more soluble in organic solvents than the parent acetylated compounds.   
 
Scheme 57. Acetate removal with hydrazine. 
 
Scheme 58. Synthesis of tert-butyl N-(2-oxo-2H-chromen-3-yl)carbamate. 
Compound 95 was isolated as a colourless powder (Scheme 58). 1H NMR showed a broad singlet 
at 8.27 ppm for the 4-H. HSQC analysis confirmed this signal was coupled to a carbon and 
therefore ruled out amide proton assignment. A doublet of doublets at 7.45 ppm occurred for the 5-
H. Coupling constants of 7.6 Hz and 1.6 Hz indicated ortho and meta coupling of the 5-H to the 6-H 
and 7-H protons respectively. A triplet of doublets at 7.41 ppm (2 H) represented the signal for the 
6-H as well as the overlapping amide proton. In comparison to the acetylated parent material, the 
proton of the nitrogen moiety was far more shielded due to the neighbouring oxygen atom of the 
carbamate group. This was reflected in the lower chemical shift. A reciprocal coupling constant of 
7.2 Hz and 1.6 Hz confirmed the interaction with the 5-H. Importantly, HSQC analysis revealed one 
signal was correlated with a carbon. An overlapping multiplet between 7.31-7.25 ppm (2 H) 
accounted for the remaining 7-H and 8-H aromatic protons. A singlet at 1.54 ppm was 
characteristic of the Boc CH3 group. 13C NMR showwed 12 individually resolved carbons. The 
methyl groups of the tert-butyl moiety are homotropic, being in the same environment. Thus, a 
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large singlet at 28.4 ppm was observed. The chemical shift of the carbonyl group of the carbamate 
at 152.6 ppm was significantly lower than the acetylated carbonyl of the parent compound 
(170.2 ppm).  This highlighted the difference in dipole moment experienced by these quaternary 
carbon atoms experimentally. IR analysis showed two absorptions at 3415 cm-1 and 3321 cm-1 
ascribed to the CON-H stretches. Absorptions at 2997 cm-1, 2973 cm-1 and 2924 cm-1 were 
attributed to sp3C-H stretches. Two almost overlapping absorptions were seen at 1702 cm-1 and 
1698 cm-1 for the lactone and carbamate carbonyl groups respectively. A large coalesced 
absorption at 1519 cm-1 was ascribed as the aromatic C=C stretches. A high-resolution accurate 
mass of 262.1071 [M+H]+ was found.  
 
Scheme 59. Synthesis of tert-butyl N-(8-methoxy-2-oxo-2H-chromen-3-yl) carbamate. 
Compound 96 was isolated as a yellow powder (Scheme 59). 1H NMR showed a broad singlet at 
8.22 ppm (1 H) attributed to the 4-H. HSQC showed this was correlated to a carbon, thus 
confirming the assignment. A broad singlet at 7.42 ppm was ascribed to the N-H. A triplet at 
7.18 ppm (J = 8.0 Hz), represented the 6-H. A doublet of doublets at 7.02 ppm and 6.95 ppm was 
assigned to the 5-H and 7-H protons respectively (J1 = 8.0 Hz and J2 = 1.2 Hz). A singlet at 
3.94 ppm was characteristic of the methoxy moiety.13C NMR showed 13 resolved carbons, the 
methyl groups of the tert-butyl group are equivalent due to a uniform environment, showing as a 
single peak at 28.3 ppm. IR analysis showed an absorption at 3317 cm-1 for CON-H stretch. Two 
absorptions at 1728 cm-1 and 1698 cm-1 were ascribed to the carbonyl groups of the lactone and 
carbamate respectively. A high-resolution accurate mass of 292.1178 [M+H]+ was observed.  
 
Scheme 60. Synthesis of tert-butyl N-(7-methoxy-2-oxo-2H-chromen-3-yl) carbamate. 
Compound 97 was isolated as a colourless powder (Scheme 60). 1H NMR showed a singlet at 
8.23 ppm ascribed to the 4-H proton. HSQC showed this was not correlated with a carbon, 
confirming the assignment. A doublet at 7.35 ppm (J = 8.0 Hz), was attributed to the 5-H. A broad 
singlet at 7.28 ppm was assigned as the N-H. A doublet of doublets at 6.86 ppm and doublet at 
6.81 ppm were ascribed to the 6-H and 8-H respectively. A singlet at 3.85 ppm (3 H) was attributed 
to the methoxy group. A prominent singlet at 1.52 ppm (9 H) unequivocally represented the Boc 
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group. 13C NMR correctly showed 13 resolved peaks for the product. IR analysis showed 
absorptions at 3423 cm-1 for the CON-H stretch. Three absorptions at 2985 cm-1, 2937 cm-1 and 
2831 cm-1 were attributed to sp3C-H stretches. Two absorptions were seen at 1713 cm-1 and 
1615 cm-1 for the lactone and carbamate carbonyl groups. The two medium intensity absorptions at 
1515 cm-1, and 1505 cm-1 were assigned to the aromatic C=C stretches. The unaccounted for C=C 
signal was likely masked by the first peak at 1515 cm-1. A strong absorption at 1130 cm-1 was 
ascribed as the methoxy ether bend. Unlike the acetylated parent compound, the COCH3 stretch 
was not visible. This is not unexpected, as the bending signal is often weak. A high-resolution 
accurate mass of 282.1182 [M+H]+ is observed.  
 
Scheme 61. Synthesis of tert-butyl N-(6-chloro-2-oxo-2H-chromen-3-yl) carbamate. 
The novel compound 98 was obtained as colourless powder (Scheme 61). 1H NMR showed a 
down field singlet at 8.13 ppm (1 H) assigned as the 4-H. A singlet at 7.39 ppm (1 H) was ascribed 
to the N-H. HSQC confirmed no correlation to a carbon atom. A doublet at 7.37 ppm was attributed 
to the 5-H. A doublet of doublets at 7.29 ppm was ascribed to the 7-H. The most shielded proton at 
position 8-H was assigned to a doublet at 7.19 ppm. Removal of the acetate was confirmed by the 
loss of a singlet (3 H) and the appearance of a larger singlet at 1.50 ppm (9 H) for the Boc moiety. 
13C NMR showed 12 resolved carbons. IR analysis showed an absorption at 3403 cm-1 for the 
CON-H stretch. A weak absorption at 3095 cm-1 was ascribed to the Ar-H stretch, whereas 
absorptions at 2986 cm-1 and 2929 cm-1 were indicative of sp3C-H stretches. A broad, strong 
absorption was seen at 1706 cm-1 and this was assigned as one of the carbonyl stretches. It likely 
overlaid the other C=O that was expected for this compound, masking it. Similarly, a broad 
absorption at 1507 cm-1 was observed, this was likely overlaying the other two absorptions 
expected for the aromatic C=C moieties. A further strong absorption at 767 cm-1 was attributable to 
the C-Cl stretch. A high-resolution accurate mass of 296.0688 [M+H]+ was observed. A [M]+ and 
[M+2]+ pattern in a 3:1 ratio was noted in the mass spectrum, and confirmed the presence of a 
chlorine substituent.  
 
Scheme 62. Synthesis of tert-butyl N-(8-chloro-2-oxo-2H-chromen-3-yl) carbamate. 
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Compound 99 was obtained as a colourless powder (Scheme 62). 1H NMR showed a broad singlet 
at 8.26 ppm ascribed to the 4-H. A doublet of doublets at 7.45 ppm was assigned as the 5-H (J1 = 
8.0Hz and the J2 = 1.6 Hz). A broad singlet at 7.43 ppm was ascribed to the N-H and this was 
confirmed by HSQC. A doublet of doublets at 7.36 ppm was attributed to the 7-H. The signal 
displayed a reciprocal coupling interaction with the 6-H and 5-H protons. Lastly, a triplet at 7.21 
ppm (J = 8.0 Hz) occurred for the 6-H. A singlet at 1.53 ppm was characteristic of the CH3 groups. 
13C NMR showed 12 resolved carbons. IR analysis showed an absorption at 3326 cm-1 for the 
CON-H stretch. Absorptions at 2983 cm-1, 2961 cm-1 and 2924 cm-1 were ascribable to the sp3C-H 
stretches. Absorptions bands at 1597 cm-1, 1567 cm-1 and 1526 cm-1 were assigned as aromatic 
C=C stretches. Two absorptions at 1731 cm-1 and 1702 cm-1 were assigned to the lactone and the 
carbamate respectively. A strong absorption at 759 cm-1 was attributed to the C-Cl stretch. A high-
resolution accurate mass of 296.0686 [M+H]+ was found. A confirmatory [M]+ and [M+2]+ pattern in 
a 3:1 ratio was noted in the spectrum, indicating the presence of a chlorine substituent.  
 
Scheme 63. Synthesis of tert-butyl N-(8-hydroxy-2-oxo-2H-chromen-3-yl) carbamate. 
Compound 100 was obtained as a colourless powder (Scheme 63). 1H NMR showed a singlet at 
8.30 ppm ascribed to the 4-H. A broad singlet at 7.37 ppm was assigned to the N-H. Two doublets 
of doublets appeared at 7.04 ppm and 7.01 ppm for the 7-H and 5-H respectively. The interaction 
was confirmed by constants of 8.0 Hz and 1.6 Hz, typical for ortho and meta coupling. For this 
compound, hydrazine monohydrate had also deacetylated the 8 position. However, due to the 
hygroscopic properties of chloroform, it was not possible to see a phenolic OH group in the 1H 
NMR spectrum. The lack of an acetyl signal in the 1H NMR supports the conclusion that successful 
removal of both protecting groups had occurred simultaneously. A prominent singlet occurred at 
1.54 ppm attributed to the CH3 groups. 13C NMR showed 12 resolved signals. IR analysis showed 
an absorption at 3419 cm-1 for the CON-H stretch. This was overlapped by a broad absorption at 
3398 cm-1 that was indicative of an alcohol group. A weak intensity band at 2970 cm-1 was ascribed 
as the sp3C-H stretch. One broad, strong absorption was seen at 1707 cm-1 assigned as a C=O 
band. This likely overlaid the other unaccounted for C=O signal. Three medium absorptions at 
1591 cm-1, 1518 cm-1 and 1515 cm-1 were attributed to the aromatic C=C stretches. A high-
resolution accurate mass of 300.9845 [M+Na]+ was found.  
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Scheme 64. Synthesis of tert-butyl N-(7-hydroxy-2-oxo-2H-chromen-3-yl) carbamate. 
Compound 101 was isolated as a colourless powder (Scheme 64). 1H NMR showed a broad singlet 
at 8.14 ppm was attributed to the 4-H as confirmed by HSQC. A doublet at 7.34 ppm was assigned 
as the 5-H. A doublet of doublets occurred at 6.77 ppm (J1 = 8.0 Hz, J2 = 2.4 Hz) for the 6-H. This 
signal showed coupling to the 5-H and 8-H positions. A doublet at 6.68 ppm was attributed to the 8-
H. 13C NMR showed 12 individually resolved signals. The Boc peak appeared at an upfield position 
of 1.52 ppm, commensurate with other analogues of this class. The lack of a signal for the 7-OH 
group is attributed to the hygroscopic CD3OD solvent used to obtain the proton 1H NMR spectrum. 
IR analysis showed a broad absorption at 3316 cm-1 for the OH group, this masked the signal for 
the CON-H stretch. A weak absorption at 3079 cm-1 was assigned as an Ar-H stretch. Further 
absorptions at 2978 cm-1 and 2929 cm-1 represented sp3C-H stretches. Two absorptions at 
1702 cm-1 and 1684 cm-1 were assigned as the lactone and carbamate groups respectively. Three 
medium signals at 1607 cm-1, 1534 cm-1 and 1510 cm-1 were assigned as aromatic C=C stretches. 
A high-resolution accurate mass of 278.1028 was observed [M+H]+.   
 
Scheme 65. Synthesis of tert-butyl-N-(6-nitro-2-oxo-2H-chromen-3-yl) carbamate. 
Compound 102 was obtained as an off white powder (Scheme 65). 1H NMR showed a doublet at 
8.38 ppm, this was ascribed to the 5-H proton. The electron-withdrawing nitro-group adjacent to the 
5-H aromatic proton accounted for the observed downfield chemical shift. A coupling constant of 
2.4 Hz was noted, and signified meta coupling of the 5-H to the 7-H proton. A singlet at 8.35 ppm 
was attributed to the 4-H. A doublet of doublets at 8.25 ppm was ascribed to the 7-H. The observed 
coupling constants of 8.0 Hz and 2.4 Hz, were concordant with coupling to the 5-H and 8-H 
protons. A doublet at 7.43 ppm was assigned as the 8-H.13C NMR showed 12 resolved signals. IR 
analysis showed an absorption at 3409 cm-1 for the CON-H stretch. An absorption at 3075 cm-1 
was assigned as an Ar-H stretch. Whereas the band at 2976 cm-1 was attributed to a sp3C-H 
stretch. A strong absorption at 1715 cm-1 was indicative of a carbonyl and likely masked the other 
unaccounted for C=O band. Two medium intensity absorptions at 1526 cm-1 and 1509 cm-1 were 
ascribed as aromatic C=C stretches. A strong band at 1338 cm-1 was attributable to the C-NO2 
stretch. A high-resolution accurate of mass of 307.0920 [M+H]+ was observed.  
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3.17 Synthesis of 3-aminocoumarins 
Tert-butyl carbamate groups can be removed under acidic conditions (Scheme 66). Although the 
original described procedure used TFA as its proton source, a higher yield was obtained using 
ethereal HCl.248 Under acidic conditions the oxygen atom of carbamate 103 a becomes protonated. 
Subsequently, this allows the tert-butyl cation to leave in an E1 elimination reaction step. The 
carbocation is stabilised via inductive effects of the adjacent alkyl groups. Decarboxylation gives 
the coumarin product 103 c as the free amine, which forms the corresponding salt 104 a in the 
presence of acid. 
 
Scheme 66. Boc removal under acidic conditions. 
To maximise the quantity of 3-aminocouamrin that could be obtained, the acid stable coumarin 
chromophore could be refluxed in concentrated HCl to remove the acetate group (Scheme 67).249 
The acetate group 105 a under the acidic conditions becomes protonated. Nucleophilic attack from 
water hydrolyses the acetate group. The product 105 e was obtained as the free amine by 
adjusting the pH of the reaction mixture to natural with a suitable aqueous base. The product was 
filtered off as a solid and washed with small aliquots of ethanol, with no further purification 
necessary. This procedure obviated the need to Boc protect the product and removed a reaction 
and purification step. Thus, the synthesis of the 3-aminocoumarin analogues was streamlined.   
 
Scheme 67. Acetate removal with acid. 
 
Scheme 68. Synthesis of 3-amino-2H-chromen-2-one. 
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Compound 104 was isolated as a yellow powder (Scheme 68). 1H NMR showed a complex splitting 
pattern. Multiplets appeared between 7.42-7.40 ppm (1 H), 7.28-7.24 ppm (1 H) and 7.22-7.17 ppm 
(2 H). However, the 4-H was ascribed to a singlet at 6.71 ppm, as confirmed by HSQC. A broad 
singlet at 5.69 ppm (2 H), was attributed to the N-H2. 13C NMR showed 9 resolved carbons. IR 
analysis showed absorptions at 3425 cm-1 and 3313 cm-1 assigned to the N-H2 asymmetric and 
symmetric stretches respectively. Weak absorptions at 3054 cm-1 and 3022 cm-1 were ascribed to 
Ar-H stretches. A strong carbonyl signal was observed for the lactone at 1702 cm-1. A medium 
absorption at 1633 cm-1 was assigned as N-H2 scissoring. A further medium intensity absorption at 
1331 cm-1 was attributed to the C-N stretch. A strong absorption at 888 cm-1 was ascribed as the N-
H2 wagging signal. A high-resolution accurate mass of 162.0550 [M+H] was found.  
 
Scheme 69. Synthesis of 3-amino-8-methoxy-2H-chromen-2-one. 
Compound 106 was isolated as a brown powder (Scheme 69). 1H NMR showed a triplet at 
7.13 ppm (1 H) and two sets of doublet of doublets at 6.97 ppm and 6.92 ppm respectively, each 
with the same integration (1 H). The 4-H signal was a singlet at 6.68 ppm followed by the N-H2 at 
5.69 ppm. Lastly, the a-H3 of the methoxy group appeared as a singlet at 3.86 ppm. The 13C NMR 
showed 10 resolved signals. IR analysis showed two absorptions at 3360 cm-1 and 3338 cm-1 for 
the N-H asymmetric and symmetric stretches respectively. Weak absorptions at 2997 cm-1, 
2969 cm-1 and 2941 cm-1 were attributed to sp3C-H stretches of the methoxy group. An intense 
absorption at 1686 cm-1 was assigned to the carbonyl group of the lactone. An equally strong 
absorption at 1633 cm-1 was ascribed as N-H2 scissoring. Medium intensity absorptions at 
1608 cm-1, 1593 cm-1 and 1571 cm-1 were attributed to C=C stretches. A broad absorption at 763 
cm-1 was assigned as the N-H wagging vibration. A high-resolution accurate mass of 192.0654 
[M+H]+ was found.  
 
Scheme 70. Synthesis of 3-amino-7-methoxy-2H-chromen-2-one. 
Compound 107 was isolated as a yellow powder (Scheme 70). 1H NMR displayed a doublet at 
7.19 ppm (1 H) ascribed to the 8-H proton, followed by a multiplet between 6.83-6.80 ppm (2 H) for 
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the remaining 6 and 5-H aromatic protons. The 4-H appeared as a singlet at 6.70 ppm. A broad 
singlet at 4.06 ppm was for the N-H2. 13C NMR showed 10 resolved signals. IR analysis showed 
absorptions at 3419 cm-1 and 3355 cm-1 for the N-H2 asymmetric and symmetric stretches 
respectively. Weaker absorptions at 3091 cm-1 and 3006 cm-1 were assigned as Ar-H stretches. 
Absorptions at 2744 cm-1, 2669 cm-1 and 2498 cm-1 were indicative of sp3C-H stretches of the 
methoxy group. A prominent absorption at 1707 cm-1 was ascribed to the carbonyl of the lactone. 
Three medium intensity absorptions at 1556 cm-1, 1543 cm-1 and 1510 cm-1 were assigned as C=C 
stretches. A strong absorption at 1250 cm-1 was ascribed as a C-N stretch. A strong absorption at 
1607 cm-1 was attributed to N-H2 scissoring. A broad absorption at 753 cm-1 was assigned as an N-
H wagging absorption. A high-resolution accurate mass of 192.0653 [M+H]+ was found.  
  
Scheme 71. Synthesis of 3-amino-6-chloro-2H-chromen-2-one. 
Compound 108 was isolated as a yellow powder (Scheme 71). 1H NMR showed a doublet at 
7.54 ppm ascribed to the 5-H with a J value of 2.4 Hz, this was more deshielded than normal due 
to the electronegativity of the neighbouring chlorine atom. The 8-H proton appeared as a doublet at 
7.29 ppm with a J value of 8.8 Hz, the adjacent 7-H signal was a doublet of doublets at 7.21 ppm. 
This proton showed long range coupling to the 5-H with J values of 8.4 Hz and 2.4 Hz respectively. 
A singlet at 6.66 ppm was characteristic of the 4-H. 13C NMR showed 9 resolved signals. IR 
analysis showed two absorptions at 3407 cm-1 and 3322 cm-1 attributed to the asymmetric and 
symmetric N-H2 stretches. Weak absorptions at 2916 cm-1 and 2847 cm-1 were indicative of Ar-H 
stretches. A strong absorption at 1708 cm-1 was ascribed to the carbonyl group of the lactone. A 
broad, medium-intensity absorption at 1644 cm-1 was assigned as the N-H2 scissoring. Three 
signals at 1614 cm-1, 1592 cm-1 and 1561 cm-1 were ascribed to the aromatic C=C stretches. A 
broad. medium-intensity absorption at 1169 cm-1 was characteristic of a C-N stretch. An absorption 
at 887 cm-1 was assigned as N-H2 wagging. Lastly, a strong, sharp absorption at 806 cm-1 was 
ascribed to the C-Cl stretch. A high-resolution accurate mass of 196.0159 [M+H]+ was found. 
 
Scheme 72. Synthesis of 3-amino-8-chloro-2H-chromen-2-one. 
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Compound 109 was isolated as a white solid (Scheme 72). 1H NMR showed two doublets of 
doublets at 7.32 ppm and 7.19 ppm. The more deshielded signal at 7.32 ppm was assigned as the 
7-H. HMBC confirmed the assignment, as the 7-H proton had no through bond coupling to the 4-H 
signal. In contrast, the other doublet of doublets at 7.19 ppm did, and this is therefore unequivocally 
was assigned as the 5-H. A triplet at 7.13 ppm was attributed to the 6-H. A singlet at 6.67 ppm was 
assigned as the 4-H. Lastly, a broad singlet at 4.35 ppm was indicative of the N-H2, as confirmed 
by HSQC. 13C NMR showed 9 individually resolved signals. IR analysis showed absorptions at 
3416 cm-1 and 3334 cm-1 for the asymmetric and symmetric N-H2 stretches respectively. A strong 
absorption at 1712 cm-1 was assigned to the carbonyl of the lactone. A medium absorption at 
1638 cm-1 was ascribed to N-H2 scissoring. Additional medium intensity absorptions at 1591 cm-1 
and 1556 cm-1 were assigned as C=C aromatic stretches. A broadened absorption at 1152 cm-1 
was attributed to the C-N stretch. A further absorption at 898 cm-1 was ascribed to N-H2 wagging. 
Lastly, a prominent absorption at 764 cm-1 was assigned as the C-Cl stretch. A high-resolution 
accurate mass of 196.0160 [M+H]+ was observed.  
 
Scheme 73. Synthesis of 3-amino-8-hydroxy-2H-chromen-2-one. 
Compound 110 was isolated as a brown solid (Scheme 73). 1H NMR showed a broad singlet at 
9.94 ppm for the OH group, a triplet at 6.68 ppm for the 6-H position and two doublet of doublets, 
as expected, for the 5-H and 7-H at 6.80 ppm and 6.75 ppm, respectively. The 4-H was shielded, 
compared to its aromatic counter part at 6.66 ppm. HMBC allowed the unequivocal assignment of 
the doublet of doublets, only one pair had through bond coupling to the 4-H singlet, this had to be 
the 5-H as the 7-H was more than 4 bonds away. 13C NMR showed 9 well-resolved signals, 
confirming the successful simultaneous deprotection of both the ester and acetate moieties. IR 
analysis showed two absorptions at 3454 cm-1 and 3456 cm-1 assigned as the N-H2 asymmetric 
and symmetric stretches respectively. A broad absorption at 3364 cm-1 was ascribed to the OH 
group. A strong absorption at 1704 cm-1 was consistent with the carbonyl group of the lactone. A 
similarly strong absorption at 1697 cm-1 was assigned as the N-H2 scissoring. Three signals at 
1611 cm-1, 1594 cm-1 and 1567 cm-1 are attributed to the C=C aromatic bond stretches. A strong 
sharp absorption at 1174 cm-1 was assigned as the C-O stretch. In contrast, a broadened 
absorption at 1144 cm-1 was representative of the C-N stretch. A strong absorption at 761 cm-1 was 
attributable to the N-H2 wagging vibration. A high-resolution accurate mass of 178.0496 [M+H]+ was 
found.  
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Scheme 74. Synthesis of 3-amino-7-hydroxy-2H-chromen-2-one. 
Compound 111 was isolated as a yellow powder (Scheme 74). 1H NMR showed a doublet at 
7.33 ppm ascribed to the 5-H. A singlet at 7.26 ppm was attributable to the 4-H. The N-H2 signal 
was not visible as exchange occurred with water present in the CD3OD, consequently masking the 
signal. A doublet of doublets at 6.80 ppm was ascribed to the 6-H (J1 = 8.0 Hz, J2 = 2.4 Hz). The 6-
H proton experienced splitting from the 5 and 8-H protons.  Lastly, a doublet at 6.73 ppm (J1 = 
2.4 Hz), was assigned as the 8-H. The coupling constant was typical for a long-range meta 
coupling to the 6-H. 13C NMR showed 9 well resolved signals. IR analysis showed two absorptions 
at 3435 cm-1 and 3344 cm-1 for the asymmetric and symmetric N-H2 stretches respectively. A broad 
absorption at 3214 cm-1 was assignable as the phenolic O-H stretch. A strong absorption at 
1678 cm-1 was for the carbonyl of the lactone. A broad medium absorption at 1608 cm-1 was 
ascribed to N-H2 scissoring. An absorption at 1557 cm-1 and 1507 cm-1 was attributed to C=C 
aromatic stretches. The preceding broad scissoring signal for the NH2 likely masked one the C=C 
bond signals.  A broad and strong absorption at 1285 cm-1 was attributed to the C-N stretch. A 
strong absorption at 1125 cm-1 was ascribed as the C-O stretch. A medium absorption at 686 cm-1 
was attributed to N-H2 wagging. A high-resolution accurate mass of 178.0498 [M+H]+ was 
observed.  
3.18 Supercoiling activity of DNA gyrase 
DNA gyrase activity is determined using a supercoiling assay. The individual A and B Gyrase 
subunits can be overexpressed, purified and mixed together to give an active species.250 The A2B2 
heterotetramer is incubated with relaxed plasmid DNA topoisomers, that is, plasmid DNA with 
different linking numbers. The experiment is performed in the presence of 1 mM of ATP at 37 °C for 
30 minutes. In the absence of an inhibitor, the enzyme will supercoil the relaxed DNA, altering the 
linking number and therefore changing the topological state. The reaction is arrested using a 
mixture of chloroform and iso-amyl alcohol (24:1) with STEB buffer. This aqueous-organic 
extraction allows the segregation of DNA into the aqueous layer leaving the enzyme protein in the 
organic solvent. After centrifuging the sample DNA is loaded onto a 1% agarose gel. The 
supercoiled form of plasmid DNA migrates differently through the gel; the condensed arrangement 
allows the DNA to migrate more quickly compared to its relaxed counterpart.  Thus, the level of 
supercoiling, or lack thereof, can be determined visually. This is achieved by resolving relaxed and 
supercoiled DNA by electrophoresis, staining with ethidium bromide and imaging under UV light. 
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The (4.3-Kb) plasmid pBR322 is derived from E. coli and has become a standard substrate for the 
assay.251 The crystal structure of SD8 bound to DNA gyrase was obtained using E. coli, gyrase, 
and as such, this became our organism of choice for screening our compounds.  
3.19 Biological evaluation of coumarin analogues 
The coumarin analogues were screened at a concentration of 50 µM. Compounds identified with 
inhibition below this concentration were predicted to serve as a good lead to progress forward with. 
The results are shown below (Figures 40-42). All of the controls show a good response with a 
strong presence of different topoisomers in the negative control and a strong visible supercoiling 
band in the positive control. SD8 a control inhibitor shows strong inhibition at 1 µM. None of the 23 
analogues show appreciable inhibition of supercoiling activity.  
 
Figure 40. Effects of acetyl protected coumarins on DNA supercoiling by wild type E. coli gyrase. 
Relaxed pBR322 plasmid DNA is used as a negative control (-), and incubated in the presence of 
gyrase as a positive control (+). SD8 is used as a comparator at a concentration of 1 µM. NC 
indicates nicked circle DNA; R, relaxed DNA; SC, supercoiled DNA. 
 
Figure 41. Effects of Boc protected coumarins on DNA supercoiling by wild type E. coli gyrase. 
Relaxed pBR322 plasmid DNA is used as a negative control (-), and incubated in the presence of 
gyrase as a positive control (+). SD8 is used as a comparator at a concentration of 1 µM. NC 
indicates nicked circle DNA; R, relaxed DNA; SC, supercoiled DNA. 
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Figure 42. Effects of free amine coumarins on DNA supercoiling by wild type E. coli gyrase. 
Relaxed pBR322 plasmid DNA is used as a negative control (-), and incubated in the presence of 
gyrase as a positive control (+). SD8 is used as a comparator at a concentration of 1 µM. NC 
indicates nicked circle DNA; R, relaxed DNA; SC, supercoiled DNA. 
3.20 Conclusions  
This work shows the modified Perkin reaction with N-acetylglycine can be applied to a variety of 
starting salicylaldehyde derivatives to furnish 3-aminocoumarins. It was observed that functional 
groups with deactivating-inductive effects, such as nitro groups, have enhanced yields in the 
modified Perkin reaction. This needs to be considered when evaluating the suitability of this route 
for coumarin synthesis. Additionally, this work demonstrates the broad applicability of refluxing in 
HCl to deprotect aminocoumarins as a viable route to streamline access to a variety of 3-
aminocoumarins. 
This work adds to previous findings with the synthesis and biological evaluation of twenty three 
diverse coumarin analogues using established and validated procedures. Four of the analogues 
are novel (83, 87, 98 and 100), which is noteworthy. This is the first body of work to evaluate small 
coumarin fragments with minimal steric bulk on the aromatic ring and 3 position for intrinsic 
inhibition of DNA gyrase to GyrA. They showed no efficacious inhibition at the concentration 
screened. It is highly likely that the inhibitory effect described with the constituent coumarin 
fragment (MGD8N2A) of SD8 is a result of the rigid tetraene linker still having an ability to sterically 
interfere with DNA binding. However, the original paper did not perform cleavage stabilisation to 
confirm the preclusion of a DNA binding event. The dihydroxylated aminocoumarin likely plays a 
crucial part in directing the positioning of the linker through the geometry of its binding. Thus, the 
lack of inhibitory effect can be rationalised as a result of the minimal steric functionalisation at the 3 
position.  
Additionally, this work demonstrates that the presence of a coumarin on its own is unlikely to be 
useful as an inhibitor. CD shows that when SD8 binds there is no conformational change in the 
protein. Therefore, one can deduce that the AC pocket is a well-defined binding area and no 
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modulation of enzyme function occurs upon coumarin binding. It is difficult to evaluate whether the 
coumarins synthesised here bind to the pocket without additional experimental results. One such 
example could be to investigate if a binding event is seen upon addition of the ligands to the DNA 
gyrase enzyme using SPR. However, a limitation of SPR is that a binding event with a small MW 
ligand is more difficult to detect. 
The structure of the aminocoumarin on its own is not favourable for the biological assay conditions. 
In relation to SD8 the presence of two OH groups likely enhances the physiochemical 
characteristics of the compound, alongside the sugar. In contrast, the small, low molecular weight 
analogues tested here do not have favourable physiochemical characteristics for water solubility. 
They can under go π-π stacking and precipitate in the conditions of the assay. This highlights the 
balancing act between lipophilic and hydrophilic characteristics needed for a useful inhibitor.  
Like the constituent fragments of SD8, we were interested to determine whether a coumarin could 
be used to anchor/direct a drug to the DNA gyrase surface. This had not been described in the 
literature and thus warranted further investigation. Individual fragments used in FBDD, derived from 
the parent natural product, often have weak affinity for their target. Thus, the lack of an inhibition 
observed with the coumarin analogues screened did not rule out using the coumarin as a low MW 
fragment. Consequently, we turned our attention to incorporating the coumarin structure into part of 
a larger hybrid molecule. SD8 and its individual fragments with their modest activity individually 
serve as a paradigm for the idea of synergy. The combined effect for the ‘bi-functional’ molecule is 
potent inhibition, with this in mind a proof of concept was to take a simple un-functionalised 
coumarin as a base template and to conjugate it to a pre-existing inhibitor to see if a streamlined 
‘bi-functional’ inhibitor could be discovered.  
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This chapter discusses the literature with respect to quinolone antibiotic hybrids, subsequently 
describing the synthesis and biological evaluation of a coumarin-quinolone hybrid and control 
analogues. The chapter goes on to outline a preliminary exploration into understanding their mode 
of action, followed by the conclusion.  
4.00 Oxazolidinone-quinolone hybrids  
The idea of tethering two chromophores together to give a dual targeting hybrid is not new. 
Previously quinolones have been tethered to the oxazolidinone class of antibiotics to generate dual 
hybrids.252 As formerly discussed (Chapter 1), the oxazolidinones target the bacterial 50S 
ribosomal subunit and interfere with protein synthesis. However, their spectrum of activity is limited 
to Gram-positive organisms.253,254 The lack of clinical efficacy against Gram-negative pathogens is 
ascribable to their inability to permeate the cytoplasm at sufficient concentrations. In contrast, 
quinolones can traverse the OM in Gram-negative organisms. The hybrids were linked through the 
C7 piperazine, taking advantage of the cyclic amine present in both classes of antibacterial. 
Additionally, investigations were made into conjugation at the N1 position (Figure 43, structures 
112-115). The hybrids were screened for antimicrobial activity to determine their minimum 
inhibitory concentrations (MICs) according to the National Committee for Clinical Laboratory 
Standards (NCCLS) guidelines.255 The strains tested were: S. aureus, including a linezolid and 
ciprofloxacin resistant strain, E. faecium, linezolid and ciprofloxacin resistant strains, H. influenza 
and M. catarrhalis the last two being Gram-negative. Linezolid and ciprofloxacin were used 
individually as control comparator compounds. Strikingly, the hybrids linked through the N1 position 
displayed severely abrogated activity for all strains tested. This is in agreement with quinolone 
SAR. In contrast, hybrids joined through the C7 piperazine showed potent activity against Gram-
positive strains. This activity was superior to either parent compound on its own. As an example 
compound 112 had a MIC of 0.25  µg/mL for S. aureus, more active compared to ciprofloxacin (0.5 
 µg/mL) and linezolid (4 µg/mL). It is important to note when the free carboxylic acid of the 
quinolone 114 was masked as an ester 115, the activity was severely attenuated, consistent with 
previously discussed quinolone SAR.  As an example 114 had an MIC of 0.5 µg/mL against S. 
aureus whereas 115 had an MIC of 8  µg/mL. No improvement was observed against Gram-
negative pathogens with the hybrids compared to parent compounds. However, the C7 hybrids 
displayed improved activity against all Gram-positive resistant strains. The authors attribute the 
lack of improved efficacy against Gram-negative organisms as an effect of the sub-optimal pKa of 
the distal nitrogen of the C7 piperazine ring in the hybrids. Building upon this body of work, a 
separate group tethered quinolones and oxazolidinones through the C7 piperazine linker and 
explored the effect of adding an additional pyrrolidinyl or amino azetidyinyl spacer (Figure 43, 
structures 116-118).256 As well as looking at MICs against selected strains, the group evaluated the 
ability to inhibit in vitro supercoiling activity and protein synthesis. 
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Figure 43. Quinolone-oxazolidinone hybrids. 
Hybrids 112 and 116 with a piperazine linker to the oxazolidinone overcame quinolone resistance 
to S. aureus with MIC of 0.25  µg/mL and 0.125  µg/mL respectively. This outperforms the parent 
ciprofloxacin (32 µg/mL).  Similarly, the compounds overcame linezolid-resistant S. aureus with 
MICs of 4 µg/mL and 8 µg/mL respectively compared to 64 µg/mL of the parent linezolid. Hybrids 
117 and 118 with additional spacers also displayed good activity against the same quinolone 
resistant strains. Intriguingly, the authors noted differing effects on supercoiling and protein 
synthesis. The piperazine-linked 112 and 116 compounds showed reasonable supercoiling 
inhibition against DNA gyrase (IC50 20 µM and 50 µM respectively) as well as topo IV (IC50 50 µM 
and 10 µM respectively) compared to ciprofloxacin (0.5 µM DNA gyrase and 5 µM topo IV). 
Nevertheless, they were also able to inhibit protein synthesis both having an IC50 of 2.8 µM 
compared to linezolid (IC50 4.1 µM).  This is in contrast to compound 118 that displays excellent 
supercoiling inhibition, with an IC50 of 0.2 µM and 1 µM for gyrase and topo IV but poor inhibition of 
protein synthesis with an IC50 above 20 µM. The results demonstrated that piperazine-linked 
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compounds are capable of dual targeting. This also highlighted that the introduction of the amino-
pyrrolidinyl moiety conferred a preference for quinolone activity. Furthermore, the work 
substantiated previous findings of dual targeting via these two classes of antimicrobial and 
strengthened the quinolone-SAR relationships.  
4.01 Macrolide-quinolone hybrids 
The quinolone scaffold has been successfully joined at the C6 and C7 positions to the macrolides 
erythromycin, clarithromycin and telithromycin via an ester linkage at the 4” position.257,258 With 
alykylamine chains the authors probed the effect of linker length on antimicrobial activity using 
seven or nine atoms and varying the substituents at the N1 and C6 position. The strains tested 
were macrolide-resistant S. aureus, S. pneumonia, S. pyogenes. Additionally, β-lactamase-
negative ampicillin-resistant H. influenzae was also investigated as a Gram-negative standard. 
Several general SAR trends were noted with the compounds (Figure 44). Hybrids 119 and 120 
showed enhanced activity over all strains tested compared to clarithromycin on its own. The shorter 
linked hybrid 119 possessed improved activity with an MIC of 0.5 µg/mL in a macrolide-resistant 
efflux-mediated S. aureus strain compared to the longer linked compound 120 (2 µg/mL). 
Interestingly, a 7-atom linker with a chlorine substituent at the C7 (121) displayed enhanced activity 
against all strains tested compared to hybrid 119 and the clarithromycin control. However, 
exceptionally, 119 was worse against S. pyrogens (<0.125 µg/mL) compared to telithromycin (0.06 
µg/mL). 
 
Figure 44. Clarithromycin-quinolone hybrids. 
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The same study noted the benefit of a halogen substituent at the C6 position in erythromycin 
quinolone hybrids and illustrated the improved potency of having a cyclopropyl group at the N1 
position. These observations were consistent with previous assessment of quinolone SAR. This 
study demonstrated that a large complex molecule can be tethered to a quinolone molecule without 
deleterious effects on macrolide activity. Moreover, they demonstrated resistance to macrolides 
can be overcome with the addition of a quinolone. A subsequent body of work using novel C4”-
substituted azithromycin macrolides attached to quinolones at the C6 and C7 position provided 
further insight with respect to potential dual targeting.258 This work added to the previous study by 
assessing ciprofloxacin-resistant strains and performing DNA supercoiling assays against DNA 
gyrase and topo IV. The authors utilised a free amine at the end of their chosen linker to facilitate 
coupling of the quinolones to macrolides using HBTU. This resulted in good yields of 60-90%. 
Subsequently, the hybrid compounds were tested against macrolide-susceptible and macrolide-
resistant strains: S. aureus, S. pneumonia, S. pyogenes as well as M. catarrhalis, and H. 
influenzae standards provided by the Pliva Research Institute culture collection.258 The quinolone 
analogues 122-128 (Figure 45) displayed no appreciable activity (MIC > 64 µg/mL) against any of 
the strains. Furthermore, they had no activity against ciprofloxacin resistant S. aureus. In contrast, 
two azithromycin-quinolone hybrids 129, and 130, displayed improved activity against all strains 
including macrolide resistant bacteria when compared to azithromycin and ciprofloxacin on their 
own. The improvement of 129 and 130 against Gram-negative M. catarrhalis (<0.125 µg/mL and, 
0.125 µg/mL respectively) and H. influenzae (both 0.5 µg/mL) compared to azithromycin (0.25 
µg/mL and 1 µg/mL respectively) or ciprofloxacin (0.125 µg/mL and, < 0.125 µg/mL respectively) is 
notable. 
 
Figure 45. Quinolone linker analogues and azithromycin-quinolone hybrids. 
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Interestingly, when the authors probed for bi-functional activity they found that the lead compounds 
129 and 130 lacked the ability to effectively inhibit E. coli DNA gyrase (IC50 70 and 60 µM 
respectively) or topo IV (60 and 50 µM respectively). Contrasting with this, 129 and 130 could act 
as potent inhibitors of protein synthesis with IC50 values of 0.28 µM and 0.35 µM compared to 
telithromycin (0.23 µM). Crucially this work shows a short linker can abolish quinolone activity. 
Furthermore, substitution of the C6 position with a piperazine ring in 123 abrogates quinolone 
activity. The results show that the hybrids demonstrate improved macrolide activity with respect to 
Gram-negative organisms. This is likely not due to dual targeting; rather the presence of the 
quinolone could enhance the ability of the hybrid to traverse the OM of Gram-negative pathogens.  
4.02 Aminoglycoside-quinolone hybrids 
 
Figure 46. NeoB-ciprofloxacin hybrid structures. 
Tethering fluoroquinolones to aminoglycoside antibiotics yields bi-functional hybrids.259 It was 
thought that the strategy of coupling a quinolone to Neomycin B (neoB) would overcome 
resistance. The authors predicted that the positive charge of neoB would be beneficial to quinolone 
binding by facilitating contacts to DNA and/or the DNA-protein interface. The hybrids were joined 
through a 1,2,3, triazole group with spacers on either side (Figure 46). Additionally, commercially 
available ciprofloxacin was alkylated at the C7 piperazine substituent with the appropriate spacer-
azide. In a reverse approach three different alkyne groups were also introduced on the neoB 
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molecule at the 5-OH group. Subsequently, the hybrids were prepared via click chemistry under 
microwave irradiation conditions to give the desired compounds. The hybrids were evaluated for 
their biological activity in vitro, against susceptible and resistant strains with both ciprofloxacin and 
neoB as controls. The study utilised E. coli, B. subtilis and MRSA. The majority of hybrids displayed 
good activity, with better inhibition than neoB on its own against Gram-negative E.coli which 
included the aminoglycoside-resistant AG100A and AG100B strains. However, none of the hybrids 
were more potent than ciprofloxacin. Compound 132 was the most potent inhibitor across all 
strains tested. The majority of these hybrids were less efficacious than the controls against the 
Gram-positive B. subtilis. However, they displayed improved activity against aminoglycoside-
resistant MRSA. To further investigate the hybrids mode of action, the authors checked for in vitro 
inhibition of DNA gyrase, topo IV, and protein synthesis. Remarkably, compounds 131, 132 and 
133 displayed potent inhibition of both DNA gyrase (73 nM, 85 nM 41 nM, respectively) and topo IV 
(0.58 µM, 0.55 µM and 7.90 µM) with better efficacy than ciprofloxacin (1.3 µM, 10.8 µM). They 
also showed good inhibition of protein synthesis (2.20 µM, 16.7 µM and 18.1 µM, respectively) 
when compared to neoB (10.5 µM). Compound 132 performed better in all three assays compared 
to the parent antibiotics. It should be stated that ciprofloxacin is inactive in the protein synthesis 
assay and neoB is inactive in the DNA gyrase and topoIV assay.  These results eloquently highlight 
the steric bulk that can be accommodated at the C7 piperazine position and still result in DNA 
gyrase inhibition. Moreover, these hybrids displayed enhanced efficacy for DNA gyrase and topo IV 
over the highly successful commercial drug, ciprofloxacin. It should be observed that the 
ciprofloxacin molecule used has a free carboxylic acid and no esterified hybrids were synthesised 
in this study. This is important because previous SAR has shown the free acid is essential for 
effective formation of the water-metal ion bridge that stabilises the quinolones during their 
intercalation into double strand breaks (as discussed in chapter 1).18 
4.03 Coumarin-quinolone hybrids 
Two publications have described the synthesis and biological evaluation of novel coumarin-
quinolone hybrids.260,261 The first study combined the structural features of N-(2-arylethyl) 
piperazinyl quinolones and a simple unfunctionalised coumarin to give novel N-[2-(coumarin-3-
yl)ethyl]piperazinyl quinolones. The synthetic strategy used converted acetyl coumarin into its 
bromine or  α-bromo oxime derivative. This was coupled directly to the quinolone derivative in the 
presence of a mild base at room temperature to give the desired product. This provided a brief and 
efficient synthesis. Subsequently, the coumarin-quinolone hybrids were evaluated in vitro for their 
potential antibacterial activity. The control comparator drugs were norfloxacin, ciprofloxacin and 
enoxacin; these compounds were assessed using the agar dilution method.262 The strains tested 
were S. aureus, B. subtilis, Klebsiella pneumonia, P. aeruginosa, Staphylococcus epidermidis, and 
MRSA.  
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The most potent compound, 134, contained a cyclopropyl moiety at the N1 position, consistent with 
quinolone SAR (Figure 47). Three of the four worst performing compounds had a naphthyridine 
core, and the most effective hybrid 134 contained the quinoline scaffold. The MIC was 0.19 µg/mL 
which was comparable to the quinolone controls for S. aureus. All of the hybrids had some activity 
against B. subtilis, but none of the hybrids demonstrated improved activity against Gram-negative 
pathogens compared to the controls.  
 
Figure 47. Structures of efficacious coumarin-quinolone hybrids. 
In this study the linker used is short, and the coumarin is linked through a ketone or oxime not an 
amide. This publication predates the first quinolone and SD8 crystal structures and highlights the 
usefulness of the quinolone scaffold. Also, this indicates the presence of a coumarin does not 
abrogate activity against gyrase.  Supplementing this work, a similarly conjugated coumarin-
gatifloxacin and coumarin-ciprofloxacin hybrids were synthesised and probed for biological 
evaluation.261 The asymmetric compounds were obtained using the bromine or bromo-oxime 
coumarin derivative combined with the appropriately substituted quinolone. In contrast to the first 
study, additional substitutions were explored on the coumarin at the 7’ position as well as the 
piperazine ring. In vitro activity was assessed against M. segmentis and M. tuberculosis. All of the 
hybrids demonstrated good activity against M. segmentis. However, this was no better than the 
control gatifloxacin, ciprofloxacin, rifampicin and moxifloxacin compounds. The best performing 
compound against M. tuberculosis was 135  (0.5 µg/mL), a 7-hydroxycoumarin derivative joined to 
ciprofloxacin. This outperformed ciprofloxacin (1.0 µg/mL), and rifampicin (2.0 µg/mL), and was 
equally as effective as 8-methoxy ciprofloxacin and moxifloxacin. No benefit was seen from 
substitution on the piperazine ring. Furthermore, no relationship was observed between the 
calculated logP values and antimicrobial activity. No supercoiling assays were performed for these 
compounds.  
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4.04 Crystal structure data and rational design  
The previously discussed structures provide a justification of the usefulness of creating quinolone 
hybrids. Furthermore, the work provides insight into the suitable locations for conjugation to 
quinolone molecules. These results combined with the 2014 crystal structure of GyrA55-SD8 
formed the foundation from which our hypothesis was derived.184 The GyrA55-SD8 structure 
revealed that two molecules of SD8 were responsible for binding to DNA gyrase. The mode of 
action of the natural product is to ‘staple’ across the surface of the GyrA homodimer interface at the 
DNA gate. Consequently, this prevents DNA strand passage and precludes the conformational 
changes necessary in order for the enzyme to bind DNA. The aminocoumarin and the polyketide of 
SD8 occupy well defined pockets. The polyketide portion spans both surfaces of the gyrase 
homodimer (Figure 48). Interestingly, the GyrA55-SD8 structure showed the orientation of the 
coumarin was different from the previous GyrA59-SD8 structure (Figure 49). The consequence of 
this alternative conformation on the angle that the linker exits the aminocoumarin pocket is 
pronounced. This highlights some of the limitations of x-ray crystallography. Careful interpretation 
is required when evaluating data, as the resultant structure could be an artefact of the 
crystallisation process and not representative of the conformation adopted in solution. Furthermore, 
what is presented is a ‘snap shot’ in time. Published crystal structures for both SD8 and quinolones 
are available. However, the most recent structures of SD8 and quinolones are supported by in vitro 
mutational data that substantiates the observed conformations. Thus, the latest SD8 crystal 
structure is likely a true reflection of the conformation adopted by SD8 at low concentrations in 
solution.  
 
Figure 48. Crystal structure of the GyrA55-SD8 complex (PDB 4CKL). Two SD8 molecules 
(magenta) span different GyrA homodimers, one is shown in orange the other in blue.184 
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It has also been shown that close sequence similarity occurs between S. aureus and E. coli 
gyrase.263 This has suggested that the binding site of the N-terminal domain of SD8 bound to E. 
coli gyrase (PDB ref 4CKL) and the interaction between ciprofloxacin, DNA and S. aureus gyrase 
(PDB ref 2XCT) warranted further investigation.88 Analysis revealed that the quinolone binding 
pocket is in close proximity to the D-olivose sugar of SD8 (Hearnshaw unpublished data), this is 
shown in Figure 50 below. Inspired by the bi-functional structure of SD8 we sought to take 
advantage of both binding pockets using a fragment based approach to develop a novel class of 
gyrase inhibitor. No coumarins with low affinity for gyrase were identified in chapter 2, thus we 
reasoned to use the most simplistic scaffold in order that we could probe future SAR. 
 
Figure 49. Different orientations of the aminocoumarin bound to GyrA. The GyrA55-SD8 structure 
is shown in magenta, the GyrA59-SD8 structure is shown in green.184 
 
Figure 50. Crystal structure of SD8 (magenta) in complex with GyrA55.184 The position of 
ciprofloxacin (yellow), from the S. aureus gyrase structure, is obtained by superposition of the E. 
coli and S. aureus gyrase structures (Hearnshaw unpublished data).88 One GyrA monomer is 
shown in orange, the other in blue. 
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It was envisaged that a simple coumarin could be tethered to a ciprofloxacin molecule using a 15 Å 
linker that would generate an asymmetric hybrid. The unfunctionalised coumarin was predicted to 
still be able to maintain hydrogen bonds with Arg91 via the lactone in the aminocoumarin pocket. 
Furthermore, it was hypothesised that the linker would preserve hydrophobic interactions with 
Ser171. It has previously been shown that dual hybrids can successfully overcome resistance and 
exert a bi-modal action on their therapeutic targets. As a strong body of literature existed for 
quinolone hybrids, we chose the validated ciprofloxacin structure. From SAR it has been well 
established that the largest accommodation of steric bulk is in the C7 position for quinolones, thus 
setting a precedent. Furthermore, efficacious targeting of gyrase would likely require a free 
carboxylic acid. Based on the information from Figure 50 it was theorised that the synthetic 
analogue 136 would be able to adopt a favourable conformation to take advantage of the two 
identified binding sites (Figure 51). 
 
Figure 51. Structure of the target hybrid 136. 
4.05 Synthesis  
With a rational starting point for the generation of asymmetric analogues, the focus turned to 
developing a viable synthetic route. Preliminary work with ciprofloxacin as a commercially available 
free acid proved unfruitful. Ciprofloxacin 137 is only soluble in aqueous acid, thus limiting the scope 
of chemistry available for downstream reactions. To surmount this problem, the carboxylic acid was 
masked as an ester. This conferred the advantage of reducing unwanted side products, and made 
the compound easier to handle in organic solvents.  This was achieved using SOCl2 to form the 
reactive acyl chloride. Both MeOH and EtOH were tried as protecting alcohols, EtOH was found to 
be more favourable with higher yields and cleaner reactions, consonant with previous work 
(Scheme 75).264 Often, a white solid was filtered off during the work up, and this was not soluble in 
either aqueous or organic solvent and was predicted to be polymerised ciprofloxacin. The acid 
chloride is free to react with the secondary amine present on another ciprofloxacin molecule in an 
intermolecular fashion. Furthermore, the secondary amine of the piperazine heterocycle has the 
capacity to form a sulphonamide. These unwanted side products could account for the moderate 
yields observed.  
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Scheme 75. Synthesis of ethyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazine-1-yl)-1,4 
dihydroquinoline-3-carboxylate. 
Compound 138 was isolated as a colourless powder (Scheme 75). The 1H NMR spectrum showed 
a deshielded singlet at 8.42 ppm for the 2-H proton, the downfield signal was due to conjugation 
with both the ketone and carbonyl of the ester. A doublet at 7.88 ppm with a JHF = 12.0 Hz value, 
was ascribed as the proton ortho to the fluorine group. These observations were confirmed by a 19F 
decoupling experiment, whereby the doublet was transformed into a singlet . The remaining doublet 
at 7.20 ppm was the aromatic proton meta to the fluorine group with JHF = 8.0 Hz. A quartet at 4.32 
ppm with an integration of 2 H was indicative of the CH2 group adjacent to the CH3 of the ester. A 
multiplet at 3.43-3.38 ppm represented the a-H of the cyclopropyl. Further upfield the piperazine 
alkyl groups displayed a distinguishing high order splitting pattern ‘roofing effect’ at 3.21-3.05 ppm 
due to a plane of symmetry from the C1’ to C4’ position. A prominent triplet at 1.35 ppm integrating 
for 3 H was the CH3 portion of the ester. Lastly, the CH2 groups of the cyclopropyl moiety formed 
disparate upfield multiplets at 1.30-1.25 ppm and 1.11-1.07 ppm respectively. COSY analysis 
confirmed the interaction between the CH of the cyclopropyl and the ascribed CH2 groups. 13C 
NMR showed the most downfield signal at 173.1 ppm (JCF = 2.0 Hz) as a doublet for the C4 
position; it was split due to the presence of fluorine. The next doublet appeared at 153.4 ppm with a 
large coupling constant of 247.0 Hz, this could easily be mistaken for two separate carbons, but 
was the C6 position experiencing the strongest effect of the halogen. Subsequently, a doublet 
occurred at 144.9 ppm (JCF = 10.0 Hz) for the C7 whereas the C4a appeared at 122.8 ppm (JCF = 
7.0 Hz). The ortho C5 signal was at 113.0 ppm (JCF = 23.0 Hz) with the meta C8 at 104.8 ppm 
having a much smaller coupling constant (JCF = 3.0 Hz). The last doublet was at 51.4 ppm (JCF = 
4.0 Hz) assigned to both the piperazine C2’ substituents. The piperazine C2’ and C3’ ring had 
equivalence showing only two signals for the four carbons, as did the cyclopropyl group Cb atoms 
with a single upfield signal at 8.2 ppm. A further 9 resolved carbons were present, giving a total of 
16 carbons which is correct for a compound with the formula C19H22FN3O3 . 19F{1H} NMR proton 
de-coupled showed a single peak at -123.7 ppm indicating a single fluorinated compound was 
present. IR analysis showed absorptions between 2942-2820 cm-1 for the CH2 and CH3 groups, two 
carbonyl absorptions occurred at 1716 cm-1 and 1617 cm-1. A high-resolution accurate mass of 
360.1720 [M+H]+ was observed.   
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The synthesis of the tetraene linker has been previously described in the literature.265 However, this 
stereoselective synthesis is complex and time consuming. It was noted that usable quantities of the 
linker could be obtained from the hydrolysis of the commercially available fumagillin 139.266,267 This 
compound could be used to circumvent the requirement for a total synthesis.  
 
Scheme 76. Synthesis of (2E, 4E, 6E, 8E)-deca-2, 4, 6, 8-tetraenedioic acid. 
Compound 140 was isolated as a pale yellow powder in 49% yield (Scheme 76). 1H NMR showed 
a broad singlet at 12.28 ppm (2 H) assigned to the carboxylic acid protons. Next, appeared a 
doublet of doublets at 7.25 ppm (J1 = 16.0 Hz, J2 = 12.0 Hz) integrating for 2 protons. This was 
ascribable to the c’ and h’-H. The splitting pattern was due to the adjacent b’/i-H and the d’/g’-H 
protons. The remaining core of the linker appeared as two multiplets between 6.82-6.75 ppm (2H) 
and 6.66-6.56 ppm (2H). Lastly, a doublet appeared at an upfield region of 5.99 ppm (J = 16.0 Hz), 
attributed to the b’ and i’-H signals. The reciprocal coupling to the c’ and h’-H was evident from the 
coupling constant. This signal was the most upfield of the protons, this was unexpected. It was 
predicted adjacent electronegative atoms would de-shield the b’ and i’-H protons and result in a 
downfield signal. One explanation is that the overlapping p-orbitals of the unsaturated linker allow 
the delocalisation of electrons. The electron density is then drawn towards the carboxylic acid 
termini via induction. 13C NMR showed 6 resolved signals due to the chemical equivalence present 
in the molecule.  IR analysis showed two broad signals at 2818 cm-1 and 2534 cm-1 assigned as O-
H stretches. A high-resolution accurate mass of 193.0505 [M-H]- was found.  
With the successful isolation of the unsaturated linker, attempts were made to couple this to a 
simple coumarin. Initial efforts were made to convert the diacid into the corresponding acyl chloride 
facilitating the coupling of the free amino coumarin (Scheme 77). These attempts failed to give the 
desired compound. Instead, a sticky insoluble mass was obtained that was difficult to work with. 
We turned to an alternative approach using standard peptide coupling conditions EDC and 30% 
pyridine in DCM. However, similar to the acid chloride product an insoluble sticky mass was 
obtained. Proton 1H NMR analysis provided little insight, other than the presence of multiple 
products. Unsuccessful attempts were made to remove impurities by triturating with solvents that 
the starting materials were known to be soluble in (DCM, MeOH, EtOAc). 
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Scheme 77. Attempted synthesis of 9-[(2-oxo-2H-chromen-3-yl) carbamoyl]. 
Empirically, it was noted that the isolated tetraene linker was very insoluble, with the NMR only 
obtainable in DMSO. This property; combined with the poor solubility of the parent coumarin, could 
account for the unsuccessful coupling. Moreover, due to the free diacid being utilised there would 
be a high possibility of dimer formation, particularly with the acid chloride methodology. Alternative 
approaches that could have been pursued included selective esterification of one end of the diacid 
followed by selective mono-coupling. However, reflecting on the poor physiochemical properties of 
the linker, it was decided to try using a commercially available saturated linker as previously a 
successful mono-coupling to a coumarin had been described.268 
 
Scheme 78.  Synthesis of 9-[(2-oxo-2H-chromen-3-yl) carbamoyl] nonanoic acid. 
3-Aminocoumarin 104 was synthesised as described previously. In order to access the asymmetric 
hybrid it was necessary to obtain a mono-coupled product 142. This was achieved using a 
previously reported procedure whereby coumarin is refluxed in the presence of sebacoyl 
chloride.268 Compound 142 was isolated as an off-white powder after purification by flash column 
chromatography (Scheme 78). 1H NMR showed a carboxylic acid peak downfield at 11.97 ppm, a 
broader singlet at 9.66 ppm represented the NH peak of the amide bond. HSQC analysis confirmed 
no carbon was correlated to the proton signal. The 4”-H of the coumarin appeared as a singlet at 
8.64 ppm. The four aromatic protons were non-equivalent, creating a complex splitting pattern 
termed an ABCD spin system. A doublet of doublets occurred at 7.70 ppm (1 H) and two multiplets 
between 7.52-7.48 ppm (1 H) and 7.40-7.32 ppm (2 H) respectively. 13C NMR showed 19 resolved 
carbon signals. IR analysis showed a broad OH signal at 3289 cm-1 which was overlapped by a 
sharp CONH stretch. The alkyl signals appeared at 2920-2843 cm-1. Furthermore, three carbonyl 
absorptions were seen at 1728 cm-1 for the lactone, as well as 1685 cm-1 and 1682 cm-1 for the 
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carboxylic acid and amide. Due to their similar values they could not be differentiated. A 
confirmatory high-resolution accurate mass of 346.1649 [M+H]+ was found. Reaction yields were 
moderate; this can be accounted for by the low reactivity of the aniline type nitrogen found on the 
coumarin, and competing dimer formation during the reaction. However, in order to circumvent a 
deprotection and purification step, a free diacid was intentionally utilised during the synthesis of the 
mono-coupled aminocoumarin. This approach had the advantage of allowing the product to be 
directly carried forward to the coupling reaction with the ciprofloxacin-ester fragment 138. 
Previously described methods successfully use 30% pyridine in DCM with EDC to partner aliphatic 
linkers with aminocoumarin scaffolds.269,270 Consequently these conditions proved fruitful for 
promoting amide bond formation to the secondary amine of the C7 piperazine group of the 
ciprofloxacin-ester fragment. Attempts to couple both fragments together via an acid chloride where 
unsuccessful. A significant disadvantage of the acid chloride methodology is the harsh reaction 
conditions, which limits its utility. In contrast, carbodiimides are a versatile class of activating 
agents for promoting amide and ester formation. Highly reactive O-acylisourea intermediates can 
be generated from the interaction between a carboxylic acid and the two basic nitrogen atoms 
found in carbodiimides. The active species readily couples with amine derivatives to form an amide 
bond. A consequence of the highly reactive nature of carbodiimides is the unwanted formation of 
side products. O-acylisoureas can undergo an intramolecular reaction to acetylate the nitrogen 
atom of the carbodiimide to form the inactive species. Additionally, cyclisation can occur to form an 
oxazolone heterocycle; whilst this can be ring opened to form the desired product, it also allows for 
racemisation to take place (Scheme 79).271,272 
 
Scheme 79. Inversion of stereochemistry via oxazolone intermediate highlighted in red and blue. 
 
Scheme 80. Synthesis of 1-cyclopropyl-6-fluoro-4-oxo-7-(4-{9-[(2-oxo-2H-chromen-3-
yl)carbamoyl]nonanoyl}piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate. 
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EDC and its by-products possess the added advantage of being water soluble and thus can easily 
be removed from the reaction mixtures by performing an aqueous/organic work up. With no 
stereocenters in the coumarin-quinolone hybrid there was no capacity for racemisation to occur. 
The mild peptide coupling conditions yielded the asymmetric protected coumarin-quinolone hybrid 
in a viable yield of 44%. Compound 144 was isolated as a colourless powder (Scheme 80). 1H 
NMR showed two singlets at 8.68 ppm and 8.50 ppm corresponding to the 4”-H and 2-H protons. 
The NH singlet at 8.06 ppm was broad and overlapped one of the aromatic ciprofloxacin doublets 
at 8.02 ppm. The aromatic protons for the simple coumarin appeared as multiplets between 7.50-
7.41 ppm (2 H) and 7.32-7.24 ppm (3 H), the latter multiplet also overlaid the remaining 
ciprofloxacin doublet signal and this accounted for the integration of 3. A quartet occurred at 
4.38 ppm for the d-H2 signal and was a defining feature of this compound. Two apparent triplets at 
3.84 ppm and 3.69 ppm corresponded to the 3’-H2 signals of the piperazine ring. It should be noted 
that these were significantly broadened; and have been reported as they appear (Figure 52).  They 
were not true triplets by virtue of the fact that the coupling constants were not the same. They did 
serve as a useful indicator of successful coupling to the secondary amine as there was no longer a 
plane of symmetry from the C1’-C4’ position. Thus, while the preceding compound had two signals, 
the product had four. These peaks were more deshielded due to the adjacent carbonyl group, 
compared to the sister 2’ signals. The HSQC data showed that the carbons correlated to these 
signals were not split by fluorine, supporting the assignment described here.   
 
 
Figure 52. Piperazine signals for compound 144. 
A multiplet between 3.44-3.39 ppm for the a-H signal of the cyclopropyl preceded the remaining 
two apparent triplets at 3.26 and 3.20 ppm assigned for the 2’-H2 protons. The b’ and i’-H2 alkyl 
groups appeared as an intermingled multiplet between 2.44-2.35 ppm integrating for 4. Similarly, 
the c’ and h’-H2 groups were sufficiently different from the main alkyl chain to appear as a separate 
multiplet between 1.74-1.64 ppm. The remaining d’, e’, f’, and g’-H2 signals overlapped the e-H3 
and one of the cyclopropyl b-H2 signals to form a large coalesced multiplet between 1.41-1.30 ppm 
integrating for 13 protons. 13C NMR showed a deshielded doublet at 173.1 ppm (JCF = 1.0 Hz) that 
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appeared for the carbonyl of the C4, followed by four non-split signals at 172.7 ppm, 171.9 ppm, 
165.9 ppm, and 159.0 ppm for the remaining carbonyl groups. A doublet occurred at 153.5 ppm 
(JCF = 247.0 Hz) for the C6 position, whilst another doublet occurred at 144.2 ppm (JCF = 10.0 Hz) 
for the C7 position followed by 123.6 ppm (JCF = 7.0 Hz) for the C4a quaternary carbon. A further 
doublet at 113.6 ppm (JCF = 23.0 Hz) indicated the aromatic C5 whilst a doublet at 105.2 ppm (JCF 
= 3.0 Hz) was allocated to the C8 position. The piperazine ring carbon atoms were distinct as the 
C2’ experienced effects from the F atom whereas the C3’ carbon atoms did not. The C2’ piperazine 
ring generated two doublets at 50.8 ppm (JCF = 6.0 Hz) and 49.7 ppm (JCF = 3.0 Hz) respectively. In 
total, 37 carbons were observed (counting doublets as one). This was correct for a compound with 
the formula C38H43FN4O7 where the cyclopropyl Cb signals were equivalent and thus showed only 
as a single observable peak. The 19F{1H} spectral data contained a single peak at -123.9 ppm, as 
expected for the proton decoupled NMR. This indicated that only one fluorine containing product 
had been isolated after purification. IR showed an absorption at 2928 cm-1 and 2851 cm-1 for the 
CH2 and CH3 groups, followed by strong bands at 1720 cm-1, 1682 cm-1 and 1615 cm-1 for three of 
the five the carbonyl groups. The spectrum was complex, as expected, and it was highly likely the 
remaining carbonyl groups were hidden under the aforementioned absorptions. A high-resolution 
accurate mass of 697.3189 [M+H]+ was obtained. RP-HPLC alongside the NMR evidence indicated 
that the product had 97% purity. 
To liberate the carboxylic acid moiety, lithium hydroxide (LiOH) monohydrate was used as a strong 
base to hydrolyse the ester, releasing methanol as the side product. The hydroxide anion acts as a 
nucleophile to attack the electropositive carbonyl of the ester. The tetrahedral intermediate loses 
the methoxide ion to reform the carbonyl bond and generate the acid. The methoxide anion is a 
good leaving group due to its ability to stabilise the negative charge. The anion can rapidly pick up 
a proton from the environment to form its corresponding alcohol. 
 
 
Scheme 81. Synthesis of 1-cyclopropyl-6-fluoro-4-oxo-7-(4-{9-[2-oxo-2H-chromen-3-
yl)carbamoyl]nonanoyl}piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid. 
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Compound 145 was isolated as a cream powder in 40% yield (Scheme 81). 1H NMR showed a 
downfield singlet at 14.9 ppm ascribed to the carboxylic acid, indicating that the deprotection was 
successful. Further evidence was provided by the lack of a quartet and triplet in the spectra. A 
second singlet occurred at 8.76 ppm and was attributable to the 2-H, followed closely by the 
coumarin 4”-H at 8.69 ppm. The NH showed itself as a broad singlet at 8.06 ppm. The remaining 
aromatic protons appeared as a doublet at 8.03 ppm (1 H), and two multiplets at 7.50-7.42 ppm (2 
H) and 7.37-7.28 ppm (3 H) and accounted for all 6 aromatic protons present in the final product. 
As observed with the parent compound, the 3’-H2 piperazine signals appeared as apparent triplets 
at 3.87 ppm and 3.72 ppm followed by the a-H of the cyclopropyl group as a multiplet at 3.57-
3.51 ppm. The remaining 2’-H2 apparent triplets occurred at 3.35 ppm and 2.39 ppm. Two triplets 
were seen for the b’ / i’-H2 at 2.43 ppm and 2.38 ppm. The c’ and h’-H2 signals were merged due to 
their similar environment and produced a multiplet at 1.75-1.67 ppm. The remaining alkyl chain was 
a coalesced multiplet at 1.42-1.33 ppm accounting for the d’, e’, f’, g’-H2 which overlapped a b-H2 
signal of the cyclopropyl group to give a total integration of 10 protons. The remaining b-H2 signal 
was assigned to an upfield multiplet at 1.22-1.18 ppm. 13C NMR showed the C4 carbonyl was a 
doublet at 177.3 ppm (JCF = 2.0 Hz) and the remaining carbonyls were accounted for at 172.7 ppm, 
172.0 ppm, 167.0 ppm, and 159.0 ppm, a characteristic region for this type of signal. The C6 
showed itself as a doublet at 153.7 ppm (JCF = 248.0 Hz), followed by the C7 doublet at 145.6 ppm 
(JCF = 10.0 Hz) and the C4a position at 120.5 ppm (JCF = 8.0 Hz). The aromatic C5 position was 
ascribed to a doublet at 112.8 ppm (JCF = 23.0 Hz) and the C8 at 105.2 ppm. The final piperazine 
C2’ signals were split at 50.5 ppm (JCF = 6.0 Hz) and 49.6 ppm (JCF = 3.0 Hz). The remaining 
carbons were well resolved giving a total of 36, with the Cb carbons being equivalent. This 
accounted for all the carbon atoms in a compound with the formula C36H39FN4O7.19F{1H} NMR 
proton decoupled showed a singlet at -121.1 ppm which indicated only one fluorine containing 
product had been obtained. This was very similar to the antecedent compound. Due to the need to 
conserve this sample for biological testing no IR or melting point analysis was performed. A 
corroborating high-resolution accurate mass of 659.2874 was found [M+H]+. The purity as judged 
by RP-HPLC was 98%.   
To establish the effect, if any, of the coumarin on DNA gyrase activity it was necessary to 
synthesise two control compounds. Aniline 146 was selected to confirm whether the binding affinity 
was driven by the ability of the aminocoumarin to bind to GyrA. It was predicted hydrogen bonding 
from the exocyclic carbonyl group would be crucial for this binding to the aminocoumarin pocket. 
There also was a need to establish the effect of linker introduction on quinolone activity. 
Consequently, this would allow us to attribute any observed activity to the aminocoumarin scaffold 
as opposed to a non-specific aromatic effect.  
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Scheme 82. Synthesis of methyl 9-(phenylcarbamoyl)nonanoic acid. 
Commercially available aniline 146 was coupled to monomethyl sebacate using the previously 
validated peptide coupling conditions (Scheme 82).273 This procedure worked well with a high yield 
of 83%.  Compound 147 was isolated as a colourless powder. 1H NMR showed a singlet integrating 
for 1 H at 7.57 ppm for the NH proton, as indicated by HSQC analysis. The remaining signals in 
this region were for the aromatic protons. Interestingly, they appeared as apparent triplets at 
7.29 ppm and 7.07 ppm. The signals were broad, indicating a dynamic self-association, most likely 
with the linker (Figure 53) which due to its flexible nature, can wrap back on itself.  
 
Figure 53. Inter/intra molecular hydrogen bonding phenomenon. 
 
Figure 54. Improved resolution of peaks using wet DMSO solvent. 
Alternatively, the compound could have been aggregating with other molecules of itself i.e. in an 
intermolecular fashion. The broad signals were reduced in the presence of wet DMSO compared to 
anhydrous CDCl3 (Figure 54). This was ascribable to the presence of water as indicated by the 
proton NMR at 3.33 ppm. Water molecules can hydrogen bond to the compound and diminish the 
inter/intra-molecular hydrogen bonding phenomenon from occurring. Although chloroform itself is 
hygroscopic, the spectrum was obtained using a dry ampoule. However, the spectrum indicated 
that no water was present. Consequently, the broadened signals were therefore not true triplets. 
NH2
30% pyridine/DCM
monomethyl sebacate
rt
19 h
83%
2"
1"
4"3" HN
O
i'
h'
g'
f'
e'
d'
c'
b'
a'
O
O
146 147
Chapter 4. Coumarin-quinolone hybrids as potential dual inhibitors of DNA gyrase 
 
 
 
 
137 
Averaging of the spectra by the experimental parameters caused the loss of resolution due to the 
exchange phenomenon. Due to second order coupling effects, the true splitting pattern was highly 
complex being an AA’BB’C system with similar chemical shifts for each coupled interacting nuclei. 
The aromatic had a plane of symmetry running through the C1’ and C4’ positions. Assignments 
have been made according to how the signals appeared in the NMR spectra. The remaining 
portion of the compound in CDCl3 can be assigned as a prominent singlet at 3.65 ppm for the 
methyl group. The alkyl chains formed overlapping multiplets between 2.36-2.28 ppm (4 H), 1.73-
1.66 ppm (2 H), 1.62-1.56 ppm (2 H) and 1.36-1.26 ppm (8H). The 13C NMR displayed 15 resolved 
signals, the aromatic core had equivalence and thus, only 4 signals instead of 6 were observed. 
Lastly, two carbons of the alkyl chain were also chemically and magnetically equivalent. This was 
attributed to the Cf’ and Ce’ in the centre of the chain which experienced an identical environment 
giving a single isochronous chemical shift. IR analysis showed a strong absorption at 3359 cm-1 
assigned to the CONH, the CH2 and CH3 appearing between 2927-2849 cm-1 and two carbonyl 
signals were observed at 1713 cm-1 and 1682 cm-1. A correct high-resolution accurate mass of 
292.1905 was found [M+H]+.  
 
Scheme 83. Synthesis of 9-(phenylcarbamoyl)nonanoic acid. 
The methyl ester 147 was de-protected using lithium hydroxide monohydrate similar to the 
previously synthesised coumarin hybrid (Scheme 83). A slight modification was made to the 
solvent system with EtOH and water being utilised in a 2:1 ratio. Similar compounds have been 
successfully de-protected with these conditions.274 Compound 148 was isolated as a colourless 
solid after being recrystalised from EtOH and washed with hexane (66%). Having observed the 
broadened signals for the parent compound, MeOD was intentionally chosen as a protic NMR 
solvent to try and obtain the best resolution of the aromatic signals. 1H NMR showed complex 
multiplets for the aromatic AA’BB’C system at 7.54-7.52 ppm (2H), 7.31-7.26 ppm (2 H) and 7.09-
7.05 ppm (1 H). The loss of the methyl peak was apparent with no singlet integrating for 3 H, 
indicating the successful removal. Two triplets appeared at 2.36 ppm and 2.27 ppm (J = 8.0 Hz), 
attributed to the b’ and i’-H2 positions of the linker. Two multiplets appeared at 1.73-1.66 ppm (2 H) 
and 1.64-1.56 ppm (2 H) for the c’ and h’-H2 peaks. The remaining alkyl signals were under one 
large multiplet at 1.41-1.32 ppm (8 H). 13C NMR showed 14 resolved signals as anticipated. IR 
showed the CONH at 3300 cm-1 overlapping a broad OH absorption. Furthermore, CH2 signals 
appeared between 2916-2848 cm-1. Lastly, two carbonyl signals showed themselves at 1689 cm-1 
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and 1659 cm-1. A corroborating high-resolution accurate mass of 276.1600 [M-H]- was found using 
electrospray ionisation in negative mode.  
 
Scheme 84. Synthesis of Ethyl 1-cyclopropyl-6-fluoro-4-oxo-7-{4-[9-
(phenylcarbamoyl)nonanoyl]piperazine-1-yl}-1, 4-dihydroquinoline-3-carboxylate. 
With the free carboxylic acid terminus available, it was possible to couple the ester-protected 
ciprofloxacin fragment 138 to form the penultimate aromatic control compound. After purification by 
flash column chromatography, compound 149 was obtained as a cream solid (Scheme 84). 1H 
NMR in CDCl3 showed the most deshielded proton was the 2-H position at 8.54 ppm as a singlet 
followed by an aromatic proton in the 5-H position. This was ortho to the fluorine and has a large 
coupling constant of 16.0 Hz. Subsequently, signals from the aniline aromatic moiety appeared as 
an apparent doublet at 7.52 ppm for the 3”-H, and an apparent triplet at 7.31 ppm for the 2”-H, 
which overlapped the NH signal. The remaining ciprofloxacin aromatic 8-H signal appeared at 
7.26 ppm (J = 8.0 Hz), consistent for para coupling. The last aromatic proton was correlated to the 
1”-H aniline aromatic, and appeared as an apparent triplet at 7.09 ppm. The d-H2 group of the ester 
occurred, as expected, as a prominent quartet at 4.38 ppm. This was followed by the two 3’-H2 
groups of the piperazine ring as very broadened apparent triplets at 3.85 ppm and 3.69 ppm. Next 
appeared a multiplet for the a-H of the cyclopropyl ring between 3.44-3.38 ppm. Subsequently, the 
remaining 2’-H2 alkyl groups of the piperazine appeared as another set of broadened apparent 
triplets at 3.26 ppm and 3.21 ppm. The linker showed as multiplets between 2.39-2.32 ppm (4 H) 
and 1.74-1.62 ppm (4 H). These were in the correct downfield region for alkyl chains, and were 
interspersed with a true triplet at 1.41 ppm (J = 8.0 Hz) for the e-H3 portion of the ethyl ester. The 
signals for the remaining core of the linker all overlapped due to their very similar environment to 
form a large coalesced multiplet between 1.38-1.29 ppm (d’, e’, f’, g’-H2). Crucially, one of the 
cyclopropyl b-H2 groups was also under this multiplet accounting for the integration of 10 H. The 
remaining cyclopropyl d-H2 was assigned to the upfield multiplet between 1.15-1.11 ppm. The 
19F{1H} NMR showed one singlet at -124.0 ppm indicating only one fluorinated product was 
present. The most deshielded signal in the 13C NMR at 173.2 ppm was ascribable to the carbonyl 
of the C4 position which was split to give a doublet (JCF = 2.0 Hz). The amide carbonyl groups were 
at 172.0 ppm and 171.9 ppm. The least deshielded carbonyl was the Cc of the ciprofloxacin 
fragment at 165.6 ppm. The C6 position was characteristic at 153.3 ppm with its large JCF of 
247.0 Hz. The C7 was a doublet at 144.1 ppm (JCF = 10.0 Hz), whereas the C4a doublet appeared 
at 123.4 ppm (JCF = 7.0 Hz). The C5 and C8 positions were assigned based on their relative 
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positions in the 1H NMR, J values and observed coupling in the HSQC. The more upfield C5 was at 
113.3 ppm (JCF = 23.0 Hz) whereas the C8 position appeared at 105.2 ppm with a much smaller 
coupling (JCF = 2.0 Hz). Lastly, the two piperazine signals of 2’ were also split at 50.5 ppm (JCF = 
4.0 Hz) and 49.7 ppm JCF = 3.0 Hz.). The linker, as expected for the C5” and C6” carbons was 
equivalent, giving a single peak at 29.2 ppm. The protons for the cyclopropyl group, were not in 
different environments, thus the carbons are equivalent, giving a single signal at 8.2 ppm. A further 
20 resolved carbon signals, as expected, are seen giving a total of 31 carbons. Taking into account 
splitting (counted as one) and equivalent environments this was the correct number for a molecule 
with 35 carbons. IR analysis showed an absorption at 3286 cm-1 for the CONH, with alkyl groups 
appearing between 2923-2853 cm-1. Only two carbonyl absorptions could be seen clearly, at 
1732 cm-1 and 1615 cm-1. A high-resolution accurate mass of 619.3290 [M+H]+ was observed. 
 
Scheme 85.  Synthesis of 1-cyclopropyl-6-fluoro-4-oxo-7-{4-[9-
(phenylcarbamoyl)nonanoyl]piperazin-1-yl}-1,4-dihydroquinoline-3-carboxylic acid. 
Deprotection of the 149 using a mixture of ethanol and water with lithium hydroxide monohydrate 
gave the desired final compound 150 as a cream powder in 64% with no further purification 
necessary (Scheme 85). 1H NMR in DMSO showed a very downfield signal at 15.19 ppm (1 H) 
typical of a carboxylic acid, followed by the NH (1 H) as a broad singlet at 9.84 ppm. The 2-H 
occurred as a singlet at 8.67 ppm. The remaining aromatic protons occured in the appropriate 
region; a true doublet appeared at 7.94 ppm (JCF = 13.2 Hz) for the 5-H signal. An apparent doublet 
at 7.58 ppm (3 H), was comprised of two signals from the aniline and one from the 8-H 
ciprofloxacin. The apparent triplet at 7.27 ppm (2 H) and 7.01 ppm (1 H) are consigned to the 
remaining aniline protons. Extra validation of the successful deprotection comes from the lack of a 
quartet and triplet for the ester. A multiplet appeared at 3.85-3.79 ppm for 1 H indicative of the a-H 
of the cyclopropyl moiety. The piperazine 3’-H2 were represented by a broadened apparent triplet at 
3.68 ppm. This was poorly resolved and integrated for 4 H. The remaining portion of the 2’-H2 
piperazine overlaped a residual water signal, and showed as a broad multiplet from 3.36-3.29 ppm. 
The alkyl linker had well resolved triplets at 2.37 ppm and 2.29 ppm for the b’ and i’-H2 positions. 
The c’ and h’-H2 positions were multiplets from 1.61-1.51 ppm (4 H) with the remaining central core 
of the linker forming the larger coalesced multiplet at 1.35-1.28 ppm. Also, a b-H2 signal from the 
cyclopropyl group was concealed by this multiplet, accounting for the total integration of 10 H. The 
last multiplet at 1.21-1.17 ppm for 2 H, was ascribed to the remaining protons of the cyclopropyl 
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group. Proton decoupled 19F{1H} NMR gave one singlet at -121.8 ppm, indicating only one fluorine 
containing product was present. 13C NMR showed the C4 as a doublet at 176.3 ppm (JCF = 8.0 Hz), 
subsequently this was followed by the C6 signal at 153.0 ppm with its characteristically large J 
value (JCF = 250.0 Hz). The next doublet carbon occurred at 144.9 ppm and this was ascribable to 
the C7 position (JCF = 10.0 Hz). The C4a doublet was next at 118.8 ppm (JCF = 8.0 Hz), followed by 
the C5 ortho to the fluorine at 111.0 (JCF = 23.0 Hz). The C8, consistent with the previous NMR, 
appeared at 106.6 ppm (JCF = 2.0 Hz), followed by the piperazine C2’ as doublets at 49.7 ppm and 
49.3 ppm (JCF = 4.0 Hz). The central linker C5” and C6” were equivalent and thus showed as a 
double height signal at 28.8 ppm. The cyclopropyl b-H2 gave a single signal at 7.6 ppm. The 
remaining 20 carbons were well resolved giving a total of 28, taking into account split doublets 
(counted as one) and the equivalence of the molecule. This was one short of the 29 carbons 
expected for a compound with the formula C33H40FN4O5. The DEPT 135 data accounts for all of the 
protonated signals. Therefore, the missing carbon was a quaternary signal. A high-resolution 
accurate mass of 659.2874 [M+H]+ was observed. Due to the value of the final sample, with 38 mg 
synthesised, IR and destructive MP analysis were not performed as the compound was conserved 
for biological testing. RP-HPLC and NMR data indicated the product had 98% purity.  
 
Scheme 86. Synthesis of Ethyl 1-cyclopropyl-6-fluoro-7-[4-(10-methoxy-10-oxodecanoyl)piperazin-
1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylate. 
The final control compound to synthesise was a ciprofloxacin fragment with the commercially 
available alkyl linker 151 attached at the 7’-position but without the secondary fragment (Scheme 
86). This would allow us to evaluate the consequence of attaching this substituent to the activity of 
the quinolone. Moreover, combined with the data from the aromatic control and contrasting with the 
effect of the coumarin moiety, this would allow analysis of the impact of different parts of the hybrid. 
Compound 152 was isolated after purification by flash column chromatography as a cream powder 
(65%). 1H NMR showed the 2-H proton as a very downfield singlet at 8.50 ppm, followed by a 
doublet for the 5-H proton ortho to the fluorine at 8.02 ppm (JHF = 13.2 Hz). The second aromatic 
meta to fluorine at 7.25 ppm (JHF = 8.0 Hz) assigned to the 5-H position also appeared as a doublet 
overlapping the residual solvent peak (CDCl3). The d-H2 of the ester appeared as a prominent 
quartet at 4.37 ppm, followed by two apparent triplets for the 3’-H2 piperazine at 3.84 ppm and 
3.68 ppm respectably. A lone singlet at 3.65 ppm (3 H) for the f-H3 of the linker was prominent, 
followed by a multiplet at 3.47-3.38 ppm ascribed to the a-H of the cyclopropyl ring. The remaining 
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two multiplets of the 2’-H2 piperazine ring showed as apparent triplets at 3.25 ppm and 3.20 ppm. 
The b’ and i’-H2 protons appeared as triplets at 2.36 ppm and 2.29 ppm (J = 8.0 Hz). A multiplet 
integrating for 4 H from 1.68-1.57 ppm represented the c’ and h’-H2. A large triplet at 1.39 ppm with 
a correct J value of 8.0 Hz for reciprocal coupling to the d-H2 signal, was attributed to the remaining 
CH3 of the ethyl ester. A large coalesced multiplet occurred at 1.35-1.29 ppm (10 H) for the 
remaining alkyl chain of the linker and one of the b-H2 signals of the cyclopropyl group. The last 
signal was assigned as the remaining b-H2 signal showed as a multiplet at 1.15-1.11 ppm. Proton 
decoupled 19F{1H} NMR gave one singlet at -124.01 ppm indicating that only one fluorine 
containing product was present. 13C NMR showed the C10” carbonyl group of the ester at 174 ppm 
was the most deshielded atom. A doublet followed at 173.1 ppm (JCF = 2.0 Hz) for the C4 position. 
The C6 atom was also a doublet at 153.5 ppm (JCF = 250.0 Hz) consonant with previously 
synthesised analogues. The C7 doublet signal appeared at 144.2 ppm (JCF = 10.0 Hz), while the 
quaternary C4a signal occurred at 123.7 ppm (JCF = 10.0 Hz) and the remaining aromatic C5 at 
113.6 ppm (JCF = 20.0 Hz). The remaining two doublets were ascribed to the C2’ atoms at 
50.7 ppm and 49.7 ppm (JCF  = 2.0 Hz). A further 20 individually resolved signals appeared in the 
spectrum giving a total of 29 carbons which when accounting for the split doublets and the 
equivalence of the cyclopropyl carbons was correct for a compound with the formula C30H41FN3O6. 
Unlike previously analysed compounds, the central d’, e’, f’, g’-H2 carbons were in sufficiently 
different environments to be individually resolved and non equivalent in the carbon NMR. IR gave 
strong carbonyl signals at 1713 cm-1, 1646 cm-1 and 1615 cm-1. A high-resolution mass of 
558.2959 was observed [M+H]+. RP-HPLC showed the compounds had 96% purity. 
 
Scheme 87. Synthesis of 7-[4-(9-carboxynonanoyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid. 
The final step was to deprotect both esters of 152 simultaneously using lithium hydroxide 
monohydrate to give compound 153 in a 51% yield (Scheme 87).  1H NMR showed two singlets at 
15.18 ppm and 11.96 ppm ascribed to the carboxylic acids. HSQC confirmed neither peak was 
correlated with a carbon signal. The 2-H followed at 8.66 ppm as a further singlet integrating for 
1 H. A doublet at 7.92 ppm (JHF = 12.0 Hz) and 7.57 ppm (JHF = 8.0 Hz) was characteristic of the 5-
H and 8-H protons respectively. The a-H of the cyclopropyl ring occurred as a multiplet between 
3.84-3.79 ppm (1 H). Followed by one apparent triplet at 3.68 ppm assigned to the piperazine ring 
3’-H2 groups and a multiplet at 3.35-3.38 ppm ascribed to the 2’-H2 that overlapped the water peak. 
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Two triplets at 2.36 ppm and 2.18 ppm (J = 8.0 Hz) were the b’ and i’-H2 of the linker. A multiplet 
between 1.53-1.47 ppm was for the c’ and h’-H2 of the linker. A large coalesced multiplet between 
1.33-1.24 ppm integrating for 10 H, was the d’, e’, f’ and g’-H2 signals as well as an overlapping b-
H2 of the cyclopropyl group. The disappearance of a singlet for 3 H, as well as a quartet (2 H) and 
triplet (3 H) highlighted that the strong base had been successful in de-protecting both esters 
simultaneously to form the final compound. 13C NMR showed a doublet at 176.2 ppm (JCF = 2.0 Hz) 
ascribed to the C4 carbonyl group. The C6 carbon maintained its large J value of 248.0 Hz and 
appeared as a doublet at 152.9 ppm. The C7 group was also remained a doublet at 144.9 ppm (JCF 
= 10.0 Hz), whilst the quaternary C4a doublet was at 118.7 ppm (JCF = 8.0 Hz). The C5 aromatic 
showed as doublet at 110.9 ppm (JCF = 20.0 Hz) whilst the C8 signal was at 106.4 ppm (JCF = 2.0 
Hz). The remaining piperazine C2’ carbons which were not equivalent, as demonstrated by all the 
analogues, still gave two doublets at 49.7 ppm (JCF = 5.0 Hz) and 49.2 ppm (JCF = 3.0 Hz). The Ce’ 
and Cf’ of the linker were in sufficiently similar environments to show as an equivalent peak at 
28.8 ppm. The two Cb carbons were also equivalent at their normal 7.6 ppm. The remaining 17 
carbons were well resolved giving a total of 25 (counting doublets as one) that accounted for all of 
the signals in a product comprised of 27 carbon atoms. 19F{1H} NMR gave a single peak at -124.0 
Hz indicating a single fluorinated product had been isolated. IR showed a broad absorption 
between 3600-2400 cm-1, and three carbonyl absorptions at 1715 cm-1, 1626 cm-1, and 1614 cm-1. 
A high-resolution accurate mass of 516.2497 [M+H]+ was observed. RP-HPLC showed the purified 
compound had 96% purity. 
4.06 Biological evaluation  
Having completed the synthesis of the target hybrids it was necessary to evaluate their in vitro 
biological activity using the previously described supercoiling assay with E. coli gyrase. In the 
previous chapter no coumarins displayed any significant activity. The most simplistic 
aminocoumarin fragment had been screened at 50 µM. Therefore, the supercoiling assay was 
repeated at higher, although physiologically irrelevant, concentrations to determine the effect, if 
any, the coumarin fragment had on gyrase. Figure 55 below shows the results. Aminocoumarin 104 
did not cause any detectable inhibition of enzyme supercoiling activity at a maximal concentration 
of 300 µM.  
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Figure 55. Effect of Compound 104 on DNA supercoiling by wild type E. coli gyrase. Relaxed 
pBR322 plasmid DNA is used as a negative control (-), and incubated in the presence of gyrase as 
a positive control (+). SD8 is used as a comparator at a concentration of 1 µM. NC indicates nicked 
circle DNA; R, relaxed DNA; SC, supercoiled DNA.  
Subsequently, the ester-protected analogues 138, 144, 149 and 152 were evaluated (Figure 56). 
Only the ester protected ciprofloxacin 138 was able to inhibit supercoiling, albeit at a concentration 
of 50 µM to 10 µM with compared to its normal IC50 of  ~0.5 µM. This demonstrates that whilst 
activity is retained, it is attenuated. It has been shown that in order for the quinolones to intercalate 
into DNA, the carboxylic acid portion forms vital contacts with serine and aspartic/glutamic acid 
residues as discussed in Chapter 1. This is mediated via a non-catalytic magnesium ion with an 
octahedral co-ordination sphere comprised of two oxygen and four water molecules. This 
phenomenon is termed the water-metal ion bridge. Efficacious binding is attributed to the free 
carboxylic acid that can delocalise a negative charge across the carbonyl group through resonance 
stabilisation. This effect is not possible with an ester. However, the presence of two carbonyl 
groups is predicted to retain a degree of co-ordination. The noted attenuated activity displayed by 
138 supports this theory. The hybrid esters 144, 149 and 152 show no effect on wild type E. coli 
gyrase at a maximal concentration of 100 µM.  
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Figure 56. Effects of Compounds, 138, 144, 149 and 152 on DNA supercoiling by wild type E. coli 
gyrase. Relaxed pBR322 plasmid DNA is used as a negative control (-), and incubated in the 
presence of gyrase as a positive control (+). SD8 is used as a comparator at a concentration of 1 
µM. NC indicates nicked circle DNA; R, relaxed DNA; SC, supercoiled DNA. 
 
Figure 57. Effects of Compounds, 150, 153 and 145 on DNA supercoiling by wild type E. coli 
gyrase. Relaxed pBR322 plasmid DNA is used as a negative control (-), and incubated in the 
presence of gyrase as a positive control (+). SD8 is used as a comparator at a concentration of 1 
µM. NC indicates nicked circle DNA; R, relaxed DNA; SC, supercoiled DNA. 
 
Chapter 4. Coumarin-quinolone hybrids as potential dual inhibitors of DNA gyrase 
 
 
 
 
145 
The effects of the compounds 145, 150 and 153 on the supercoiling activity are shown in Figure 
57. The aniline compound 150 has activity only at high concentrations from 100 µM to 75 µM when 
comparing the intensity of the supercoiling band to the negative control (-). This is a minor 
improvement over the ester protected sister analogue (149), suggesting that 150 cannot make 
favourable contacts in the coumarin binding site. Similarly, a moderate improvement in activity of 
the ciprofloxacin linker control 153 is observed with inhibition occurring from 100 to 50 µM. 
Strikingly, the introduction of a coumarin scaffold in compound 145 dramatically restores inhibitory 
activity. Potent inhibition can be seen from 100 µM to 10 µM, as exhibited by the lack of a 
supercoiling band. The compound has an IC50 of 3 µM, with complete supercoiling apparent at 
0.3 µM. This assay data unequivocally attributes the restored activity to the coumarin moiety. 
These results demonstrate a favourable interaction when fragments 104 and 143 are combined 
that is not seen when a simple aromatic ring 146 is combined to 143. This is in contrast to the poor 
inhibition displayed by each fragment individually. This implies that a synergistic effect is vital for 
the observed activity. After repeated freeze thawing, compound 145 degraded, losing its ability to 
inhibit gyrase. To confirm the results, the compound was re-synthesised and the assays repeated 
with same results observed.  
Noting that the coumarin scaffold contributes to the inhibitory activity of the hybrid compound, it 
was necessary to explore the mode of action. The effect of the compounds 145, 150 and 153 on 
the gyrase cleavage-religation equilibrium was investigated (Figure 58). The assay is carried out as 
previously described for the supercoiling reaction, with the addition of a termination step. Cessation 
of a reaction between gyrase and DNA in the presence of a quinolone inhibitor like ciprofloxacin by 
the addition of SDS and proteinase K results in cleaved DNA. The SDS and proteinase K denature 
the gyrase protein and cause the separation of the enzyme from the DNA. The cleaved DNA is a 
manifestation of the covalent bonds formed between the enzyme and DNA that are stabilised by a 
drug (such as ciprofloxacin), as described in the introduction. Experimentally, when supercoiled 
DNA is used as the substrate, this is represented by the appearance of a linear band. SD8 was 
used as a negative control, its ability to block DNA binding and prevent strand passage cycle taking 
place by stapling across the surface of the enzyme resulted in no linear band being visible. 
Ciprofloxacin 137 was used as positive control for comparison with strong linear bands visible from 
3 µM to 0.3 µM. Linear bands are visible only at 100 µM to 75 µM for 150 and from 100 µM to 
50 µM for 153. Conversely, compound 145 displays a consistent linear band from 100 µM to 3 µM. 
The results demonstrate the ability of all the hybrids to stabilise cleaved DNA. The loss of the linear 
band occurs at approximately the same concentration as inhibition in the corresponding 
supercoiling assay. This is consistent with observations with ciprofloxacin which shows a 
correlation between supercoiling and cleavage stabilisation inhibitory concentrations.  
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Figure 58. Effects of compounds 145, 150 and 153 on cleavage complex formation by wild type E. 
coli gyrase in the absence of ATP. Supercoiled pBR322 plasmid DNA is used as a positive control 
(+), and incubated in the presence of gyrase as a negative control (-). SD8 is used as an additional 
control at a concentration of 1 µM. Ciprofloxacin 137 is used as a comparator. NC, nicked circle; L, 
linear band; SC, supercoiled DNA. 
Lastly, the final compounds 145, 150 and 153 were tested against DNA gyrase with a substitution 
from lysine42 to alanine. It was anticipated that a decrease in activity would be observed with the 
mutant enzyme, due to impaired binding by the coumarin chromophore. As a control experiment, 
the wild type and mutant enzymes were tested at the same time using the same serial dilutions. 
The results are shown in Figure 59 and Figure 60. Ciprofloxacin 137 and SD8 were used as 
comparators from 50 µM to 0.1 µM. There is inhibition from the asymmetric hybrid compound only 
at 50 µM and 25 µM. This is the same for both the wild type and mutant enzyme. Ciprofloxacin is 
unaffected by the mutant enzyme, as would be expected; conversely SD8 has less efficacy at 
inhibiting the lysine mutant with an IC50 of 3 µM compared to 0.3 µM in this wild type assay. This is 
consistent with previous reported observations. The decreased activity in both the wild type and the 
mutant is a strong indication that the stock solution of compound 145 had started to degrade. Thus 
the conclusions drawn from this data must be considered alongside future work.  
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Figure 59. Effects of Compound 145 on DNA supercoiling by wild type E. coli gyrase. Relaxed 
pBR322 plasmid DNA is used as a negative control (-), and incubated in the presence of gyrase as 
a positive control (+). Ciprofloxacin 137 and SD8 are used as comparators. NC indicates nicked 
circle DNA; R, relaxed DNA; SC, supercoiled DNA. 
 
Figure 60. Effects of Compound 145 on DNA supercoiling by Lys42Ala mutant E. coli gyrase. 
Relaxed pBR322 plasmid DNA is used as a negative control (-), and incubated in the presence of 
gyrase as a positive control (+). Ciprofloxacin 137 and SD8 are used as comparators. NC indicates 
nicked circle DNA; R, relaxed DNA; SC, supercoiled DNA. 
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4.07 Conclusions  
Ten analogues were synthesised, purified and characterised with seven being biologically 
evaluated for their effects on DNA gyrase. The rational fragment based strategy utilised simple 
chemistry to generate six novel hybrids not previously described in the literature, driven by crystal 
structure data and inspired by SD8. This body of work supports findings that modification of the 
carboxylic acid is detrimental to quinolone activity. This is in agreement with the quinolones mode 
of action via a water-metal ion stabilisation with key amino acid residues from the carboxylic acid 
miety. Not unexpectedly, the ester protected ciprofloxacin fragment 138 retains some activity 
against gyrase. A degree of co-ordination of metal ions would still be permitted to take place from 
the two carbonyl groups. However, the results presented substantiate the favourable effect of 
having a free acid present. This extends to all final asymmetric hybrids tested, as seen with 145, 
150 and 153. Strikingly, a coumarin moiety on its own possesses no intrinsic inhibition, but when 
coupled to ciprofloxacin via a 15 Å linker contributes to a significant restoration of inhibitory activity 
when included in the hybrid. This is the first example of a coumarin demonstrating an ability to have 
a synergistic effect on a quinolone inhibitory activity. Moreover, we have revealed this effect is, in 
part, mediated through stabilisation of ligated DNA. Thus all de-protected hybrids retained an ability 
to stabilise cleaved DNA and is noteworthy. Preliminary attempts were made towards screening 
these compounds against DNA gyrase with a mutation in the aminocoumarin pocket. However, due 
to possible degradation with the final compound further work is required. That said, as the inhibition 
is the same in both wild type and mutant, albeit at reduced efficacy, the change in one hydrogen-
bonding residue may not be enough to drastically alter the effect of the hybrid. Furthermore, it 
highlights that it would be prudent to screen a wider concentration range as well as trying multiple 
mutant enzymes. Commensurate with previous coumarin-quinolone antibiotics, these results build 
upon earlier findings by investigating the effects on cleavage stabilisation. The lack of inhibition 
with the aniline and ciprofloxacin controls is rationalised as a function of poor binding to the 
coumarin pocket. However, to substantiate this theory more experimental data is required. A 
number of areas warrant further attention, this will be discussed in Chapter 5.  
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5.1 Overall conclusion and future work 
The publication of the new crystal structure of SD8 bound to DNA gyrase provided an 
unprecedented level of information regarding the bonding interactions made to the target 
enzyme.145 This thesis focused on efforts towards the structural components of SD8 as well as 
generating and screening a range of coumarin analogues. The eventual aim was to take a lead 
compound forward and produce a hybrid inhibitor.  
The synthesis of a novel isomerised pericyclic adduct 62 provides a crucial platform from which 
further enatioselective synthesis can take place. A natural progression is to continue efforts 
towards the total synthesis of the PK. The reported biological evaluation of the novel 7-oxo-SD8 
illustrates that changing a single functional group on the PK has a deleterious effect on inhibitory 
activity.146 The noted good inhibition of SD4, which has structural parity with SD8 except for the 
chlorine substituent, indicates a halogen is not a prerequisite for efficacious binding to the AC site. 
This should be carefully considered when designing future rational inhibitors.  
A diverse set of 23 AC compounds were synthesised and evaluated using an enzyme supercoiling 
assay. It was demonstrated that a wide variety of salicylaldehydes can be used as starting 
reagents in the modified Perkin reaction. Furthermore, the widespread resilience of the AC 
chromophore to highly acidic conditions provides a streamlined route to accessing a free amine via 
deacetylation.  
Using the well-studied inhibitor ciprofloxacin a novel coumarin hybrid 145 was successfully 
synthesised and evaluated alongside appropriate controls 150 and 153. This work shows for the 
first time that the introduction of the coumarin chromophore 104 unequivocally contributes to 
observed inhibition of DNA gyrase. The exact mode of action needs further investigation. 
Preliminary results indicated that cleavage stabilisation is still able to take place. This is an exciting 
step towards the development of inhibitors of DNA gyrase and represents a proof of principle 
fragment based approach to the design of novel compounds. The basic coumarin framework 
provides a starting point from which future SAR can now be undertaken. The work can progress in 
two fundamental directions. Firstly, to investigate linker length and its contribution to activity. 
Secondly, to investigate substitution of the basic coumarin for functionalised coumarins.  
Elucidation of the mechanism of action and an exploration of the hybrids ability to overcome 
quinolone resistance could be achieved through testing against mutant DNA gyrase enzymes. 
Mutations to Arg91, Lys42, His45 and Ser172 should provide substantial evidence of weather or 
not the coumarin binds to the same pocket as SD8. Whilst mutations to the serine/glutamic acid 
residues in the QRDR would check for an ability to overcome quinolone resistance. The biological 
assays conducted so far are in vitro, examination using an in vivo model would provide insights as 
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to the lead compounds ability to traverse cell membranes. Whilst the hybrid is potent in the 
supercoiling assays, this may not necessarily translate into in vivo activity. The molecule is of a 
medium molecular weight, and relatively hydrophobic. This work would be crucial alongside the 
SAR for optimising the hybrid.  
 
Figure 61. Surface plasmon resonance.275 
A technique that could facilitate the mechanistic understanding of the hybrid compound is to use 
surface plasmon resonance (SPR). This is a real time experiment whereby polarised light is 
focused onto a gold-coated glass sensor (Figure 61). The light is reflected off the surface and hits a 
photo-detector. An enzyme can be immobilised to the surface of the gold and a drug flowed across 
the surface of the enzyme. If the drug binds to the enzyme a change in mass of the surface will 
take place at the interface resulting in a change in the reflected signal.275 This is measured and 
plotted as a function of time to give a sensorgram. Thus, a binding event can be seen. This is a 
very sensitive technique and even small changes at the molecular surface will shift the SPR curve.  
Finally, efforts towards obtaining a crystal structure of the hybrid bound to the target DNA gyrase 
enzyme could be pursued. This would provide detailed information of the binding orientation of the 
hybrid and would expedite the design of analogues based on the lead compound.  
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1H and 13C NMR spectra were obtained in Fourier Transform mode on a BrukerTM Ultrashield PLUS 
400 spectrometer operating at a normal frequency of 400 MHz using the specified deuterated 
solvent. All spectra have been calibrated to the residual deuterated solvent peak and chemical 
shifts reported in ppm. All fluorine NMR experiments are externally referenced to 
trichlorofluoromethane. Spectra were analysed and processed using Topspin 3.2 software. 
Multiplicities in the NMR are described as: br s = broad singlet, d = doublet, dd = doublet of 
doublets, t = triplet, td = triplet of doublets, q = quartet, m = multiplet, br = broad, app = apparent; 
coupling constants are reported in Hz. Melting points were recorded using capillary tubes on a Mel-
TempTM electro thermal melting point apparatus. Infrared spectra were recorded from neat samples 
using a Perkin-Elmer Spectrum BX FT-IR spectrometer and analysed using Spectrum v5.3.1 
software. RP-HPLC were obtained using a Agilent 1200 apparatus with a Eclipse XDB-C18 column 
(5 µM, 4.6 x 15 mm) running a gradient over 20 minutes. MeOH:H2O  (5:95) to MeOH:H2O (95:5) at 
a flow rate of 1mL/min. Wavelength of detection as a 214 nm and 254 nm. Accurate masses were 
provided by the EPSRC National Mass Spectrometry Service in Swansea.  
6.1 Chromatography 
Thin layer chromatography was performed using Merck aluminium plates coated with 0.2 mm silica 
gel-60 F254. After elution TLC plates were visualised under UV light. Flash chromatography was 
performed using silica gel (particle size 60 µM) unless otherwise specified all samples were dry 
loaded onto silica prior to separation. Chromatography was performed using a Biotage Isolera 
ACITM with wave monitoring set to 254 nm and 214 nm.  
6.2 Reagents and Glassware  
All chemicals used were purchased from Sigma-Aldrich or Thermo-Fisher Scientific. All glassware 
was oven dried prior to use. Anhydrous solvents were commercially purchased and assumed to 
conform to manufacturers specifications. All water for reagents, reactions and assays was purified 
using a Merk Millipore Milli-Q direct water purification system. 
6.3 Biological Procedures  
E. coli gyrase supercoiling and cleavage assay kits were purchased from Inspiralis. Gyrase was 
prepared from overexpressing strains JMtacA and JMtacB and supplied as an A2B2 complex in 
dilution buffer. Dilution buffer consisted of 50 mM Tris.HCl (pH 7.5), 100 nM KCl, 2 mM DTT, 1 mM 
EDTA and 50% (w/v) glycerol. Supercoiling assay buffer consisted of 35 mM Tris.HCl (pH 7.5), 24 
mM KCl, 4 mM MgCl2, 2 mM DTT, 1.8 mM spermidine, 1 mM ATP. The same dilution buffer was 
utilised for cleavage stabilisation assays. Cleavage assay buffer consisted of 35 mM Tris.HCl (pH 
7.5), 24 mM KCL, 4 mM MgCl2, 2 mM DTT, 1.8 mM spermidine, 6.5% (w/v) glycerol, 0.1 mg/mL 
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albumin. All enzymes were stored at -80°C. Supercoiled or relaxed pBR322 DNA was supplied with 
the assay kits. TAE buffer was used for electrophoresis containing 40 mM Tris acetate and 1 mM 
EDTA.  
6.4 Agarose gel electrophoresis 
1% (w/v) agarose was added to TAE buffer and brought to the boil until the agarose had completely 
dissolved. The gel was allowed to cool for 5 minutes prior to being cast into a rack with a comb. 
The gel was allowed to solidify for 45 minutes and the comb removed; the gel was placed into an 
electrophoresis tank and covered with TAE buffer. Experimental samples were then loaded into the 
wells.  
6.5 Supercoiling assay 
The inhibitory effect of compounds on gyrase supercoiling activity was assessed using the 
Inspiralis assay kits and following the manufacturers instructions. Compounds were weighed into 
an eppendorf tube and dissolved in DMSO. Serial dilutions were performed using water. For each 
compound a master mix (MM) was prepared using 0.5 µL of relaxed pBR322 DNA, 6 µL of dilution 
buffer, 6 µL of assay buffer and 15.5 µL of water. Diluted samples and MM were prepared whilst in 
ice prior to incubation to minimise intrinsic supercoiling activity. A 28 µL aliquot of MM was used for 
the negative control and the volume made up to 30 µL with water. Subsequently 1 µL of enzyme 
was added for every compound to be tested including the positive control, the MM was 
homogenised. Afterwards 29 µL of MM was dispensed into an eppendorf, with 1 µL of compound 
added to each eppendorf. Samples were centrifuged at 13,200 RPM, for 5 seconds prior to 
incubation at 37°C for 30 minutes. To arrest the reaction 30 µL of a mixture of iso-amyl alcohol and 
chloroform (1:24) and 15 µL of 40% (w/v) sucrose, 0.1 M Tris.HCl (pH 8.0), 0.1 M EDTA, 
0.5 mg/mL bromophenol blue (STEB buffer) were added. The samples were centrifuged at 13,200 
RPM, for 5 minutes, and 15 µL of aqueous layer loaded onto a 1% agarose gel. The topoisomers 
and supercoiled DNA were separated by electrophoresis. The gel was stained in mixture of TAE 
and ethidium bromide (1 µg/mL) for 15 minutes before being distained using TAE buffer for 15 
minutes. The gel was then visualised under UV light. 
6.6 Cleavage stabilisation assay 
Compounds were weighed into an eppendorf tube and dissolved in DMSO. Serial dilutions were 
carried out using water. For each compound a master mix (MM) was prepared using 0.3 µL of 
supercoiled pBR322 DNA, 6 µL of dilution buffer, 6 µL of cleavage assay buffer and 15.7 µL of 
water. Diluted samples and MM were prepared whilst on ice prior to incubation to minimise intrinsic 
supercoiling activity. A 28 µL aliquot of MM was used for the negative control and the volume made 
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up to 30 µL with water. Subsequently 1 µL of enzyme was added for every compound to be tested 
including the positive control, the MM was homogenised. Afterwards 29 µL of MM was dispensed 
into an eppendorf tube, with 1 µL of compound added to each eppendorf. Samples were 
centrifuged at 13,200 RPM, for 5 seconds prior to incubation at 37°C for 30 minutes. After which, 
0.3 µL of 20% SDS and 0.5 µL of proteinase K were added to each sample, a further incubation 
was performed for an additional 30 minutes. To arrest the reaction, a mixture of 30 µL iso-amyl 
alcohol and chloroform (1:24) and 15 µL of 40% (w/v) sucrose, 0.1 M Tris.HCl (pH 8.0), 0.1 M 
EDTA, 0.5 mg/mL bromophenol blue (STEB buffer) were added. The samples were centrifuged at 
13,200 RPM, for 5 minutes, and 15 µL of aqueous layer loaded onto a 1% agarose gel. The 
topoisomers and supercoiled DNA were separated by electrophoresis. The gel was stained in 
mixture of TAE and ethidium bromide (1 µg/mL) for 15 minutes before being distained using pure 
TAE buffer for 15 minutes. The gel was then visualised under UV light. 
6.7 Experimental procedures and characterisation  
1,3-diethyl 2-{[(tert-butoxy) carbonyl] amino} propanedioate (17) 
 
Diethyl aminomalonate hydrochloride (25 g, 118 mmol) was dissolved in a mixture of 1 M NaOH 
(119 mL) and 1,4 dioxane (100 mL). Subsequently Boc2O (28.5 g, 130.73 mmol) dissolved in 1,4 
dioxane (50 mL) was added dropwise to the solution of starting material. The reaction was stirred 
at rt for 17 h before the solvent was removed under reduced pressure. The residue was taken up 
into EtOAc and the organic layer washed with 5% KHSO4, sat. NaHCO3 and brine. The organic 
layer was dried over MgSO4 and the solvent removed under reduced pressure to give the desired 
product as a colourless oil (24.7 g, 76%). 1H NMR (400 MHz, DMSO-d6) δH ppm: 7.63 (d, J = 
8.0 Hz, 1 H, NH), 4.86 (d, J = 8.0 Hz, 1 2-H), 4.22-4.11 (m, 4 H, CH2), 1.39 (s, 9 H, Boc), 1.20 (t, J 
= 8.0 Hz, 6 H, CH3). 13C NMR (100 MHz, DMSO-d6) δc ppm: 166.6, 155.1, 79.0, 61.5, 57.4, 28.0, 
13.8. IR vmax (neat) / cm-1  3371 (N-H), 2979 (CH2/CH3) 2941 (CH2/CH3), 1745 (C=O), 1714 (C=O), 
1368 (C-N), 1182 (C-O) 1158 (C-O). HRMS (ESI+) calculated for C12H22NO6 [M+H]+ 276.1442 
found 276.1442.  
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2-{[(tert-butoxy) carbonyl] amino}-3-ethoxy-3-oxopropanoic acid (18) 
 
Compound 17 (5 g, 18.18 mmol) was added to a solution of KOH (1 g, 17.82 mmol) in EtOH 
(20 mL). The mixture was stirred at room temperature for 3 hours before 90% of the solvent was 
removed under pressure. EtOAc was added and the organic extract removed to eliminate 
unreacted starting material. Consequently the aqueous layer was acidified with 1 M NaHCO3 and 
extracted with EtOAc. The organic layer was dried over MgSO4 and the solvent removed under 
vacuum to furnish a white solid (2.56 g, 57%). 1H NMR (400 MHz, DMSO-d6) δH ppm: 7.47 (d, J = 
8.1 Hz, 1 H, NH), 4.71 (d, J = 8.1 Hz, 1 H, 2-H), 4.18-4.10 (m, 2 H, CH2), 1.38 (s, 9 H, Boc), 1.19 (t, 
J = 7.2 Hz, 3 H, CH3) .13C NMR (100 MHz, DMSO-d6) δC ppm: 167.8, 167.3, 155.1, 79.0, 61.4, 
57.6, 28.1, 14.0. IR vmax (neat) / cm-1 3272 (CON-H), 2980 (Ar-H), 2933 (Ar-H), 1747 (C=O), 1723 
(C=O), 1650 (C=O), 1182 (C-O), 1154 (C-O). HRMS (ESI+) calculated for C10H18NO6 [M+H]+ 
248.1129 found 248.1130. Mp. 75-79°C.  
2,4-bis(actyloxy) benzoic acid (20) 
 
Commercially available 2,4-dihydroxybenzoic acid (500 mg, 3.24 mmol) was dissolved in a mixture 
of pyridine (3 mL) and DMAP (5 mg, 0.04 mmol). Subsequently acetic anhydride (1.53 mL, 16.19 
mmol) was added drop wise to the reaction mixture. The reaction vessel was flushed with nitrogen, 
covered in foil and stirred for 4 h at rt. To quench the reaction ice was added and the mixture 
acidified with 3 M HCl causing a precipitate to form. The mixture was washed with EtOAc three 
times and the organic layer dried over MgSO4 the solvent was removed under reduced pressure 
immediately to give the desired product as a white powder (0.74 g, 97%). 1H NMR (400 MHz, 
DMSO-d6) δH ppm: 13.13 (s, 1 H, OH), 7.92 (d, J = 8.0 Hz, 1 H, ArH), 7.18 (dd, J1 = 8.8 Hz, J2 = 
2.4 Hz, 1 H, ArH), 7.08 (d, J = 2.4 Hz, 1 H, ArH) 2.29 (s, 3 H, CH3), 2.24 (s, 3 H, CH3). 13C NMR 
(100 MHz, DMSO-d6) δC ppm: 168.9, 168.6, 164.9, 154.0, 151.0, 132.4, 121.6, 119.6, 117.6, 
20.82, 20.77. IR vmax (neat) / cm-1 2981 (C-H3), 2941 (C-H3), 2645 (Ar-H), 2539 (Ar-H), 1773 (C=O), 
1681 (C=O), 1607 (C=O). HRMS calculated for C11H9O6 [M-H]- 237.0405 found 237.0405. Mp. 149-
150°C.  
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3-(acetyloxy)-4-(carbonochloridoyl) phenyl acetate (21) 
 
Compound 20 (4 g, 16.79 mmol) was taken up in anhydrous DCM (40 mL) and added to SOCl2 (24 
mL). The mixture was refluxed for 4 h after which the reagent and solvent was evaporated under 
reduced pressure to give a sticky oil, this was taken up into anhydrous DCM and used directly in 
the next procedure.  
Ethyl 3-[2,4-bis(acetyloxy)phenyl]-2-{[(tert-butoxy) carbonyl] amino}-3-oxopropanoate (22) 
 
Compound 18 (4.45 g, 23.51 mmol) was added to a mixture of anhydrous THF (45 mL), 
triethylamine (14.63 mL, 105 mmol) and MgCl2 (5.44 g, 57.1 mmol). The slurry was stirred 
vigorously for 2.5 h before crude 21 was added dropwise to the mixture. Upon addition a colour 
change was noted from grey suspension to an orange brown suspension. The mixture was stirred 
at rt for 15.5 h after which the reaction was quenched with sat. NH4Cl causing the mixture to clarify. 
The solution was extracted three times with EtOAc and the organic layer dried over MgSO4. The 
solvent was removed under reduced pressure to give a crude brown oil (7.08 g). The product was 
used directly in the following reaction without further purification. 
Tert-butyl N-(4,7-dihydroxy-2-oxo-2H-chromen-3-yl) carbamate (23) 
 
A mixture of MeOH (40 mL) and 1.5 M NaOH (50 mL) was added to crude compound 22 (7.08 g). 
The mixture was stirred for 3.5 h after which the reaction was acidified with 1 M HCl causing a 
precipitate to form. The reaction was extracted three times with EtOAc and the organic fraction 
dried over MgSO4 and the solvent removed under reduced pressure to give a crude orange brown 
solid (4.04 g). This was used directly in the next step without further purification.  
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4,7-dihydroxy-2-oxo-2H-chromen-3-aminium chloride (24) 
 
Crude compound 23 (4.04 g) was added to a mixture of ethereal 1M HCl (30 mL) and MeOH (20 
mL) and stirred at rt for 29 h after which the solid precipitate was filtered and washed with a small 
amount of EtOAc to give the desired compound as a brown solid (881 mg, 23% over 3 steps). 1H 
NMR (400 MHz, CD3OD) δH ppm: 7.88 (d, J = 8.0 Hz, 1 H, ArH), 6.90 (dd, J1 = 8.8 Hz, J2 = 2.4 Hz, 
1 H), 6.77 (d, J = 2.0 Hz, 1 H, ArH). 1H NMR (100 MHz, CD3OD) δc ppm: 164.5, 161.9, 161.4, 
155.7, 126.1, 115.0, 108.0, 104.0, 96.5. IR vmax (neat) / cm-1 3345 (O-H), 2929 (O-H), 1710 (C=O), 
1639 (N-H bend), 1564 (C=C), 1526 (C=C). HRMS (ESI-) calculated for C9H6NO4 [M-H]- 192.0302 
found 192.0303. Mp. 237-238°C. 
3-chloro-2,4-dihydroxybenzaldehyde (27) 
 
2,4-dihydroxybenzaldehyde (2 g, 14.49 mmol) was suspended in H2O (10 mL) and dissolved in a 
solution of KOH (2 g, 35.71 mmol) in H2O (15 mL). Subsequently commercial NaOCl 10-15% (20 
mL) was added dropwise to the vigorously stirred solution that turned dark brown on addition. After 
1 hour stirring at room temperature the reaction was acidified with 1 M HCl and extracted with 
EtOAc and the organic layer dried over MgSO4. The crude extract was purified by flash column 
chromatography (EtOAc/Hexanes 1:1) and recrystallized from DCM to give the product as an off 
white solid (1.12 g, 45%). 1H NMR (400 MHz, CD3OD) δH ppm: 9.69 (s, 1 H, COH), 7.49 (d, J = 8.6 
Hz, 1 H, ArH), 6.59 (d, J = 8.6 Hz, 1 H, ArH). 13C NMR (100 MHz, CD3OD) δC ppm: 195.8, 162.6, 
160.8, 134.3, 116.2, 109.6, 108.7. IR vmax (neat) / cm-1 3294 (O-H), 3084 (C-H), 2878 (C-H), 1618 
(C=O). HRMS (APCI+) calculated for C7H5ClO3H [M+H]+ 173.0000 found 173.0000. Mp. 156-
158°C, (Lit 146-148°C).210 
3,5-dichloro-2,4-dihydroxybenzaldehyde (28) 
 
2,4-dihydroxybenzaldehyde (2 g, 14.49 mmol) was suspended in H2O (10 mL) and dissolved in a 
solution of KOH (2 g, 35.71 mmol) in H2O (15 mL). Subsequently commercial NaOCl 10-15% (20 
mL) was added dropwise to the vigorously stirred solution that turned dark brown on addition. After 
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3 hours stirring at room temperature the reaction was acidified with 6 M HCl and extracted three 
times with EtOAc and the organic layer dried over MgSO4. The crude was purified by flash column 
chromatography (EtOAc/hexanes ) to give the product as an off white solid (0.83 g, 28%). 1H NMR 
(400 MHz, DMSO-d6) δH ppm: 11.48 (br s, 1 H, OH), 9.88 (s, 1 H, COH), 7.77 (s, 1 H, 6-H). (100 
MHz, DMSO-d6) δC ppm: 192.6, 156.9, 156.1, 130.8, 115.5, 113.3, 109.6. . IR vmax (neat) / cm-1 
2941 (C-H), 1623 (C=O), 741 (C-Cl), 714 (C-Cl). HRMS (ESI-) calculated for C7H3Cl2O3 [M-H]- 
204.9465 found 204.9461. Mp. 203-205°C. 
3-chloro-2,4-dimethoxybenzaldehyde (34) 
 
Compound 27 (3.56 g, 20.70 mmol) was added to a suspension of K2CO3 (14.21 g, 102.17 mmol) 
in acetone (50 mL). Iodomethane (14.59 g, 103.47 mmol) was added dropwise and the suspension 
refluxed for 2 hours. The solvent was removed under vacuum and the residue dissolved in water 
(50 mL). The remaining solid was filtered and dried in a desiccator to yield a white solid (4.14 g, 
100%). 1H NMR (400 MHz, CDCl3) δH ppm: 10.17 (s, 1 H, COH), 7.72 (d, J = 8.80 Hz, 1 H, ArH) 
6.79 (d, J = 8.80 Hz, 1 H, ArH) 3.94 (s, 3 H, CH3), 3.93 (s, 1 H, CH3). 13C NMR (100 MHz, CDCl3) 
δC ppm: 188.0, 161.2, 160.6, 127.9, 123.9, 116.7, 107.8, 63.0, 56.7. IR vmax (neat) / cm-1 2950 (O-
CH3), 2869 (O-CH3), 1673 (C=O). HRMS (ES+) calculated for C9H10O3Cl [M+H]+ 201.0313 found 
201.0309. Mp. 109-111°C, (Lit 109-111°C).276 
3-chloro-2,4-dimethoxybenzoic acid (35) 
 
Compound 34 (8.39 g, 41.95 mmol) was dissolved in anhydrous acetonitrile (100 mL). 
Subsequently Cu(II)Br (467 mg, 2.09 mmol) was added and the reaction flask purged with nitrogen. 
Luperox 70%™ TBH70X (15.12 g, 167.80 mmol) was added dropwise and a colour change 
observed from a clear green to brown and finally to a green suspension. After 25 hours at room 
temperature an additional aliquot of Luperox was added (1.80 g, 20 mmol) and the mixture left for a 
further 3 hours. The suspension was filtered through activated charcoal, the solvent removed under 
vacuum and the product recrystallized from EtOAc to furnish a white solid (3.99 g, 44%). 1H NMR 
(400 MHz, DMSO-d6) δH ppm: 12.82 (s, 1 H, OH), 7.75 (d, J = 8.8 Hz, 1 H, ArH), 6.99 (d, J = 8.9 
Hz, 1 H, ArH), 3.90 (s, 3 H, CH3), 3.80 (s, 3 H, CH3). 13C NMR (100 MHz, DMSO-d6) δC ppm: 
165.8, 158.7, 156.9, 130.8, 118.9, 116.5, 107.7, 61.4, 56.7. IR vmax (neat) / cm-1 2950 (C-H), 2564 
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(O-H), 1664 (C=O), 1583 (C-C), 1284 (C-O), 1221 (C-O). HRMS (ES+) calculated for C9H10ClO4 
[M+H]+ 217.0262 found 217.0261. Mp. 171-172°C, (Lit 168-170°C).210 
3-chloro-2,4-dihydroxybenzoic acid (33) 
 
To a suspension of compound 35 (3.58 g, 16.57 mmol) in anhydrous DCM (35 mL) under nitrogen 
at reduced temperature (-78°C) was added BBr3 dropwise (16.57 g, 66.28 mmol). The reaction was 
stirred for 1 h and then allowed to warm to room temperature and stirred overnight. The suspension 
was poured onto crushed ice and extracted with EtOAc, a white residue was filtered off. The 
remaining solution was dried under reduced pressure and the residue dissolved in MeOH (25 mL). 
This was left overnight forming a red solution before being evaporated off and purified by flash 
column chromatography (MeOH/DCM 2:8) to give the product as a white powder (2.17 g, 70%). 1H 
NMR (400 MHz, CD3OD) δH ppm: 7.64 (d, J = 8.0 Hz, 1 H, ArH), 6.46 (d, J = 8.0 Hz, 1 H, ArH). 13C 
NMR (100 MHz, CD3OD) δC ppm: 173.4, 160.9, 160.8, 130.4, 108.7, 108.3, 106.6 IR vmax (neat) / 
cm-1 3445 (O-H), 3056 (COO-H), 1643 (C=O). HRMS (APCI+) calculated for C7H6ClO4 [M+H]+ 
188.9949 observed 188.9947. Mp. 208-210°C.  
2,4-bis(acetyloxy)-3-chlorobenzoic acid (39) 
 
To a light protected and cooled solution of compound 33 (50 mg, 0.27 mmol) in pyridine (1 mL) was 
added DMAP (5 mg, 0.04 mmol). The flask was purged with nitrogen and Ac2O (0.5 mL, 5.14 
mmol) added dropwise. After 4 hours at room temperature crushed ice was added to the reaction 
mixture forming a precipitate. The suspension was extracted with EtOAc and the organic layer 
dried over MgSO4. The solvent was removed under pressure to furnish the labile product as a 
brown solid (62.42 mg, 85%). The solid was used directly in the next step without further 
purification. 1H NMR (400 MHz, DMSO-d6) δH ppm: 7.96 (d, J = 8.7 Hz, 1 H, ArH), 7.40 (d, J = 8.6 
Hz, 1 H, ArH), 2.37 (s, 3 H, CH3), 2.33 (s, 3 H, CH3). HRMS calculated for C11H8ClO6 [M-H]- 
271.0015 found 271.0016.  
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4-hydroxy-2H-chromen-2-one (48) 
	
Sodium (2.11 g, 91.91 mmol) in mineral oil was washed with hexane and added portion wise to a 
vigorously stirred mixture of 2-hydroxyacetaphenone (5 g, 36.76 mmol) and diethyl carbonate (13 
g, 110.28 mmol). The mixture was brought to 160°C and diluted with xylene (30 mL). After 1 hour 
the mixture was allowed to cool to room temperature and quenched with H2O. Sodium Hydroxide (2 
M) was added and the aqueous extracted once with diethyl ether. This was discarded and the 
remaining aqueous layer acidified with HCl. The resultant precipitate was filtered; dissolved in 
MeOH and the solvent removed under reduced pressure. The remaining solid was triturated with 
diethyl ether and filtered to give the desired product as a cream powder (4.34 g, 73%). 1H NMR 
(400 MHz, DMSO-d6) δH ppm: 12.62 (s, 1 H, OH), 7.82 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H, 5-H), 
7.66-7.62 (m, 1 H, 6-H), 7.37-7.32 (m, 2 H, 7 and 8-H), 5.65 (s, 1 H, 3-H). 13C NMR (100 MHz, 
DMSO-d6) δC ppm: 165.7, 161.9, 153.5, 132.7, 123.9, 123.2, 116.4, 115.8, 91.0. IR vmax (neat) / 
cm-1. 2941-2555 (Ar-H overlapping broad OH), 2896 (O-H), 1608 (C=O), 1556 (C=C), 1562 (C=C), 
1504 (C=C), 1273 (O-H bending). HRMS (ES) calculated for found. HRMS (ESI-) calculated for 
C9H5O4 [M-H]- 161.0244 found 161.0244. Mp. 212-214°C, (Lit 213-215°C).277 
4-hydroxy-3-nitro-2H-chromen-2-one (51) 
	
70% HNO3 (0.78 mL, 18.52 mmol) was added carefully to conc. H2SO4 (0.82 mL, 15.43 mmol) at 
0°C. The nitrating mixture was then added dropwise to compound 48 (1 g, 6.17 mmol) suspended 
in CHCl3 (40 mL) at room temperature. After 5 minutes the reaction mixture turned to a brown clear 
solution. After 1 hour the reaction was poured onto crushed ice. The resultant solution was 
extracted three times with CHCl3 and the organic fractions dried over MgSO4. The solvent was 
removed under reduced pressure and the product recrystallized from MeOH to furnish the product 
as orange needles (345 mg, 27%). 1H NMR (400 MHz, DMSO-d6) δH ppm: 7.89 (dd, J1 = 8.0 Hz, J2 
= 1.6 Hz, 1 H, ArH), 7.55-7.50 (m, 2 H, ArH), 7.24-7.17 (m, 2 H, ArH). 13C NMR (100 MHz, DMSO-
d6) δC ppm: 166.8, 157.3, 152.5, 132.6, 125.6, 123.3, 121.5, 120.7, 116.2. IR vmax (neat) / cm-1 
2941 (Ar-H), 2555 (Ar-H, overlapping OH), 1605 (C=O), 1422 (N-O), 1144 9 (N-O). HRMS (ESI-) 
calculated for C9H4NO5 [M-H]- 206.0095 found 206.0092. Mp. 176-178°C, (Lit 174-175°C).278 
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1-[4-(benzyloxy)- 2-hydroxyphenyl] ethan-1-one (53) 
 
2,4-dihydroxyacetaphenone (10 g, 65.79 mmol) was added to a mixture of K2CO3 (10.89 g, 78.91 
mmol) in acetone (200 mL). The mixture was brought to reflux for 2 hours before benzyl bromide 
(7.86 mL, 65.79 mmol) was added dropwise. The mixture was refluxed for a further 3 hours before 
being cooled to room temperature. The mixture was filtered and the solvent removed under 
reduced pressure. The title compound was recrystalised from MeOH to give magenta crystals 
(15.5 g, 97%). 1H NMR (400 MHz, DMSO-d6) δH ppm: 12.63 (s, 1H, OH), 7.84 (d, J1 = 8.0 Hz, 1 H, 
ArH), 7.46-7.32 (m, 5 H, ArH), 6.60 (dd, J1 = 8.8 Hz, J2 = 2.4 Hz, 1 H, ArH), 6.56 (d, J = 2.4 Hz, 1 
H, ArH), 5.19 (s, 2 H, CH2), 2.55 (s, 3 H, CH3). 13C NMR (100 MHz, DMSO-d6) δC ppm: 203.1, 
164.7, 164.0, 136.3, 133.3, 128.5, 128.0, 127.8, 113.9, 107.8, 101.7, 69.6, 26.6. IR vmax (neat) / cm-
1 3026 (Ar-H), 3002 (Ar-H), 2937 (Ar-H), 1617 (C=O), 1363 (C-O). HRMS (ESI+) calculated for 
C15H15O3 [M+H]+ 243.1016 found 243.1018. Mp. 107-108°C, (Lit 104-105 °C).279 
1-[4-(benzyloxy)-3-chloro-2-hydroxyphenyl] ethan-1-one (54) 
 
Compound 53 (1 g, 4.13 mmol) was added to a mixture of KOH (850 mg), THF (150 mL) and water 
(25 mL). Subsequently, NaOCl (5.5 mL) was added dropwise to the vigorously stirred solution. 
After 1.5 h the solution was acidified with 6 M HCl and the organic solvent removed under reduced 
pressure to cause the crude product to precipitate in the remaining aqueous fraction. The 
precipitate was filtered and dried. The desired compound was recrystalised from MeOH as 
colourless crystals (217 mg, 19%). 1H NMR (400 MHz, DMSO-d6) δH ppm: 13.14 (s, 1 H, OH), 7.94 
(d, J = 8.0 Hz, 1 H, ArH), 7.49-7.33 (m, 5 H, ArH), 6.91 (d, J = 9.2 Hz, 1 H, ArH), 5.36 (s, 2 H, CH2), 
2.62 (s, 3 H, CH3). 13C NMR (100 MHz, DMSO-d6) δc ppm: 204.1, 159.7, 158.8, 136.0, 131.6, 
128.6, 128.1, 127.5, 114.6, 104.9, 70.4, 26.6. IR vmax (neat) / cm-1 3048 (Ar-H), 3029 (Ar-H), 2940 
(Ar-H), 2881 (Ar-H), 1627 (C=O), 1277 (C-O), 1055 (C-O), 919 (O-H bend), 840 (C-Cl). HRMS 
(ESI+) calculated for C15H14ClO3 [M+H]+ 277.0626 found 277.0628. Mp. 127-129°C.  
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 (+) 3-ethoxy-5-methylcyclohex-2-en-1-one (58) 
 
p-Toluenesulfonic acid (340 mg, 1.98 mmol) was added to a solution of 5-methyl-1,3-
cyclohexanedione (4 g, 31.75 mmol) in EtOH (100 mL). The reaction was heated to 60°C for 70 h, 
subsequently the solvent was removed under pressure and the crude product purified by flash 
column chromatography (EtOAc/Hexanes 4:6) to give the title compound as a clear yellow oil (3.32 
g, 68%). 1H NMR (400 MHz, CDCl3) δH ppm: 5.30 (s, 1 H, 2-H), 3.90-3.83 (m, 2 H), 2.41-2.39 (m, 1 
H), 2.37-2.35 (m, 1 H), 2.25-2.16 (m, 1 H), 2.15-2.08 (m, 1 H, CH2), 2.03-1.96 (m, 1 H, CH2), 1.33 
(t, 3 H, CH3), 1.04 (dd, J = 6.36 Hz, 3 H, CH3). 13C NMR (100 MHz, CDCl3) δC ppm: 199.9, 177.4, 
102.4, 64.3, 45.2, 37.3, 28.9, 21.0, 14.2. IR vmax (neat) / cm-1 2973-2872 (C-H3 and C-H2), 1650 
(C=O), 1597 (C=C). HRMS (ESI+) calculated for C9H15O2 [M+H]+ 155.1067 found 155.1063. 
(+) 3-ethynyl-5-methylcyclohex-2-en-1-one (59) 
 
Compound 58 (2 g, 12.99 mmol) was dissolved in anhydrous THF (3 mL) and added dropwise to a 
vigorously stirred solution of ethynylmagnesium chloride in THF (1 M, 39 mL, 19.49 mmol). The 
reaction mixture was stirred at room temperature for 25 h before being acidified with 1 M HCl and 
extracted with DCM. The organic layer was dried over MgSO4 and the solvent evaporated under 
pressure to furnish the crude product as a dark brown oil. The product was purified via flash 
column chromatography (EtOAc/hexanes 4:6) to give the title compound as a pale yellow oil (1.27 
g, 73%). 1H NMR (400 MHz, CDCl3) δH ppm: 6.25 (s, 1 H, α,βH), 3.52 (s, 1 H, alkyne-H), 2.52-2.50 
(m, 1 H, CH2), 2.48-2.46 (m, 1 H, CH2), 2.28-2.20 (m, 1 H, C-H), 2.19-2.05 (m, 2 H, CH2), 1.07 (d, J 
= 6.36, 3 H, CH3) 13C NMR (100 MHz, CDCl3) δC ppm: 199.0, 141.6, 133.8, 87.2, 82.6, 45.6, 38.4, 
30.2, 21.0. IR vmax (neat) / cm-1 3242 (alkyne-H), 2956-2876 (C-H3 and C-H2), 2092 (alkyne stretch) 
1658 (C=O), 1592 (C=C). HRMS (APCI+) calculated for C9H11O1 [M+H]+ 135.0804 found 135.0803 
(+) 3-[(E)-2-methoxyethenyl]-5-methylcyclohex-2-en-1-one (60) 
 
4-methylmorpholine (75.86 mg, 0.75 mmol) was added to a solution of compound 59 (100 mg, 0.75 
mmol) and MeOH (95.80 mg, 2.99 mmol) in anhydrous toluene (3 mL). The reaction was stirred at 
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room temperature for 24 h, after which an additional aliquot of 4-methylmorpholine (75.86 mg, 0.75 
mmol) and MeOH (95.80 mg, 2.99 mmol) was added. The reaction was stirred for a further 5 h 
before the solvent was removed under pressure and the crude was purified by flash column 
chromatography immediately (EtOAc/hexanes 3:7) to furnish the labile diene product as a clear, 
yellow oil (58 mg, 46%). 1H NMR (400 MHz, CDCl3) δH ppm: 7.03 (d, J = 12.88, 1 H, C=CH), 5.83 
(s, 1 H, α,β-H) 5.64 (d, J = 12.84, 1 H, C=CH), 3.70 (s, 3 H, CH3), 2.54-2.43 (m, 2 H, CH2), 2.27-
2.15 (m, 1 H, CH), 2.11-2.00 (m, 2 H, CH2), 1.09 (d, J = 6.48, 3 H, CH3) 13C NMR (100 MHz, 
CDCl3) δC ppm: 199.8, 156.4, 154.4, 123.9, 107.1, 57.2, 45.8, 33.8, 30.0, 21.5. IR vmax (neat) / cm-1 
2952-2835 (C-H2) 1613 (C=O) 1227 (C=C-O-C). 
 
8-hydroxy-3-methyl-1,2,3,4,7,12-hexahydrotetraphene-1,7,12-trione (Ochromycinone) 
 
Compound 60 (537 mg, 3.23 mmol) was added dropwise to a light protected mixture of 
commercially available 5-hydroxy-1,4-naphthoquinone (500 mg, 2.87 mmol) and tetraacetoxy 
diboroxane (881 mg, 0.66 mmol) in anhydrous DCM (10 mL) at 0°C. The reaction was stirred 
vigorously for 2 minutes before being quenched with ice water to form a black sticky solid. The 
mixture was extracted with DCM, dried over MgSO4 and purified by flash column chromatography 
immediately (EtOAc/Hexanes 3:7) to furnish the product as an orange solid (63 mg, 7%). 1H NMR 
(400 MHz, CDCl3) δH ppm: 12.28 (s, 1 H, OH), 8.28 (d, J = 8.0, 1 H, ArH), 7.69-7.64 (m, 2 H, ArH), 
7.55 (d, J = 8.00, 1 H, ArH), 7.27 (dd, J1 = 7.2, J2 = 2.4, 1 H, ArH), 3.06-2.97 (m, 2 H, CH2), 2.61 
(dd, J1 = 16.0 Hz, J2 = 4.0 Hz, 1 H) 2.50 (dd, J1 = 16.0 Hz, J2 = 4.0 Hz, 1 H), 2.52-2.42 (m, 1 H, 
CH), 1.21 (d, J = 6.5, 3 H, CH3). (100 MHz, CDCl3) δC ppm: 199.3, 187.7, 183.2, 162.2, 150.5, 
137.2, 136.8, 136.1, 135.3, 133.6, 133.2, 129.1, 123.8, 119.7, 115.6, 47.6, 38.5, 30.9, 21.6. IR vmax 
(neat) / cm-1 2955-2872 (C-H2 and C-H3 and O-H overlapping), 1698 (C=O), 1666 (C=O), 1631 
(C=O). HRMS (ESI+) calculated for C19H15O4 [M+H]+ 307.0965 found 307.0965 found 307.0964. 
Mp. 145-148°C. 
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8-hydroxy-6-methoxy-3-methyl-1,2,3,4,5,6,6a,7,12,12a-decahydrotetraphene-1,7,12-trione 
(62) 
 
Compound 60 (110 mg, 0.66 mmol) was added to commercially available 5-hydroxy-1,4-
naphthoquinone (115 mg, 0.66 mmol) and tetraacetoxy diboroxane (180 mg, 0.66 mmol) in 
anhydrous DCM (3 mL). After stirring at room temperature for 5 minutes the reaction was quenched 
with water and extracted three times with DCM. The organic layer was dried onto silica and 
columned (EtOAc-Hexanes 4:6). The crude oil was re-purified by flash column chromatography 
(DCM 100%) and the product recrystallized from hexane and diethyl ether (1:1) to give the product 
as an orange brown solid. (16 mg, 8%). 1H NMR (400 MHz, CDCl3) δH ppm: 12.20 (s, 1 H, OH), 
7.61 (t, J = 8.0 Hz, 1 H, ArH), 7.47 (dd, J1 = 8.0 Hz, J2 = 1.16, 1 H, ArH), 7.19 (dd, J1 = 8.36, J2 = 
1.12, 1 H, ArH), 4.34 (dd, J = 6.92, 1 H, CH), 4.0-3.98 (m, 1 H, CH), 3.07 (dd, J = 6.90, 1 H, CH), 
3.00 (s, 3 H, OCH3), 2.61-2.42 (m, 4 H, CH2), 2.33-2.22 (m, 3 H, CH2 and CH overlapping), 1.13 (d, 
J = 5.92, 3 H, CH3). (100 MHz, CDCl3) δC ppm: 205.0, 197.8, 193.4, 161.7, 152.6, 137.33, 137.26, 
128.6, 122.5, 118.5, 118.0, 76.8, 57.6, 52.3, 45.8, 42.5, 39.4, 35.1, 30.6, 21.7. IR vmax (neat) / cm-1 
2953-2871 (C-H3 and C-H2 & O-H overlapping), 1698 (C=O), 1667 (C=O), 1633 (C=O). HRMS 
(ESI+) calculated for C20H21O5 [M+H]+ 341.1384 found 341.1381. Mp. 155-156°C.  
N-(2-oxo-2H-chromen-3-yl) acetamide (77) 
 
Salicylaldehyde (6.1 g, 50 mmol) was added to N-acetylglycine (5.85 g, 50 mmol), anhydrous 
NaOAc (16 g, 195 mmol) and Ac2O (30 mL). The mixture was heated to reflux for 5 hours. After 
which the mixture was allowed to cool to room temperature before being quenched and triturated 
with ice water. Small portions of EtOAc were added and the precipitated solid collected and 
washed with small aliquots of EtOAc to furnish the product as a yellow powder (1.39 g, 14%). 1H 
NMR (400 MHz, DMSO-d6) δH ppm: 9.76 (s, 1 H, NH), 8.60 (s, 1 H, 4-H), 7.69 (dd, J1 = 8.0 Hz, J2 
= 1.6 Hz, 1 H, ArH), 7.50 (td, 1 H, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H, ArH), 7.38  (app d, J = 8.0 Hz, 1 H, 
ArH), 7.33 (td, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H, ArH), 2.16 (s, 3 H, b-H3). 13C NMR (100 MHz, DMSO-
d6) δC ppm: 170.2, 157.4, 149.6, 129.5, 127.8, 124.9, 124.6, 123.5, 119.5, 115.8, 23.9. 
IR vmax (neat) / cm-1 3328 (N-H), 1707 (C=O), 1680 (C=O). HRMS (ESI+) calculated for C11H9NO3H 
[M+H]+ 204.0655 found 204.0655. Mp. 205-207°C, (Lit 203-204°C).280 
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N-(8-methoxy-2-oxo-2H-chromen-3-yl) acetamide (79) 
 
A mixture of O-vanillin (3.8 g, 25.0 mmol), N-acetylglycine (2.9 g, 24.76 mmol), anhydrous sodium 
acetate (8.2 g, 100 mmol) and acetic anhydride (12.5 mL) was brought to reflux for 3.5 hours. After 
this the reaction was allowed to cool to room temperature before being triturated with water. EtOAc 
was added to cause the product to precipitate into the organic layer. The solid was collected and 
washed well with small aliquots of EtOAc to furnish the desired product as a yellow powder (1.05 g, 
18%). 1H NMR (400 MHz, CDCl3) δH ppm: 8.65 (s, 1 H, 4-H), 8.08 (br s, 1 H, NH), 7.23 (t, J = 8.0 
Hz, 1 H, ArH), 7.09 (dd, J1 = 8.0 Hz, J2 = 1.2 Hz, 1 H, ArH), 7.01 (dd, J1 = 8.0 Hz, J2 = 1.2 Hz, 1 H, 
ArH), 3.97 (s, 3 H, c-H3), 2.23 (s, 3, b-H3). 13C NMR (100 MHz, CDCl3) δC ppm: 169.4, 158.5, 
147.0, 139.5, 125.1, 124.4, 123.4, 120.7, 119.5, 111.8, 56.3, 24.8. IR vmax (neat) / cm-1 3333 (CON-
H), 3087-2839 (Ar-H), 1707 (C=O), 1676 (C=O). HRMS (ESI+) calculated for C12H11NO4H [M+H]+ 
234.0761 found 234.0756. Mp. 240-242°C, (Lit 237-238°C).248 
N-(7-methoxy-2-oxo-2H-chromen-3-yl) acetamide (81) 
 
4-Methoxysalicylaldehyde (3.8 g, 25 mmol), was added to N-acetylglycine (2.9 g, 24.79 mmol), 
anhydrous NaOAc (8.2 g, 100 mmol) and Ac2O (15.5 mL). The mixture was refluxed for 24 hours, 
after which it was allowed to cool to room temperature. The reaction was quenched and triturated 
with water. Subsequently EtOAc was added, the resultant precipitate was filtered and washed with 
a small amount of EtOAc to furnish the product as a yellow powder (666 mg, 11%). 1H NMR 
(400 MHz, CDCl3) δH ppm: 8.63 (s, 1 H, 4-H), 7.98 (br s, 1 H, NH), 7.40 (d, J = 8.4, 1 H, 5-H), 6.88 
(dd, J1 = 8.4, J2 = 2.4, 1 H, 6-H), 6.81 (d, J = 2.0, 1 H, 8-H), 3.86 (s, 3 H, c-H3), 2.22 (s, 3 H, b-H3). 
13C NMR (100 MHz, CDCl3) δC ppm: 169.3, 161.4, 159.2, 151.6, 128.8, 124.2, 121.7, 113.3, 113.2, 
100.9, 55.9, 24.8. IR vmax (neat) / cm-1 3347 (CON-H), 3060 (CO-CH3), 2949-2843 (C-H3), 1702 
(C=O), 1676 (C=O), 1523 (C=C), 1519 (C=C), 1504 (C=C). HRMS (ESI+) calculated for C12H12NO4 
[M+H]+ 234.0761 found 234.0762 Mp 237-240 °C, (Lit 234-235 °C).248 
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N-(6-chloro-2-oxo-2H-chromen-3-yl) acetamide (83) 
 
A mixture of 2-hydroxy-5-chlorobenzaldehyde (5 g, 32.05 mmol), N-acetylglycine (3.75 g, 32.05 
mmol), anhydrous sodium acetate (10.51 g, 128 mmol) and acetic anhydride (15.13 mL) was 
refluxed for 3.5 hours before being allowed to cool to room temperature. The resultant yellow solid 
was triturated with water and then EtOAc added to precipitate the product in the organic layer. The 
solid was filtered and washed with small aliquots of EtOAc to give the desired compound as a 
yellow powder (2.65 g, 35%). 1H NMR (400 MHz, DMSO-d6) δH ppm: 9.82 (s, 1 H, NH), 8.60 (s, 1 
H, 4-H), 7.87 (d, J = 2.4 Hz, 1 H, ArH), 7.52 (dd, J1 = 8.8 Hz, J2 = 2.8 Hz, 1 H, ArH), 7.42 (d, J = 8.8 
Hz, 1 H, ArH), 2.17 (s, 3 H, b-H3). 13C NMR (100 MHz, CDCl3) δC ppm: 169.5, 158.4, 148.3, 130.7, 
129.7, 127.1, 125.0, 121.9, 121.1, 117.9, 24.9. IR vmax (neat) / cm-1 3337 (CON-H), 3093 (Ar-H) 
3056 (Ar-H), 3030 (Ar-H), 1711 (C=O), 1676 (C=O), 1568 (C=C), 1537 (C=C), 1524 (C=C), 828 (C-
Cl). HRMS (APCI+) calculated for C11H9ClNO3 [M+H]+ 238.0265 found 238.0269. Mp 263-264°C.  
N-(8-chloro-2-oxo-2H-chromen-3-yl) acetamide – (85) 
 
A mixture of 3-chlorosalicylaldeyde (1 g, 6.41 mmol), N-acetylglycine (750 mg, 6.41 mmol), 
anhydrous sodium acetate (2.1 g, 25.64 mmol), and acetic anhydride (16 mL) was refluxed for 4 
hours before being allowed to cool to room temperature. Ice was added to quench the reaction and 
the solid triturated with water. EtOAc was added to precipitate the product and the filtered solid was 
washed with small aliquots of EtOAc. The organic filtrate had the solvent removed under pressure 
and the crude was purified by flash column chromatography (EtOAc/hexanes 3:7) to give a white 
powder (0.68 g, combined yield 45%). 1H NMR (400 MHz, DMSO-d6) δH ppm: δ 9.87 (s, 1 H, NH), 
8.64 (s, 1 H, 4-H), 7.66 (dd, J1 = 7.6 Hz, J2 = 1.2, 1 H, ArH), 7.61 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H, 
ArH), 7.33 (t, J = 8.0 Hz, 1 H, ArH), 2.18 (s, 3 H, b-H3). 13C NMR (DMSO-d6, 100 MHz) δC ppm: 
170.4, 156.7, 144.9, 129.4, 126.8, 125.5, 125.3, 122.6, 121.4, 119.2, 24.0. IR vmax (neat) / cm-1 
3337 (CON-H), 1711 (C=O), 1676 (C=O), 767 (C-Cl). HRMS (ESI+) calculated for C11H9O3N1Cl1 
[M+H]+ 238.0265 found 238.0265. Mp. 248-249°C.  
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3-acetamido-2-oxo-2H-chromen-8-yl acetate (87) 
 
A mixture of 2,3-dihydroxybenzaldehyde (4.5 g, 32.60 mmol), N-acetylglycine (3.81 g, 32.60 mmol), 
anhydrous sodium acetate (10.69 g, 130 mmol) and acetic anhydride (12 mL) was refluxed for 3 
hours. After this the mixture was allowed to cool to room temperature. The crude solid was 
triturated with water and EtOAc added to precipitate the product. The solid was filtered and washed 
with small aliquots of EtOAc to furnish the desired compound as a off white powder (3.57 g, 42%). 
1H NMR (400 MHz, CDCl3) δH ppm: 8.68 (s, 1 H, 4-H), 8.06 (br s, 1 H, NH), 7.39 (dd, J1 = 8.0 Hz, 
J2 = 1.6 Hz, 1 H, ArH), 7.28 (t, J = 8.0 Hz, 1 H, ArH), 7.20 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H, ArH), 
2.42 (s, 3 H, d-CH3), 2.25 (s, 3 H, b-CH3). 13C NMR (100 MHz, CDCl3) δC ppm: 169.6, 168.7, 157.9, 
141.7, 137.7, 125.4, 125.2, 124.5, 123.3, 123.0, 121.4, 24.9, 20.8. IR vmax (neat) / cm-1 3284 (CON-
H), 1773 (C=O), 1711 (C=O), 1676 (C=O). HRMS (ESI+): calculated for C13H11NO5H [M+H]+ 
262.0710 found 262.0712. Mp 215-217°C.   
3-acetamido-7-acetoxy-2H-chromen-2-one (88) 
 
A mixture of 2,4-dihydroxybenzaldehyde (13.82 g, 100 mmol), N-acetylglycine (11.70 g, 100 mmol), 
anhydrous sodium acetate (32.8 g, 400 mmol) and acetic anhydride (60 mL) was refluxed for 
3.5 hours before being cooled to room temperature and quenched with crushed ice. The mixture 
was triturated well with water and then EtOAc added to precipitate the product. The solid was 
filtered and washed with small aliquots of EtOAc to furnish the desired product as a pale yellow 
powder (10.44 g, 40%). 1H NMR (400 MHz, CDCl3) δH ppm: δ 8.67 (s, 1 H, 4-H), 8.03 (br s, 1 H, 
NH), 7.51 (d, J = 8.0 Hz, 1 H, ArH), 7.13 (d, J = 2.4 Hz, 1 H, ArH), 7.07 (dd, J1 = 8.4 Hz, J2 = 2.0 
Hz, 1 H, ArH), 2.34 (s, 3 H, d-H3), 2.25 (s, 3 H, b-H3). 13C NMR (100 MHz, CDCl3) δC ppm: 169.5, 
169.0, 158.6, 151.5, 150.3, 128.5, 123.7, 122.9, 119.3, 117.8, 110.2, 24.9, 21.2. IR vmax (neat) / cm-
1 3340 (CON-H), 3079 (C=O overtone ester) 1757 (C=O), 1716 (C=O), 1678 (C=O), 1532 (C=C), 
1200 (C-O stretch ester). HRMS (ESI+) calculated for C13H11NO5H [M+H]+ 262.0710 found 
262.0714. Mp. 238-239°C, (Lit 234-236°C).248 
 
 
6
7
5
O
1
2
3
4
O
H
N
O
8
c
O
d
a
O
b
6
7
8
5
O
1
2
3
4
O
H
N a
O
b
Ocd
O
Chapter 6. Experimental 
 
 
 
169 
N-(6-nitro-2-oxo-2H-chromen-3-yl) acetamide (90) 
 
A mixture of 5-nitrosalicylaldhyde (5 g, 29.94 mmol), N-acetylglycine (3.50 g, 29.94 mmol), 
anhydrous sodium acetate (1119.76 mmol) and Ac2O (14.13 mL) was refluxed for 3.5 hours. After 
which the mixture was allowed to cool to room temperature. The solid was triturated with water and 
EtOAc added to precipitate the product in the organic layer. The solid was filtered and washed with 
small aliquots of EtOAc to furnish the desired product as a pale yellow solid (3.71 g, 50%). 1H NMR 
(400 MHz, CDCl3) δ 8.76 (s, 1 H, 4-H), 8.44 (d, J = 2.6 Hz, 1 H, ArH), 8.30 (dd, J1 = 8.0 Hz, J2 = 2.4 
Hz, 1 H, ArH), 8.08 (br s, 1 H, NH), 7.46 (d, J = 8.0 Hz, 1 H, ArH), 2.28 (s, 3H, c-H3). 13C NMR (100 
MHz, CDCl3) δC ppm: 169.6, 157.7, 153.1, 145.0, 125.7, 124.4, 123.5, 121.4, 120.5, 117.6, 24.9. IR 
vmax (neat) / cm-1 3372 (CON-H), 3096-3080 (Ar-H), 1722 (C=O), 1686 (C=O), 1519 (C=C), 1515 
(C=C), 1504 (C=C), 1332 (C-NO2). HRMS (ESI+) calculated for C11H9N2O5 [M+H]+ 249.0506 found 
249.0509. Mp. 277-278°C, (Lit 274-277°C).248 
Tert-butyl N-(2-oxo-2H-chromen-3-yl) carbamate (95) 
 
To a mixture of compound 77 (1 g, 4.92 mmol) and DMAP (60 mg, 0.49 mmol) in THF (15 mL) was 
added Boc2O (3.21 g, 14.72 mmol). The mixture was stirred vigorously at room temperature for 1 
hour before hydrazine hydrate (0.78 g, 24.63 mmol) and methanol (10 mL) were added. The 
reaction was allowed to stir for a further 3 hours after which the solvent was removed under 
vacuum. The crude was then dissolved in DCM, washed with 1M HCl, Cu(II)SO4 and sat. NaHCO3. 
The organic layer was dried over MgSO4 the solvent removed under pressure and the product 
purified by flash column chromatography (ethyl acetate/hexanes 1:9) to furnish the product as a 
white powder (0.64 g, 50%). 1H NMR (400 MHz, CDCl3) δH ppm: 8.27 (br s, 1 H, 4-H) 7.45 (dd, J1 = 
7.6 Hz, J2 = 1.6 Hz, 1 H, ArH) 7.41 (td, J1 = 7.2 Hz, J2 = 1.6 Hz, 2 H, ArH overlapping NH), 7.31-
7.25 (m, 2 H, 7 and ArH), 1.54 (s, 9 H, c-H3). 13C NMR (CDCl3 100 MHz) δC ppm: 158.7, 152.6, 
149.6, 129.1, 127.4, 125.1, 124.7, 120.5, 120.1, 116.4, 81.8, 28.3. IR vmax (neat) / cm-1 3415 (CON-
H), 3321 (CON-H), 2997-2924 (Ar-H), 1702 (C=O) 1698 (C=O), 1519 (C=C). HRMS (ESI+) 
calculated for C14H15NO4H [M+H]+ 262.1074 found 262.1071. Mp. 96-98°C, (Lit 85-86 °C).248 
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Tert-butyl N-(8-methoxy-2-oxo-2H-chromen-3-yl) carbamate (96) 
 
To a mixture of compound 79 (0.5 g , 2.15 mmol) and DMAP (26.23 mg, 0.22 mmol) in THF was 
added Boc2O (1.87 g, 8.58 mmol). The reaction mixture was stirred at rt for 19 hours after which 
hydrazine was added (345 mg, 10.75 mmol) followed by MeOH (6 mL). The reaction was stirred for 
a further 50 minutes before the solvent was removed under pressure. The crude was dissolved in 
DCM, washed once with 1M HCl, Cu(II)SO4 and sat. NaHCO3. The organic layer was then dried 
over MgSO4, the solvent removed under pressure and the product purified by flash column 
chromatography (EtOAc/hexanes 3:17) to give a yellow powder (0.3 g, 48%). 1H NMR (400 MHz, 
CDCl3) δH ppm: 8.22 (br s, 1 H, 4-H), 7.42 (br s, 1 H, NH), 7.18 (t, J = 8.0 Hz, 1 H, ArH), 7.02 (dd, 
J1 = 8.0 Hz, J2 = 1.2 Hz, 1 H, ArH), 6.95 (dd, J1 = 8.0 Hz, J2 = 1.2 Hz, 1 H, ArH), 3.94 (s, 3 H, d-H3), 
1.52 (s, 9 H, c-H3). 13C NMR (100 MHz, CDCl3) δC ppm: 158.2, 152.6, 147.1, 139.1, 125.0, 124.9, 
120.9, 120.5, 119.0, 111.2, 81.8, 56.3, 28.3. IR vmax (neat) / cm-1 3317 (CON-H), 2984 (Ar-H), 1728 
(C=O), 1698 (C=O). HRMS (ESI+) calculated for C15H18NO5 [M+H]+ 292.1179 found 292.1178. Mp. 
145-147°C, (Lit 97-99°C).248 
Tert-butyl N-(7-methoxy-2-oxo-2H-chromen-3-yl) carbamate (97) 
 
To a mixture of compound 81 (1 g, 4.29 mmol), and DMAP (2.62 g, 21.46 mmol) in THF (30 mL) 
was added Boc2O (4.68 g, 21.46 mmol). After 2 hours hydrazine monohydrate (1.06 g, 21.17 
mmol) followed by 15 mL of MeOH was added and the reaction stirred vigorously for a further hour 
before the reaction solvent was removed under vacuum. The crude residue was dissolved in DCM 
and washed once with 1M HCl, 1M Cu(II)SO4 and sat. NaHCO3. The organic layer was dried over 
MgSO4 and the solvent removed under reduced pressure. The product was isolated by flash 
column chromatography (EtOAc/hexanes 1:4) to furnish the product as a white powder (372 mg, 
30%). 1H NMR (400 MHz, CDCl3) δH ppm: 8.23 (s, 1 H, 4-H), 7.35 (d, J = 8.0 Hz, 1 H, ArH), 7.28 (s, 
1 H, NH), 6.86 (dd, J1 = 8.0 Hz, J2 = 2.4 Hz, 1 H, ArH), 6.81 (d, J = 2.4 Hz, 1 H, ArH), 3.85 (s, 3 H, 
d-H3), 1.52 (s, 9 H, c-H3). 13C NMR (100 MHz, CDCl3) δC ppm: 160.9, 159.0, 152.7, 151.1, 128.2, 
122.3, 121.4, 113.4, 113.2, 100.8, 81.6, 55.8, 28.4. IR vmax (neat) / cm-1 3423 (CON-H), 2985 (Ar-
H), 2939 (Ar-H), 2831 (Ar-H), 1713 (C=O), 1615 (C=O). HRMS (ESI+) calculated for C15H18NO5 
[M+H]+ 292.1179 found 2921182. Mp.119-120°C, (Lit 117-118°C).248 
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Tert-butyl N-(6-chloro-2-oxo-2H-chromen-3-yl) carbamate (98) 
 
To a mixture of compound 83 (250 mg, 0.52 mmol) and DMAP (64 mg, 1.05 mmol) in THF (4 mL) 
was added Boc2O (0.9 g, 4.13 mmol). The reaction mixture was stirred for 18 hours at room 
temperature. Subsequently hydrazine monohydrate (254 µL, 10.5 mmol) and MeOH (4 mL) were 
added and the reaction left for 1 hour before the solvent was removed under reduced pressure. 
The crude residue was dissolved in DCM, washed with 1M HCl, sat. CuIISO4, Sat. NaHCO3 and 
dried over MgSO4. The product was purified by flash column chromatography (EtOAc/hexanes 1:1) 
to give the desired compound as a white powder (62 mg, 20%). 1H NMR (400 MHz, CDCl3) δH 
ppm: 8.13 (br s, 1 H, 4-H), 7.39 (br s, 1 H, NH), 7.37 (d, J = 2.4 Hz, 1 H, ArH), 7.29 (dd, J1 = 8.8 
Hz, J2 = 2.4 Hz, 1 H, ArH), 7.19 (d, J = 8.8 Hz, 1 H, ArH), 1.50 (s, 9 H, c-H3). 13C NMR (100 MHz, 
CDCl3) δC ppm: 158.1, 152.3, 147.8, 130.4, 128.8, 126.4, 125.6, 121.4, 118.8, 117.7, 82.0, 28.2. IR 
vmax (neat) / cm-1 3403 (CON-H), 3095 (Ar-H), 2986 (C-H3), 2929 (C-H3) 1706 (C=O), 1507 (C=O), 
767 (C-Cl). HRMS (ESI+) calculated for C14H15ClNO4 [M+H]+ 296.0684 found 296.0688. Mp.113-
114°C.  
Tert-butyl N-(8-chloro-2-oxo-2H-chromen-3-yl) carbamate (99) 
 
To a mixture of compound 85 (1 g, 4.22 mmol) and DMAP (257 mg, 2.11 mmol) in THF (15 mL) 
was added Boc2O (3.68 g, 16.88 mmol). The mixture was stirred at room temperature for 28 h after 
which hydrazine monohydrate (1.06 g, 21.10 mmol) was added followed by MeOH (15 mL). After a 
further 2 hours of vigorous stirring the solvent was removed under pressure and the crude 
dissolved in DCM. The organic layer was washed once with 1M HCl, sat. Cu(II)SO4, sat. NaHCO3 
and dried over MgSO4. The product was purified by flash column chromatography (EtOAc/hexanes 
1:9) to furnish the product as a white powder (320 mg, 26%). 1H NMR (400 MHz, CDCl3) δH ppm: 
8.26 (br s, 1 H, 4-H), 7.45 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H, ArH), 7.43 (br s, 1 H, NH), 7.36 (dd, J1 
= 8.0 Hz, J2 = 1.6 Hz, 1 H, ArH), 7.21 (t, J = 8.0 Hz, 1 H, ArH), 1.53 (s, 9 H, c-H3). 13C NMR (CDCl3, 
100 MHz) δC ppm: 157.9, 152.5, 145.2, 129.5, 125.9, 125.4, 125.3, 121.6, 121.4, 119.8, 82.2, 28.3. 
IR vmax (neat) / cm-1 3326 (CON-H), 2983-2924 (Ar-H), 1731 (C=O), 1702 (C=O), 1597 (C=C), 1567 
(C=C), 1526 (C=C), 759 (C-Cl). HRMS (ESI+) calculated for C14H15ClNO4 [M+H]+ 296.0684 
observed 296.0686. Mp. 145-147°C. 
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Tert-butyl N-(8-hydroxy-2-oxo-2H-chromen-3-yl) carbamate (100) 
 
To a mixture of compound 87 (0.5 g, 1.92 mmol) and DMAP (117 mg, 0.96 mmol) in THF (8 mL) 
was added Boc2O (1.67 g, 7.68). The mixture was stirred for 2 hours at room temperature after 
which hydrazine monohydrate (460 mg, 9.60 mmol) was added followed by MeOH (8 mL). The 
reaction mixture was stirred for a further 4 hours before the solvent was removed under vacuum. 
The residue was dissolved in DCM and washed once with 1M HCl, Cu(II)SO4, sat. NaHCO3 and 
brine. The organic layer was dried over MgSO4, the solvent removed under pressure, and the 
product was purified by flash column chromatography (EtOAc/hexanes 3:7) to give a white powder 
(111 mg, 21%). 1H NMR (400 MHz, CDCl3) δH ppm: 8.30 (br s, 1 H, 4-H), 7.37 (br s, 1 H, NH), 7.04 
(dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H, ArH), 7.01 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H, ArH), 1.54 (s, 9 H, 
c-H3). 13C NMR (100 MHz, CDCl3) δC ppm: 157.9, 152.5, 143.1, 137.5, 125.7, 124.7, 121.1, 120.6, 
119.0, 115.7, 82.0, 28.4. IR vmax (neat) / cm-1 3419 (CON-H), 3398 (O-H), 2970 (Ar-H), 1707 (C=O). 
HRMS (ESI+) calculated for C14H15NO5Na [M+Na]+ 300.0842 found 300.0845. Mp. 165-167°C. 
Tert-butyl N-(7-hydroxy-2-oxo-2H-chromen-3-yl) carbamate (101) 
 
To a mixture of compound 88 (2.17 g, 8.25 mmol) and DMAP (250 mg, 2.04 mmol) in THF (85 mL) 
was added Boc2O (7.19 g, 32.96 mmol). The reaction mixture was stirred at room temperature for 
45 minutes after which hydrazine monohydrate (2.06 g, 41.20 mmol) was added followed by MeOH 
(40 mL). After a further 40 minutes the solvent was removed under reduced pressure and the 
residue taken up in DCM. The organic layer was washed once with 1M HCl, 1M Cu(II)SO4 and sat. 
NaHCO3. The organic layer was dried over MgSO4 the solvent removed. The product was purified 
by flash column chromatography (EtOAc/hexane 3:17) to give the desired compound as a white 
powder (480 mg, 21%). 1H NMR (400 MHz, CD3OD) δH ppm: δ 8.14 (br s, 1 H, 4-H), 7.34 (d, J = 
8.0 Hz, 1 H, ArH), 6.77 (dd, J1 = 8.0 Hz, J2 = 2.4 Hz, 1 H, ArH), 6.68 (d, J = 2.4 Hz, 1 H, ArH), 1.52 
(s, 9 H, c-H3). 13C NMR (100 MHz, CD3OD) δC ppm: 160.8, 160.2, 154.5, 152.8, 129.6, 124.5, 
122.8, 114.8, 113.4, 103.2, 82.1, 28.5. IR vmax (neat) / cm-1 3316 (O-H), 3079 (C-H3 and C-H2), 
2978 (C-H3 and C-H2) 1702 (C=O), 1684 (C=O), 1607 (C=C), 1534 (C=C), 1510 (C=C). HRMS 
(ESI+) calculated for C14H15NO5H [M+H]+ 278.1028 found 278.1028. Mp. 174-176°C, (Lit 177-
178°C).248 
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Tert-butyl-N-(6-nitro-2-oxo-2H-chromen-3-yl) carbamate (102) 
 
To a mixture of compound 90 (1 g, 4.03 mmol) and DMAP (245 mg, 2.01 mmol) in THF (50 mL) 
was added Boc2O (3.51 g, 16.12 mmol). The reaction mixture was stirred at room temperature for 
19 h after which hydrazine monohydrate (1 g, 20.15 mmol) was added followed by MeOH (25 mL). 
After a further 2 hours of vigorous stirring at room temperature the solvent was removed under 
reduced pressure and the crude dissolved in DCM. The organic layer was washed once with 1M 
HCl, sat. Cu(II)SO4 and sat. NaHCO3. Subsequently the organic layer was dried over MgSO4 and 
the solvent removed to furnish crude compound. The desired product was obtained by flash column 
chromatography (EtOAc/hexanes 1:9) as an off white powder (228 mg, 18%). 1H NMR (400 MHz, 
CDCl3) δH ppm: 8.38 (d, J = 2.4 Hz, 1 H, ArH), 8.35 (s, 1 H, 4-H), 8.25 (dd, J1 = 8.0 Hz, J2 = 2.4 Hz, 
1 H, ArH), 7.43 (d, J = 8.0 Hz, 2 H, ArH overlapping NH), 1.54 (s, 9 H, c-H3). 13C NMR (100 MHz, 
CDCl3) δC ppm: 157.5, 152.7, 152.2, 144.9, 126.5, 123.8, 123.0, 120.8, 118.5, 117.5, 82.6, 28.3. IR 
vmax (neat) / cm-1 3409 (CON-H), 3075 (C-H3), 2976 (Ar-H), 1715 (C=O), 1526 (C=C) 1509 (C=C), 
1338 (C-NO2). HRMS (ACPI+) calculated for C14H15N2O6 [M+H]+ 307.0925 found 307.0920. Mp. 
145-146°C, (Lit 132-134).248 
3-amino-2H-chromen-2-one (104) 
 
Compound 77 (1.99 g, 9.08 mmol) was added to a mixture of conc. HCl and EtOH (2:1) and 
refluxed for 5 hours. Subsequently the solution was allowed to cool to room temperature. The pH 
was adjusted with NaOH to pH 7 and the precipitate filtered and desiccated to furnish the product 
as a yellow powder (866 mg, 54%). 1H NMR (400 MHz, DMSO-d6) δH ppm: 7.42-7.40 (m, 1 H, 
ArH), 7.28-7.24 (m, 1 H, ArH), 7.22-7.17 (m, 2 H, ArH), 6.71 (s, 1 H, 4-H), 5.69 (s, 2 H, NH2). 13C 
NMR (DMSO-d6, 100 MHz) δC ppm: 158.6, 147.9, 133.3, 125.3, 124.8, 124.5, 121.8, 115.4, 107.6. 
IR vmax (neat) / cm-1 3425 (N-H), 3313 (N-H), 3054 (Ar-H), 3022 (Ar-H), 1702 (C=O), 1633 (N-H2 
scissor), 1331 (C-N), 888 (N-H2 wag). HRMS (APCI+) calculated for C9H7NO2H [M+H]+ 162.0550 
found 162.0548. Mp. 136-138°C, (Lit 138-140°C).281 
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3-amino-8-methoxy-2H-chromen-2-one  (106) 
 
A mixture of conc. HCl (5 mL) and EtOH (5 mL) was added to compound 79 (1.2 g, 5.15 mmol). 
The suspension was refluxed for 3 hours before being allowed to cool to room temperature. The pH 
was adjusted to neutral with NaOH. The resultant precipitate was filtered and washed with small 
aliquots of EtOH to furnish the desired product (0.49 g, 50%). 1H NMR (400 MHz, DMSO-d6) δH 
ppm: 7.13 (t, J = 8.0 Hz, 1 H, ArH), 6.97 (dd, J1 = 8.0 Hz, J2 = 1.3 Hz, 1 H, ArH), 6.92 (dd, J1 = 8.0 
Hz, J2 = 1.2 Hz, 1 H, ArH) 6.68 (s, 1 H, 4-H), 5.69 (br s, 2 H, NH2), 3.86 (s, 3 H, a-H3). 13C NMR 
(100 MHz, DMSO-d6) δC ppm: 158.3, 146.3, 137.0, 133.5, 124.4, 122.4, 116.6, 108.3, 107.8, 55.8. 
IR vmax (neat) / cm-1 3360 (N-H), 3338 (N-H), 2997 (C-H3), 2969 (C-H3), 2941 (C-H3), (Ar-H) 1686 
(C=O), 1633 (N-H2 scissor), 1608 (C=C), 1593 (C=C), 1571 (C=C), 763 (N-H2 wag). HRMS (ESI+) 
calculated for C10H9NO3H [M+H]+ 192.0655 found 192.0654. Mp. 133-135 °C, (Lit 124-125 °C).281 
3-amino-7-methoxy-2H-chromen-2-one (107) 
 
Compound 81 (1 g, 4.29 mmol) was added to a mixture of conc. HCl and EtOH (2:1) and refluxed 
for 18 hours. Subsequently the solution was allowed to cool to room temperature and quenched 
with H2O. The pH was adjusted with KOH to pH 8 and the aqueous phase extracted three times 
with chloroform. The organic fractions were pooled, dried over MgSO4 and the solvent removed 
under vacuum. The crude was purified by flash column chromatography using a gradient 
(EtOAc/Hexanes 1:9 to 1:4) to furnish the product as a yellow powder (213 mg, 26%). 1H NMR 
(400 MHz, CDCl3) δH ppm: 7.19 (d, J = 8.0 Hz, 1 H, ArH), 6.83-6.80 (m, 2 H, ArH), 6.70 (s, 1 H, 4-
H), 4.06 (br s, 2 H, NH2). 13C NMR (100 MHz, CDCl3) δC ppm: 159.9, 159.2, 150.5, 129.9, 126.0, 
114.5, 112.7, 112.4, 100.9, 55.8. IR vmax (neat) / cm-1 3419 (N-H), 3355 (N-H), 3091 (Ar-H), 3006 
(Ar-H), 2745-2498 (C-H3), 1707 (C=O), 1607 (N-H2 scissor), 1556 (C=C), 1543 (C=C), 1510 (C=C), 
1250 (C-N), 753 (N-H2 wag). HRMS (ESI+) calculated for C10H10NO3 [M+H]+ 192.0655 found 
192.0653. Mp. 220-222°C, (137-139°C).248 
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3-amino-6-chloro-2H-chromen-2-one (108) 
 
A suspension of compound 83 (1 g, 4.22 mmol), in conc. HCl and EtOH (2:1) was refluxed for 3.5 
hours. After which it was allowed to cool to room temperature and the suspension cooled to zero 
degrees. The pH was adjusted with KOH to neutral. A cream solid was filtered, washed with small 
aliquots of EtOH and subsequently desiccated to give the desired compound (735 mg, 90%). 1H 
NMR (400 MHz, DMSO-d6) δH ppm: 7.54 (d, J = 2.4 Hz, 1 H, ArH), 7.29 (d, J = 8.4 Hz, 1 H, ArH), 
7.21 (dd, J1 = 8.8 Hz, J2 = 2.4 Hz, 1 H, ArH), 6.66 (s, 1 H, 4-H), 5.94 (br s, 2 H, NH2). 13C NMR (100 
MHz, DMSO-d6) δC ppm: 158.2, 146.3, 134.2, 128.4, 124.5, 123.7, 123.6, 117.2, 105.8. IR vmax 
(neat) / cm-1 3407 (N-H), 3322 (N-H), 1708 (C=O), 810 (C-Cl). HRMS (APCI+) calculated for 
C9H7NOCl [M+H]+ 196.0160 found 196.0159. Mp. 213-215°C, (Lit 204-206°C).282 
3-amino-8-chloro-2H-chromen-2-one (109) 
 
A mixture of conc. HCl and EtOH (2:1) was added to compound 85 (1 g, 4.22 mmol). The 
suspension was refluxed for 3.5 hours after which the reaction was cooled to 0 °C and taken to a 
neutral pH with KOH. The solvent was removed under reduced pressure. The product was purified 
by flash chromatography (EtOAc/hexanes 2:3) to give the product as white solid. (59 mg, 7%). 1H 
NMR (400 MHz, CDCl3) δH ppm: 7.32 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H, ArH), 7.19 (dd, J1 = 8.0 Hz, 
J2 = 1.6 Hz, 1 H, ArH), 7.13 (t, J = 8.0 Hz, 1 H, ArH) 6.67 (s, 1 H, 4-H), 4.35 (br s, 2 H, NH2). 13C 
NMR (CDCl3, 100 MHz) δC ppm: 158.6, 144.7, 132.6, 127.2, 125.0, 123.6, 122.8, 121.2, 110.1. IR 
vmax (neat) / cm-1 3416 (N-H), 3334 (N-H), 1712 (C=O), 1638 (N-H2 scissor), 15591 (C=C), 1556 
(C=C), 1152 (C-N), 898 (N-H2 wag) 764 (C-Cl). HRMS (ESI+) calculated for C9H7ClNO2 [M+H]+ 
196.0160 found 196.0160. Mp. 127-128°C. 
3-amino-8-hydroxy-2H-chromen-2-one (110) 
 
A mixture of conc. HCl (3 mL) and EtOH (3mL) was added to compound 87 (1 g, 3.83 mmol). The 
suspension was refluxed for 3 hours before being allowed to cool to room temperature. The 
suspension was taken to pH 7 with NaOH and the solid filtered and washed with a small aliquot of 
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EtOH to furnish the desired product as a brown solid (0.27 g, 40%). 1H NMR (400 MHz, DMSO-d6) 
δH ppm: 9.94 (s, 1 H, OH) 6.68 (t, J = 8.0 Hz, 1 H, ArH), 6.80 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1 H, 
ArH), 6.75 (dd, J1 = 8.0 Hz, J 2= 1.6 Hz, 1 H, ArH), 6.66 (s, 1 H, 4-H), 5.62 (br s, 2 H, NH2). 13C 
NMR (100 MHz, DMSO-d6) δC ppm: 158.5, 144.2, 136.6, 133.2, 124.4, 122.7, 115.0, 112.4, 108.2. 
IR vmax (neat) / cm-1 3454 (N-H), 3456 (N-H), 3364 (OH), 1704 (C=O), 1697 (N-H scissor), 1611 
(C=C), 1594 (C=C), 1567 (C=C), 1174 (C-O), 1144 (C-N). HRMS: (ESI+) calculated for C9H7NO3H 
[M+H]+ 178.0499 found 178.0496. Mp. 203-204°C, (Lit 192°C).283 
3-amino-7-hydroxy-2H-chromen-2-one (111) 
 
A suspension of compound 88 (4.13 g, 15.82 mmol) in conc. HCl and EtOH (2:1) was heated to 
reflux for 2 hours. The reaction was allowed to cool to room temperature before the pH was 
adjusted to neutral with 10% NaOH. The resultant solid was filtered and washed with small aliquot 
of EtOH to give the desired compound (0.87 g, 31%). 1H NMR (400 MHz, CD3OD) δH ppm: δ 7.33 
(d, J = 8.0 Hz, 1 H, ArH), 7.26 (s, 1 H, 4-H), 6.80 (dd, J1 = 8.0 Hz, J2 = 2.4 Hz, 1 H, ArH), 6.73 (d, J 
= 2.4, 1 H, ArH). 13C NMR (100 MHz, CD3OD) δC ppm: 168.5, 165.9, 159.1, 139.1, 135.5, 122.9, 
122.5, 120.6, 111.4. IR vmax (neat) / cm-1 3435 (N-H stretch), 3344 (N-H stretch), 3214 (O-H), 1678 
(C=O). HRMS (ESI+) calculated for C9H7NO3H [M+H]+ 178.0499 found 178.0498. Mp. 240-241°C, 
(Lit 237-238°C).248 
Ethyl 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazine-1-yl)-1,4-dihydroquinoline-3-carboxylate 
(138) 
 
Thionyl chloride (8 mL, 13 g, 109.67 mmol) was added to ciprofloxacin (2 g, 6.04 mmol) at room 
temperature. Subsequently EtOH (30 mL) was added dropwise whilst vigorously stirring. Care was 
taken as the reaction was very exothermic. The reaction mixture went from a suspension to a clear 
orange solution, it was then refluxed for 30 h before being allowed to cool to room temperature. 
The crude was taken up into sat. NaHCO3 and extracted three times with DCM, dried over MgSO4 
and the solvent removed under pressure. The product was obtained as a white powder (1.3 g, 
60%). 1H NMR (400 MHz, CDCl3) δH ppm: 8.42 (s, 1 H, 2-H), 7.88 (d, JHF = 12.0 Hz, 1 H, 5-H), 7.2 
(d, JHF = 7.2 Hz, 1 H, 8-H), 4.32 (q, J = 7.1 Hz, 2 H, d-H2), 3.43-3.38 (m, 1 H, a-H), 3.21-3.19 (m, 4 
H, 2’ or 3’-H2), 3.07-3.05 (m, 4 H, 2’ or 3’-H2), 2.35 (br s, 1 H, NH), 1.35 (t, J = 7.1 Hz, 3 H, e-H3), 
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1.30-1.25 (m, 2 H, b-H2), 1.11-1.07 (m, 2 H, b-H2). 13C NMR (100 MHz, CDCl3) δC ppm: 173.1 (d, 
JCF = 2.0 Hz), 165.6, 153.4 (d, JCF = 247.0 Hz), 148.1, 144.9 (d, JCF = 10.0 Hz), 138.0, 122.8 (d, JCF 
= 7.0 Hz), 113.0 (d, JCF = 23.0 Hz), 110.2, 104.8 (d, JCF = 3.0 Hz), 60.8, 51.4 (d, JCF = 4.0 Hz), 
46.0, 34.6, 14.5, 8.2. 19F NMR (376 MHz, CDCl3) δF ppm: -123.7 (s). IR vmax (neat) / cm-1 2942-
2820 cm-1 (C-H2 and C-H3), 1716 cm-1 (C=O), 1617 cm-1 (C=O). HRMS (ESI+) calculated for 
C19H23FN3O3 [M+H]+ 360.1718 found 360.1720. Mp. 218-223°C, (Lit 179-180).284 RP-HPLC 
showed 99% purity at 254 nm. 
(2E, 4E, 6E, 8E)-deca-2, 4, 6, 8-tetraenedioic acid (140) 
 
Commercially available Fumadil BTM (1 g, 2.18 mmol) was added to EtOAc (200 mL) and washed 
three times with an equal volume of water to remove unwanted excipients. The organic layer was 
dried over MgSO4 and the solvent removed under reduced pressure. The resultant product was 
added to 100 mL of 1M NaOH and stirred at rt for 72 h. Subsequently the mixture was washed 
three times with diethyl ether to remove any unreacted starting material. The remaining aqueous 
fraction was acidified with conc. HCl until pH 1 causing a yellow precipitate to form. This was 
filtered, and desiccated to give the desired product as a yellow powder (207 mg, 49%). 1H NMR 
(400 MHz, DMSO-d6) δH ppm: 12.28 (br s, 2 H, OH), 7.25 (dd, J1 = 16.0 Hz, J2 = 12.0 Hz, 2 H, 
c’/h’-H), 6.82-6.75 (m, 2 H, d’-H), 6.66-6.56 (m, 2 H, c’-H), 5.99 (d, J = 16.0 Hz, b’/i’-H). 13C NMR 
(100 MHz, DMSO-d6) δC ppm: 167.4, 143.4, 139.2, 133.8, 123.6, 69.8. IR vmax (neat) / cm-1 2818 
(COO-H), 2534 (COO-H), 1659 (C=O), 1614 (C=O). HRMS (ESI-) calculated for C10H9O4 [M-H]- 
193.0506 found 193.0505. Mp. 240-245°C, (Lit 271-280°C).285 
9-[(2-oxo-2H-chromen-3-yl) carbamoyl] nonanoic acid (142) 
 
3-aminocoumarin (1 g, 5.07 mmol) in pyridine (15 mL) was added to a mixture of refluxing sebacoyl 
chloride (1.46 g, 6.09 mmol) in pyridine (15 mL) and stirred for 16 h before being cooled to rt. The 
reaction mixture was quenched with water and taken to pH 7 with 1 M HCl. Subsequently the 
product was extracted three times with EtOAc and washed with 10% Cu(II)SO4 to remove pyridine. 
The organic layer was then dried over MgSO4 and the solvent removed under reduced pressure. 
The product was purified by flash column chromatography by running a gradient from 1-10% 
MeOH in DCM. The desired compound was obtained as a white powder (0.45 g, 26%). 1H NMR 
(400 MHz, DMSO-d6) δH ppm: 11.97 (s, 1 H, OH), 9.66 (s, 1 H, NH), 8.64 (s, 1 H, 4”-H), 7.70 (dd, 
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J1 = 7.7, J2 = 1.60, 1 H, ArH), 7.52-7.48 (m, 1 H, ArH), 7.40-7.32 (m, 2 H, ArH), 2.48-2.46 (t, 2 H, b’ 
or i’-H2, overlaps DMSO), 2.18 (t, 2 H, b’ or i’-H2), 1.58-1.55 (m, 2 H, c’ or h’-H2), 1.50-1.47 (m, 2 H, 
c’ or h’-H2) 1.29-1.23 (m, 8 H, d’, e’, f’, g’-H2). 13C NMR (100 MHz, DMSO-d6) δC ppm: 174.5, 
173.2, 157.5, 149.6, 129.5, 127.8, 124.9, 124.5, 123.6, 119.6, 115.8, 35.9, 33.7, 28.7, 28.6, 28.54, 
28.53, 25.0 24.5. IR vmax (neat) / cm-1  3289 (O-H & CON-H overlapping), 2920-2843 (C-H2), 1728 
(C=O), 1685 (C=O), 1682 (C=O). HRMS (ESI+) calculated for C19H24N1O5 [M+H]+ 346.1649 found 
346.1652. Mp 149-152°C.   
1-cyclopropyl-6-fluoro-4-oxo-7-(4-{9-[(2-oxo-2H-chromen-3-
yl)carbamoyl]nonanoyl}piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate (144) 
 
EDC (56.72 mg, 0.29 mmol) was added to a solution of compound 142 (94 mg, 0.27 mmol) in 30% 
pyridine/ DCM (10 mL) and stirred vigorously for 5 minutes to allow activation of the carboxylic acid. 
Subsequently compound 138 (96 mg, 0.27 mmol) was added and the reaction stirred for 23 h. After 
which it was acidified with 1 M HCl, extracted three times with EtOAc and the organic layer dried 
over MgSO4. The solvent was removed under reduced pressure and the resultant product triturated 
with diethyl ether and DCM. The product was purified by flash chromatography using a gradient 
(EtOAc/hexanes 1:1 to 100% EtOAc). The product was obtained as a white solid (81.50 mg, 44%). 
1H NMR (400 MHz, CDCl3) δH ppm: 8.68 (s, 1H, H, 4’-H), 8.50 (s, 1 H, 2-H), 8.06 (br s, 1 H, NH, 
overlaps doublet), 8.02 (d, J = 13.2 Hz, 1 H, ArH), 7.50-7.41 (m, 2 H, ArH), 7.32-7.24 (m, 3 H, ArH 
overlapping CDCl3 peak), 4.38 (q, J = 8.0 Hz, 2 H, d-H2), 3.84 (app t, 2 H, 2’ or 3’-H2), 3.69 (app t, 
2 H, 2’ or 3’-H2), 3.44-2.38 (m, 1 H, a-H), 3.26 (app t, 2 H, 2’ or 3’-H2), 3.20 (app t, 2 H, 2’ or 3’-H2), 
2.44-2.35 (m, 4 H, b’ or i’-H2), 1.74-1.64 (m, 4 H, c’ or h’-H2), 1.41-1.30 (m, 13 H, d’, e’, f’, g’, 
overlapping, b-H2 and e-H3), 1.15-1.11 (m, 2 H, b-H2). 13C NMR (100 MHz, CDCl3) δC ppm: 173.1 
(d, JCF = 1.0 Hz), 172.7, 171.9, 165.9, 159.0, 153.5 (d, JCF = 247.0 Hz), 150.0, 148.4, 144.2 (d, JCF 
= 10.0 Hz), 138.1, 129.8, 127.9, 125.3, 124.1, 123.6 (d, JCF = 7.0 Hz), 123.3, 120.0, 116.5, 113.6 
(d, JCF = 23.0 Hz), 110.7, 105.2 (d, JCF = 3.0 Hz), 61.1, 50.8 (d, JCF = 6.0 Hz), 49.7 (d, JCF = 3.0 
Hz), 45.7, 41.4, 37.8, 33.6, 33.4, 29.5, 29.31 29.28, 29.19, 25.40, 25.37, 14.6, 8.3.19F NMR (376 
MHz, CDCl3) δF ppm: -123.9 (s). IR vmax (neat) / cm-1 2928-2851 (C-H2 and C-H3), 1720 (C=O), 
1682 (C=O), 1615 (C=O). HRMS (ESI+) calculated for C38H44FN4O7 [M+H]+ 687.3189 found 
687.3181. RP-HPLC showed 97% purity at 214 nm.   
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1-cyclopropyl-6-fluoro-4-oxo-7-(4-{9-[2-oxo-2H-chromen-3-yl)carbamoyl]nonanoyl}piperazin-
1-yl)-1,4-dihydroquinoline-3-carboxylic acid (145) 
 
Compound 144 (39 mg, 0.057 mmol) was added to a solution of lithium hydroxide monohydrate 
(7.1 mg, 0.17 mmol) in a mixture of THF:MeOH:H2O (3:2:1). The solution was stirred vigorously, 
after 23 hours another portion of lithium hydroxide monohydrate was added (7 mg, 0.017 mmol) 
and the solution stirred for a further for a further 50 hours at room temperature, after which 1 M HCl 
was added to form a precipitate. The suspension was extracted once with CHCl3 and twice with 
DCM. The organic fractions were pooled and dried over MgSO4. The crude orange solid was 
purified by flash column chromatography (DCM/MeOH 95:5) to give the desired product as a white 
powder (15 mg, 40%). 1H NMR (400 MHz, CDCl3) δH ppm: 14.9 (s, 1 H, OH), 8.76, (s, 1 H, 2-H), 
8.69 (s, 1 H, 4”-H), 8.06 (br s, 1 H, NH), 8.03 (d, J = 12.0 Hz, 1 H, ArH), 7.50-7.42 (m, 2 H, ArH), 
7.37-7.28 (m, 3 H, ArH), 3.87 (app t, 2 H, 3’-H2), 3.72 (app t, 2 H, 3’-H2), 3.57-3.51 (m, 1 H, a-H), 
3.35 (app t, 2 H, 2’-H2), 3.29 (app t, 2 H, 2’-H2), 2.43 (t, J = 8.0 Hz, 2 H, b’ or i’-H2), 2.38 (t, 2 H, b’ 
or I’-H2), 1.75-1.67 (m, 4 H, c’ and h’-H2), 1.42-1.33 (m, 10 H, c’, d’, e’, f’, g’-H2 overlapping b-H2), 
1.22-1.18 (m, 2 H, b-H2). 13C NMR (100 MHz, CDCl3) δC ppm: 177.3 (d, JCF = 2.0 Hz), 172.7, 172.0, 
167.0, 159.0, 153.7 (JCF = 248.0 Hz), 150.0, 147.8, 145.6 (d, JCF = 10.0 Hz), 139.2, 129.8. 127.9, 
125.4, 124.1, 123.4, 120.5 (d, JCF = 8.0 Hz), 120.0, 116.5, 112.8 (d, JCF = 23.0 Hz), 108.5, 105.2 (d, 
JCF = 3.0 Hz), 50.5 (d, JCF = 6.0 Hz), 49.6 (d, JCF = 3.0 Hz), 45.4, 41.2, 37.9, 35.4, 33.3, 29.5, 
29.30, 29.28, 29.19, 25.4, 25.3, 8.4. 19F NMR (376 MHz, CDCl3) δF ppm: -121.1 (s). HRMS (ESI+) 
calculated for C36H40FN4O7 [M+H]+ 659.2876 found 659.2874. RP-HPLC showed 98% purity at 
214 nm. 
Methyl 9-(phenylcarbamoyl) nonanoic acid (147) 
 
EDC (884 mg, 5.56 mmol) was added to a stirred solution of sebacic acid monomethyl ester (1 g, 
4.63 mmol) in 30% pyridine/DCM solution. After 5 minutes, aniline (430.5 mg, 4.63 mmol) was 
added and the reaction stirred at room temperature for 19 h. Subsequently the reaction mixture 
was acidified with 1 M HCl and extracted three times with DCM. The organic layers were dried over 
MgSO4 and the solvent removed under pressure. The crude product was taken up into sat. 
NaHCO3 and extracted three times with DCM. The organic layers were pooled together, dried over 
MgSO4 and the solvent removed to furnish the title product as a white solid (1.13 g, 83%). 1H NMR 
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(400 MHz, CDCl3) δH ppm: 7.57 (s, 1 H, NH), 7.51 (app d, J = 7.9 Hz, 1 H, ArH), 7.29 (app t, 2 H, 
ArH), 7.07 (app t, 2 H, ArH), 3.66 (s, 3 H, k’-H3), 2.35-2.27 (m, 4 H, b’ or i’-H2), 1.73-1.66 (m, 2 H, c’ 
or h’-H2), 1.62-1.56 (m, 2 H, c’ or h’-H2), 1.36-1.26 (m, 8 H, overlapping d’, e’, f’, g’-H2). 13C NMR 
(100 MHz, CDCl3) δC ppm: 174.5, 171.7, 138.2, 129.0, 124.2, 119.9, 51.6, 37.8, 34.2, 29.25, 29.20, 
29.12, 25.7, 25.0. IR vmax (neat) / cm-1 3359 cm-1 (CON-H), 2927-2849 cm-1 (C-H2 and C-H3), 1713 
cm-1 (C=O), 1682 cm-1 (C=O). HRMS (ESI+) calculated for C17H26NO3 [M+H]+ 292.1907 found 
292.1905. Mp. 70-73 °C.  
9-(phenylcarbamoyl) nonanoic acid (148) 
 
Compound 147 (1g, 3.44 mmol) was added to a solution of LiOH monohydrate (422 mg, 10.31 
mmol) in EtOH and H2O (2:1). The reaction was stirred at room temperature for 20 h after which 
sat. NaHCO3 was added and extracted once with DCM. The remaining aqueous layer was acidified 
with 1 M HCl, extracted three times with DCM and dried over MgSO4. The solvent was removed 
under pressure and hot EtOAc added; the product was allowed to recrystallize at room 
temperature, filtered off and washed with cold hexane to furnish the desired compound as a white 
solid (626 mg, 66%). 1H NMR (400 MHz, CD3OD) δH ppm: 7.54-7.52 (m, 2 H, ArH), 7.31-7.26 (m, 2 
H, ArH), 7.09-7.05 (m, 1 H, ArH), 2.36 (t, J = 8.0 Hz, 2 H, 2, b’ or i’-H2), 2.27 (t, J = 8.0 Hz, 2 H, 2, 
b’ or i’-H2), 1.73-1.66 (quint, 2 H, c’ or d’-H2), 1.62-1.56 (quint, 2 H, c’ or d’-H2), 1.41-1.32 (m, 8 H, 
overlapping e’, f’, g’, h’-H2). 13C NMR (100 MHz, CD3OD) δC ppm: 177.7, 174.7, 139.9, 129.8, 
125.1, 121.3, 38.0, 35.0, 30.28, 30.26, 30.17, 26.9, 26.1. IR vmax (neat) / cm-1 3300 cm-1  (CON-H 
overlapping O-H), 2916-2848 cm-1 (C-H2), 1689 cm-1  (C=O), 1659 cm-1 (C=O). HRMS (ESI-) 
calculated for C16H22NO3 [M-H]- 276.1605 found 276.1600. Mp: 120-123°C. 
Ethyl 1-cyclopropyl-6-fluoro-4-oxo-7-{4-[9-(phenylcarbamoyl)nonanoyl]piperazine-1-yl}-1, 4-
dihydroquinoline-3-carboxylate (149) 
 
A mixture of 148 (500 mg, 1.81 mmol) and EDC (414 mg, 2.17 mmol) was added to a solution of 
30% pyridine/DCM. The mixture was stirred vigorously for 5 minutes after which compound 138 
(649 mg, 1.81 mmol) was added. The mixture was stirred at room temperature for 19 hours then 
acidified with 1 M HCl, extracted three times DCM and the organic fractions dried over MgSO4. The 
dried organic fraction was azeotroped with toluene to furnish an orange solid. The product was 
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purified by flash column chromatography (DCM/MeOH 95:5) to remove major impurities and the 
desired product recrystallized from the eluent using EtOAc and Hexane to give a cream solid (247 
mg, 22%). 1H NMR (400 MHz, CDCl3) δH ppm: 8.54 (s, 1 H, 2-H), 8.10 (d, J = 16.0 Hz, 5-H), 7.52 
(app d, 2 H, ArH), 7.31 (app t, 3 H, ArH overlapping NH), 7.26 (d, J = 8.0 Hz, 1 H, 8-H), 7.09 (app t, 
1 H, ArH), 4.38 (q, J = 8.0 Hz, 1 H, d-H2), 3.85 (app t, 2 H, 3’-H2), 3.69 (app t, 2 H, 3’-H2), 3.44-3.38 
(m, 1 H, a-H), 3.26 (app t, 2 H, 2’-H2), 3.21 (app t, 2 H, 2’-H2), 2.39-2.32 (m, 4 H, b’ or i’-H2), 1.74-
1.62 (m, 4 H, c or h’-H2), 1.41 (t, J = 8.0 Hz, 3 H, e-H3 overlapping multiplet), 1.38-1.29 (m, 10 H, 
(d’, e’, f’, g’ overlapping b-H2), 1.15-1.11 (m, 2 H, b-H2). 13C NMR (100 MHz, CDCl3) δC ppm: 173.2 
(d, JCF = 2.0 Hz), 172.0, 171.9, 165.6, 153.3 (d, JCF = 247.0 Hz), 148.3, 144.1 (d, JCF = 10.0 Hz), 
138.4, 138.0, 128.9, 124.0, 123.4 (d, JCF = 7.0 Hz), 119.9, 113.3 (d, JCF = 23.0 Hz), 110.4, 105.2 (d, 
JCF = 2.0 Hz), 60.8, 50.5 (d, JCF = 4.0 Hz), 49.7 (d, JCF = 3.0 Hz), 45.6, 41.3, 37.6, 34.7, 33.3, 29.4, 
29.2, 25.6, 25.3,  29.1, 14.5, 8.2. 19F NMR (376 MHz, CDCl3) δF ppm: -124.0 (s). IR vmax (neat) / 
cm-1 3286 (CON-H), 2923-2853 (C-H2 and C-H3), 1732 (C=O), 1615 (C=O). HRMS (ESI+) 
calculated for C35H44FN4O5 619.3290 [M+H]+ found 619.3275. Mp. 145-147°C.  RP-HPLC showed 
95% purity at 214 nm. 
1-cyclopropyl-6-fluoro-4-oxo-7-{4-[9-(phenylcarbamoyl)nonanoyl]piperazin-1-yl}-1,4-
dihydroquinoline-3-carboxylic acid (150) 
 
Compound 149 (50 mg, 0.08 mmol) was added to a mixture of LiOH monohydrate (14 mg, 0.34 
mmol) in 1.5 mL EtOH/H2O (2:1) and stirred vigorously at room temperature for 20.5 hours. After 
which sat. NaHCO3 was added, the mixture was extracted with DCM, dried over MgSO4 and 
evaporated under reduced pressure. The resultant film was triturated with ether and a few drops of 
DCM to furnish a cream powder (38 mg, 64%). 1H NMR (400 MHz, DMSO-d6) δH ppm: 15.19 (s, 1 
H, OH), 9.83 (br s, 1 H, NH), 8.67 (s, 1 H, 2-H) 7.94 (d, JHF = 13.2 Hz, 1 H, 5-H), 7.58 (app d, 3 H, 
ArH overlapping 8-H), 7.27 (app t, 2 H, ArH), 7.01 (app t, 1 H, ArH), 3.85-3.79 (m, 1 H, a-H), 3.68 
(app t, 4 H, 3’-H2), 3.36-3.27 (m, 4 H, 2’-H2 overlapping water peak), 2.36 (t, J = 8.0 Hz, 2 H, b’ or i’-
H2), 2.29 (t, J = 8.0 Hz, 2 H, b’ or i’-H2), 1.60-1.50 (m, 4 H, c’ or h’-H2), 1.33-1.28 (m, 10 H, (d’, e’, f’, 
g’-H2 overlapping b-H2), 1.21-1.17 (m, 2 H, b-H2). 13C NMR (100 MHz, DMSO-d6) δC ppm: 176.3 
(d, JCF = 8.0 Hz), 171.2, 170.8, 165.9, 152.95 (d, JCF = 250.0 Hz), 148.07, 144.94 (d, JCF = 10.0 
Hz), 139.3, 139.1, 128.6, 122.9, 119.0, 118.81 (d, JCF = 8.0 Hz), 111.0, 106.8, 106.63 (d, JCF = 3.0 
Hz), 49.7 (d, JCF = 4.0 Hz), 49.3 (d, JCF = 4.0 Hz), 44.6, 40.60, 36.4 35.9, 32.2, 28.8, 28.6, 25.1, 
24.7, 7.6. 19F NMR (376 MHz, DMSO-d6) δF ppm: -121.8 (s). HRMS (ESI+) calculated for 
C33H40FN4O5 [M+H]+ 591.2977 found 591.2970. RP-HPLC trace showed 98% purity at 214 nm.  
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Ethyl 1-cyclopropyl-6-fluoro-7-[4-(10-methoxy-10-oxodecanoyl)piperazin-1-yl]-4-oxo-1,4-
dihydroquinoline-3-carboxylate (152) 
 
EDC (382 mg, 2 mmol) was added to monomethyl sebacate (360 mg, 1.69 mmol) in 30% 
pyridine/DCM and stirred vigorously for 5 minutes. Compound 138 (600 mg, 1.67 mmol) was added 
to the solution and stirred for 21 h at room temperature after which sat. NaHCO3, was added and 
extracted three times with DCM. The organic layers were dried over MgSO4 and the solvent 
removed under pressure. The crude was purified by flash column chromatography (EtOAc 100%) 
to give the product as a white solid (612 mg, 65%). 1H NMR (400 MHz, CDCl3) δH ppm: 8.50 (s, 1 
H, 2-H), 8.02 (d, JHF = 13.2, 5-H), 7.25 (d, overlaps solvent peak, JHF = 8.0 Hz, 1 H, 8-H), 4.37 (q, J 
= 7.1 Hz, 2 H, d-H2), 3.84 (app t, 2 H, 3’-H2), 3.68 (app t, 2 H, 3’-H2), 3.65 (s, 3 H, k’-H3), 3.44-3.38 
(m, 1 H, a-H), 3.25 (app t, 2 H, 2’-H2), 3.20 (app t, 2 H, 2’-H2), 2.38-2.34 (t, J = 8.0 Hz, 2 H, b’-H2), 
2.31-2.27 (t, J = 8.0 Hz, 2 H, i’-H2), 1.66-1.59 (m, 4 H, c’ and h’-H2), 1.39 (t, J = 8.0 Hz, 3 H, e-H3) 
1.35-1.29 (m, 10 H, d’, e’, f’, g’-H2 overlapping b-H2), 1.15-1.11 (m, b-H2). 13C NMR (100 MHz, 
CDCl3) δC ppm: 174.4, 173.1 (d, JCF = 2.0 Hz), 171.9, 165.9, 153.5 (d, JCF = 250.0 Hz), 148.3, 
144.2 (d, JCF = 10.0 Hz), 138.1, 123.7 (d, JCF = 10.0 Hz), 113.6 (C5, JCF = 20.0 Hz), 110.7, 105.2 
(d, JCF = 2.0 Hz),  61.03, 51.6, 50.7 (d, JCF = 5.0 Hz) , 49.7 (d, JCF = 2.0 Hz), 45.7, 41.4, 34.6, 34.2, 
33.4, 29.5, 29.3, 29.2, 29.18, 25.4, 25.0, 14.6, 8.3. 19F NMR (376 MHz, CDCl3) δF ppm: -124.0 (s). 
IR vmax (neat) / cm-1 2973-2850 cm-1 (C-H2 and C-H3), 1713 cm-1 (C=O), 1646 cm-1 (C=O), 1615 cm-
1 (C=O). HRMS (ESI+) calculated for C30H41FN3O6 [M+H]+ 558.2974 found 558.2959. Mp: 104-
105°C. RP-HPLC showed 96% purity at 254 nm. 
7-[4-(9-carboxynonanoyl)piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-
3-carboxylic acid (153) 
 
Compound 152 (262 mg, 0.47 mmol) was added to a solution of LiOH monohydrate (58 mg, 1.4 
mmol) in EtOH and H2O (2:1) and stirred vigorously at room temperature for 7 days. After which the 
solution was acidified with 1 M HCl and extracted three times with DCM. The organic phases were 
pooled together and dried over MgSO4, the solvent was removed under reduced pressure to furnish 
the crude product. This was purified by flash column chromatography (DCM/MeOH 95:5) to give 
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the desired compound as a cream solid (123 mg, 51%). 1H NMR (400 MHz, DMSO-d6) δH ppm: 
15.18 (s, 1 H, OH), 11.96 (s, 1 H, OH), 8.66 (s, 1 H, 2-H), 7.92 (d, JHF = 12.0 Hz, 5-H), 7.57 (d, 1 H, 
JHF = 8.0 Hz, 8-H), 3.84-3.79 (m, 1 H, a-H), 3.68 (app t, 4 H, 3’-H2), 3.35-3.38 (m, 4 H, 2’-H2 
overlaps water peak), 2.36 (t, J = 8.0 Hz, 2 H, b’-H2), 2.18 (t, J = 8.0 Hz, 2 H, i'-H2), 1.53-1.47 (m, 4 
H, c’ and h’-H2), 1.33-1.24 (m, 10 H, d’, e’, f’, g’-H2 overlapping b-H2), 1.20-1.16 (m, 2 H, b-H2). 13C 
NMR (100 MHz, DMSO-d6) δC ppm: 176.2 (d, JCF = 2.0 Hz), 174.5, 170.8, 165.8, 152.9 (d, JCF = 
248.0 Hz), 147.8, 144.89 (d, JCF = 10.0 Hz), 139.0, 118.67 (d, JCF = 8.0 Hz), 110.9 (d, JCF = 20.0 
Hz), 106.7, 106.43 (d, JCF = 2.0 Hz), 49.7 (d, JCF = 5.0 Hz), 49.2 (d, JCF = 3.0 Hz), 44.6, 40.6, 35.8, 
33.7, 32.2, 28.8, 28.73, 28.66, 28.6, 24.8, 24.5, 7.60. 19F NMR (376 MHz, DMSO-d6) δF ppm: -
121.8 (s). IR vmax (neat) / cm-1 3600-2400 cm-1 (O-H), 2923-2852 cm-1 (C-H2 and C-H3), 1715 cm-1 
(C=O), 1626 cm-1 (C=O), 1614 cm-1 (C=O). HRMS (ESI+) calculated for C27H35FN3O6 [M+H]+ 
516.2504 found 516.2497. Mp. 190-192 °C. RP-HPLC showed 96% purity at 214 nm.  
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